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Glossary of Terms and Abbreviations 
Units, measurements, physical and chemical quantities 
c 10-2 centi 
m 103 milli 
10-6 micro 
n 10-9 nano 
p 10-12 pico 
f 10-15 femto 
a 10-18 atto 
k 103 kilo 















A ampere (current) 
V volt (potential) 
ohm (resistance) 
J joule 
°C degree Celsius 
M molar 
cpm counts per minute 
Ci curie (1 Ci=37 GBq, 1 Bq=60 dpm) 
rpm 	revolutions per minute 
U 	 units 
OD optical density 







DNA deoxyribonucleic acid 
RNA ribonucleic acid 
mRNA messenger RNA 
cDNA complementary DNA 
rRNA ribosomal RNA 
RNase ribonuclease 
DNase deoxyribonuclease 
dNTP deoxy nucleotide triphosphate 
NIP nucleotide triphosphate 
(d) (A/T/C/G) (T/D)P 	(Deoxy) (base) (tri/di)phosphate 
cAMP cyclic adenosine monophosphate 
nt nucleotide(s) 
oligo oligodeoxyribonucleotide 
poly(A) polyadenylat(-e, -tion) polyadenylic acid 
bp base pair(s) 
kb kilobase(s) 
aa amino acid(s) 
Klenow 	DNA polymerase I, large fragment 




Asp aspartic acid 
Cys cysteine 
Gin giutamine 













Other chemicals, materials 	 - 
ab antibody 
amp ampicillin 
APS ammonium persuifate 
BE S N,N-bis-(2-hydroxyethyi)-2-aminoethane sulfonic acid 
BSA bovine serum albumin (fraction V) 
CAT chioramphenicoi acetyltranferase 
DAB 3,3! diaminobenzidine tetrahydrochioride 
DEPC diethyi pyrocarbonate 
DMEM Dulbecco's modified eagle medium 
DMSO dimethyi suiphoxide 
DLPC phosphatidyicholine (L-(x lecithin) solution 
DTT dithiothreitol 
EDTA ethylenediaminetetraacetic acid 
EtBr ethidium bromide 
HEPES N-2-hydroxyethylpiperazine-N-2-ethanesuiphonic acid 
IPTG isopropyl L-D-thiogaiactopyranoside 
MOPS 	3- [N-morpholino]propanesulphonic acid 
MU 4-methylumbelliferone 
NGF nerve growth factor 
PAGE polyacrylamide gel electrophoresis 
PBS phosphate buffered saline 
PCA phenol-chioroform-isoamylalcohol 
PCR polymerase chain reaction 
PEG polyethylene glycol 
PIPLC phospholipase C 
PK proteinase K 
PMSF phenylmethanesulfonyl fluoride 
RT reverse transcript(ion/ase) 
RT-PCR reverse transcription coupled to polymerase chain reaction 
SDS sodium dodecyl sulphate 
TCA trichloroacetic acid 
TBE Iris-borate electrophoresis buffer 
TE 10 mM Tris.HC1 (pH 7.4)/1 mM EDTA 
TEMED N,N,N',N'-tetramethyl-ethylenediamine 
TESPA 3-aminopropyltrioxysilane 




A1 (I-AP, 1-amyloid peptide 
or I/A4) 
ACE adenylation control elements 
AD Alzheimer's disease 
APP amyloid precursor protein 
BAC bacterial artificial chromosome 
BSE bovine spongiform encephalopathy 
C. elegans Caenorhabditis elegans 
CJD Creutzfeldt-Jakob disease 
CMV cytomegalovirus 
hCMV human cytomegalovirus 
CNS central nervous sytem 
CoA coenzyme A 
CPEs cytoplasmic polyadenylation elements 
CIA clinical target areas 
E. coli Esherichia coli 
GABAA y-aminobutyric acid type A 
GAG glycosaminoglycans 
GFAP glial fibrillary acidic protein 
GPI glycosyl-phosphatidylinositol phospholipid 
GSS Gerstmann-Sträussler-Scheinker syndrome 
CWD chronic wasting disease 
DY drowsy 
FF1 fatal familial insomnia 






IRE iron responsive element 
IRE-BP(IRF) iron responsive binding protein 
lacZ -galactosidase 
LCR locus control region 
L-DOPA L-dihydroxyphenylalanine 
LRS lymphoreticular system 
LIP long-term potentiation 
MAR matrix-attachment region 
MCS multiple cloning site 
NNE non-neuronal enolase 
neo neomycin 
NSE neuron specific enolase 
ORF open reading frame 
PAB poly(A)-binding protein 
PNS peripheral nervous system 
PrP prion protein, 
(HaPrP hamster PrP 
HuPrP human PrP 
MoPrP mouse PrP) 
PrPC cellular prion protein 
PrPSc proteinase K resistant prion protein 
Pm-i prion-incubation time gene 
PRNP human PrP gene complex 
Pm-p mouse PrP gene complex 
Prnpa mouse PrP gene allele a 
prn...pb mouse PrP gene allele b 
RML Rocky Mountain Laboratory 
RRL rabbit reticulosyte lysate 
SAF scrapie-associated fibrils 
Sinc scrapie incubation gene (in mice) 
Sinc 7 scrapie incubation gene allele s7 (in mice) 
SincP 7 scrapie incubation gene allele p7" (in mice) 
Sip scrapie incubation gene (in Cheviot sheep) 
SipsA scrapie incubation gene, allele sA (in Cheviot sheep) 
SippA scrapie incubation gene, allele pA (in Cheviot sheep) 
5V40 simian virus 40 
Tg transgenic 
TB tyrosine hydroxylase 
TK thymidine kinase 
TME transmissible mink encephalopathy 
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Abstract 
To investigate the role of PrP in confering susceptibility to transmissible 
spongiform encephalopathies and furthermore to investigate the effect' 
of restricted hamster PrP expression on the susceptibility to the hamster 
scrapie agent, we attempted to generate transgenic mice by using the 
hamster PrP open reading frame only, linked to appropriate regulatory 5' 
flanking sequences of brain specific genes. Low-level mRNA expression 
was achieved only in some of the transgenic lines generated and 
problems were encountered with PrP protein production. These data 
indicated that the promoter fragments used in the transgenic constructs 
did not contain all necessary elements to achieve high-level and specific 
expression and also that PrP translation was possibly regulated. Itwas 
postulated that other PrP sequences could be important for PrP mRNA 
regulation and efficient translation. The examination of the role of 
untranslated regions of the PrP mRNA was considered of major 
importance. The effect of 5' and 3' untranslated sequences of hamster 
PrP was tested on the translation of both PrP and lacZ. The effect of other 
regulatory sequences (a generic intron and an altered translation of 
initiation consensus sequence) was also investigated. However, none of 
the sequences tested appeared to have a significant effect on either PrP or 
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CHAPTER 1 
Transmissible spongiform encephalopathies 
Introduction 
Transmissible spongiform encephalopathies (TSEs), comprise a 
complex set of neurodegenerative disorders, including kuru, 
Creutzfeldt-Jakob disease (CJD) and Gerstmann-Sträussler-Scheinker 
syndrome (GSS) of humans, scrapie and bovine spongiform 
encephalopathy (BSE) of animals. These fatal diseases share prolonged 
incubation periods with progressive spongiform (vacuolar) degeneration 
of the cental nervous system (CNS) and variable amyloid plaque 
formation. TSEs are infectious diseases which can be transmitted to 
experimental animals. In addition, there are sporadic and genetic forms 
of TSEs. 
Despite intensive investigations into the nature of the infectious 
agent, this issue remains one of the most intriguing in contemporary 
biology. Radiobiological and physicochemical data suggest that the 
infectious agent is different from conventional viruses and viroids. 
Although it appears to possess some viral properties, such as strain 
variation and mutation, there is no conclusive evidence that it contains 
any nucleic acid. On the contrary, the only characterised molecule that 
copurifies with infectivity is an abnormal isoform of a host encoded 
protein, designated cellular prion protein (PrPC). During the course of 
the disease, PrPC appears to undergo post-translational modification 
resulting in the infectious form, termed PrPSC, which is partially 
resistant to proteinase K digestion. 
Recent molecular genetic studies have provided evidence 
supporting a key role of the gene encoding PrP in the course of the 
disease. This gene is termed PRNP in human, Pm-p in mouse, but for 
simplicity the term PrP gene is used here to designate the gene encoding 
PrP protein irrespective of species. 
Experiments with transgenic mice expressing PrP genes from 
various species have demonstrated that the PrP gene has an important 
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effect upon disease susceptibility, clinical-neuropathological features, 
incubation times and transmission between species. 
In vitro studies involving expression of different PrP genes in cell 
lines and infection of tissue culture cells with the agent have provided 
models for studying certain aspects of TSEs. 
The forms and main features of TSEs, as well as models developed 
to improve understanding of these diseases, are discussed in the 
following chapter. 
1.1 Transmissible spongiform encephalopathies of man and other 
animals 
The similarities in the clinical features and the neuropathological 
changes in the CNS, the long incubation periods leading to a protracted 
disease course and the species specificity of infection, were the main 
characteristics that led to the classification of six transmissible 
neurodegenerative diseases of animals and four of humans, as 
transmissible spongiform encephalopathies (Table 1). The association of 
PrPSc (proteinase K resistant PrP) with the pathogenesis of the disease 
and with neurodegeneration, and its accumulation in infected brains, 
have lately been recognised as the main features of TSEs. 
Table 1. Transmissible spongiform encephalopathjes 
TSE 	 - 	 - host 
kuru humans 
Creutzfeldt-Jakob disease (CJD) humans 
Gerstmann-Sträussler-Scheinker syndrome (GSS) humans 
fatal familial insomnia (FF1) humans 
scrapie sheep, goats 
bovine spongiform encephalopathy (BSE) cattle 
transmissible mink encephalopathy (TME) mink 
chronic wasting disease (CWD) mule deer, elk 
feline spongiform encephalopathy (FSE) cat, cheetah, puma 




1.2 TSEs : clinical features, transmissibility and epidemiology 
1.2.1 TSEs of animals 
1.2.1.1 Scrapie 
Scrapie is a fatal ataxia of sheep and occasionally goats, that has been 
recognised for over two centuries and has a widespread distribution in 
Europe, Asia and America (Gajdusek, 1990). Affected animals show 
progressive ataxia, tremor, wasting and severe pruritis leading to wool 
and skin lesions (Sigurdsson, 1954). 
The disease was first shown to be transmissible by inoculation of 
diseased brain tissue from sheep to a recipient ewe (Bensoit 1899, cited in 
(Gajdusek, 1990). In subsequent studies the transmissibility of scrapie to 
sheep was confirmed and the resemblance of the agent to viruses was 
demonstrated (cited in Gajdusek, 1990). When scrapie was first 
transmitted to mice, the neuropathological features appeared similar to 
those of sheep (Zlotnik and Rennie, 1962). Two different forms, or 
strains, of the disease were observed when scrapie was transmitted to 
goats (Pattison. and Millson, 1961; Pattison and Millson, 1962): 
"scratching" and "drowsy", which were also transmitted to mice 
(Chandler, 1961). Transmission of the disease to hamsters produced a 
short incubation period model (Kimberlin and Walker, 1977). The 
passage of the infectious agent to laboratory animals led to the 
establishment of various scrapie models - since those initial experiments 
over 20 different strains of experimental scrapie have been characterised 
(Bruce and Fraser, 1991). 
The way in which the disease spreads between sheep has not been 
established, although experimental infection of animals by oral route, 
scarification and via the conjunctiva point out possible natural routes 
(Kimberlin, 1990a). Evidence suggesting infection of lambs through the 
placenta (fetal membranes contain high amounts of infectivity), or from 
the dam after parturition, implied that maternal transmission might. 
play a role in the natural spread of the disease (Kimberlin, 1990a). 
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1.2.1.2 Transmissible mink encephalopathy (TME) 
TME is very similar to scrapie on the basis of pathological features 
and the physicochemical properties of the transmissible agent. First 
observed in 1947 in a Wisconsin mink herd (Hatsough and Burger, 
1965), the disease has also been recognised in Canada and Finland 
(Gajdusek, 1990). Affected animals initially show subtle behavioural 
changes progressing to locomotor incoordination, ataxia, somnolence 
and, invariably, death. (Hatsough and Burger, 1965). 
TME has been transmitted to several hosts, including monkey, 
sheep, goat and ferret (Gajdusek, 1990). Transmission to Syrian hamsters 
has also been established (Marsh and Kimberlin, 1975) and further 
studies using this experimental model revealed two different strains of 
the infectious agent: hyper (HY) and drowsy (DY) (Bessen and Marsh, 
1992). 
It was suggested that TME was caused by feeding of mink with cattle 
infected with an unrecognised scrapie-like agent (cited in Gajdusek, 
1990). This view was supported by the finding that mink can be infected 
by oral dosing or intracerebral inoculation with sheep scrapie, producing 
a disease indistinguishable from scrapie (Hanson et al., 1971). The high 
rate of horizontal spread of the disease was due to cannibalism and 
fighting between minks on the farms (Hatsough and Burger, 1965). 
1.2.1.3 Chronic wasting disease (CWD) of mule deer and elk 
Chronic wasting disease of mule deer was first described in a 
captive mule deer herd in a wildlife park in Colorado during 1967-1979 
and later in Wyoming (Williams and Young, 1980). Disease signs closely 
resembled scrapie, but also included polydipsia, polyuria, excessive 
salivation and teeth grinding. Experimental transmission of the disease 
to other mule deer has been demonstrated (cited in Gajdusek, 1990). In 
the same wildlife park, a similar wasting disease occurred in captive 
Rocky Mountain elk (Williams and Young, 1982). 
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1.2.1.4 Bovine spongiform encephalopathy (BSE) 
BSE, or "mad cow disease" was recognised retrospectively in 1985 in 
English dairy herds (Wells et al., 1987). Predominant clinical features 
include hyperaesthesia, apprehension and hind-limb ataxi. The 
similarities of clinical, neuropathological (Wells et al., 1987) and 
biochemical (Hope et al., 1988) features of BSE and scrapie suggested that 
it was a novel TSE. 
The disease has been experimentally transmitted to mice by a 
combination of intraperitoneal and intracerebral inoculation (Fraser et 
al., 1988) and feeding with infectious brain homogenates (Barlow and 
Middleton, 1990). When other organs of the infected cattle were fed to 
mice, BSE transmission was not observed. The disease has also been 
experimentaly transmitted to pigs, cattle (Dawson et al., 1990), 
marmosets (Baker et al., 1993), sheep and goats (Foster et al., 1993). 
Epidemiological studies (Wilesmith et al., 1988; Wilesmith et a!;, 
1991) suggest that the disease is not of genetic origin. It manifested as an 
epidemic caused by a common infectious source. The initial exposure of 
cattle to this source was estimated to be in the early 1980's (1981-1982). 
Incubation periods range from 2.5 to 8 years. No maternal, paternal or 
horizontal transmission of the disease has been observed (Bradley and 
Wilesmith, 1993). The most likely way that the disease spread to cattle 
was by the consumption of meat and bone meal supplement 
contaminated with sheep scrapie. The presence of infectivity in cattle 
feed was probably linked to changes in the rendering process. In 
particular, hydrocarbon solvent extraction from carcasses and steam 
treatment, part of the traditional extraction procedure, were 
discontinued during the early 1980's enabling the survival, or 
enrichment, of the scrapie agent (Wilesmith et al., 1991; Bradley and 
Wilesmith, 1993). In that case, it has been hypothesised that the agent 
crossed the "species barrier" and created a novel diseasein cattle. Other 
factors that could account for the BSE epidemic include an increase of 
the incidence of scrapie, the use of more sheep heads for rendering, the 
emergence of a new scrapie strain more pathogenic to cattle, or even a 
sporadic TSE of cattle. (Kimberlin, 1990a; Bradley and Wilesmith, 1993). 
Since the feed ban was introduced in 1988, ruminant protein was 
removed from cattle feed resulting in a decrease in the incidence of BSE 
in younger animals (Wilesmith et al., 1992). Measures were also taken in 
order to prevent the exposure of humans to BSE. The consumption of 
bovine offal was banned and it was recommended to destroy carcasses of 
suspect animals and their milk. Major issues concerning the human 
health risk, such as the amount of BSE-contaminated tissue that has 
already entered the human food chain and the frequency of BSE 
transmission to humans, still remain contentious. However, recent 
studies involving transgenic mice expressing the human PrP gene 
suggest that the BSE agent might not initiate the, formation of human 
PrPsc in mice (see section 1.12.1). 
1.2.1.5 Other TSEs of animals 
Recently, TSE has been reported in members of the feline family 
including cat (Wyatt et al., 1991), cheetah and puma (Willoughby et al., 
1992). Other captive exotic animals have been infected with the disease, 
such as nyala, eland, greater kudu, gemsbok and Arabian oryx. 
Transmission could have been through feed concentrates containing 
meat and bone-meal contaminated with scrapie or BSE (Wilesmith et al., 
1988), but in other cases in kudu, maternal transmission is also likely 
(Kirkwood et al., 1993). 
1.2.2 TSEs of man 
1.2.2.1 Kuru 
Kuru was described first in 1957 as an unusual progressive 
neurological disorder in the Fore tribe of Papua New Guinea (Gajdusek 
and Zigas, 1957). In the 1950s and 1960s it was the most common cause of 
death among the Fore population (approximately 35000) (Gajdusek, 
1990). The disease (reviewed in Gajdusek, 1977; Gajdusek, 1990) is 
recognised by a progressive impairment of motor coordination with 
dysarthria, shivering-like tremor, cerebellar ataxia, and often dementia 
in the terminal stages. Victims would usually die within 2 years of onset 
after long incubation periods of approximately 4-30 years. The similarity 
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between kuru and scrapie, based on neuropathological features, was first 
pointed out in 1959 (Hadlow, 1959). 
This link was strengthened when kuru was demonstrated to be 
transmissible to chimpanzees (Gajdusek et al., 1966). Later, the disease 
was transmitted to New World and Old World monkeys and to mink 
and ferret. Many other nonprimate species, including laboratory rodents, 
have remained resistant to inoculation with kuru infectious agent 
(Gajdusek, 1990). 
Epidemiological studies (Gajdusek, 1977; Gajdusek, 1990) have 
revealed that the spread of kuru was connected to the endocannibalism 
of dead relatives, a rite of mourning among the Fore tribe. This ritual 
was performed by females and their young children. Apart from the oral 
route, infection via intradermal (damaged skin), nasal and ocular routes 
could have occurred. Males over 6 years old did not usually handle or 
eat dead kinsmen, accounting for the high incidence of disease among 
women and the distinct age distribution. The incidence of Kuru has 
declined since the cessation of ritualistic cannibalism in 1956 and the 
disease no longer appears in children or young adults. 
1.2.2.2 Creutzfeldt-Jakob disease (CJD) 
CJD presents as a progressive dementing illness of man, first 
reported by Creutzfeldt in 1920 and Jakob in 1921 (cited in Bell and 
Ironside, 1993). It was not until 1959 that its resemblanceto scrapie was 
noted (Klatzo et al., 1959) and 1979 that a more thorough analysis of the 
disease was presented (Masters et al., 1979). The onset of the disease is 
usually during the sixth decade of life (Will and Matthews, 1984) and the 
course between one and thirty-five months (Kretzschmar, 1993). Clinical 
signs can be variable (Brown et al., 1993). Typical features include initial 
memory loss and diminished intellect, followed by rapidly progressive 
dementia leading to death. Other cases present as cerebellar syndromes 
with diminished coordination, myoclonous, tremor and ataxia, that 
eventually result in dementia. 
The disease has been successfully transmitted to chimpanzees and 
New and Old World monkeys. Only some of the CJD isolates can be 
transmitted to cat, guinea pig, hamster and mouse (cited in Gajdusek, 
1990). 
CJD occurs mainly as a sporadic illness, with no correlation between 
the incidence of the disease (1 case per million per annum) and any 
possible source of infection (Masters et al., 1981a; Brown et al., 1987). 
Approximately 5-15% of CJD cases are familial, showing an autosomal 
dominant pattern of disease segregation (Will, 1993; Masters et al., 1979). 
A very small proportion of disease incidence is due to iatrogenic 
transmission, which depends on direct exposure of the recipient with 
contaminated material. These cases have been reported to arise through 
contaminated neurosurgical instruments, depth electrodes, corneal and 
dura mater grafts, pituitary derived gonadotropin and growth hormone 
from affected donors (Will, 1993; Brown et al., 1992; Smith and Collinge, 
1995). 
1.2.2.3 Gerstmann-Sträussler-Scheinker syndrome (GSS) 
GSS was described in 1928 as a slowly progressive ataxia. It is now 
regarded as a familial disorder with an autosomal dominant pattern of 
inheritance, clinically characterised by lack of coordination, speech 
difficulties, limb weakness and chronic cerebellar ataxia with dementia 
occurring later in the course of the disease. Typically the disease 
manifests at the fifth decade of life, with duration ranging between 1 and 
twenty years. The incidence of GSS is very low : 2 cases per 100 million 
per year (Prusiner, 1993a). It was succesfully transmitted to primates in 
1981 (Masters et al., 1981a). 
1.2.2.4 Fatal familial insomnia (FF1) 
Recently FF1 was described as another familial TSE disease (Medori 
et al., 1992) with an autosomal dominant pattern of disease segregation. 
Clinical signs include agitation during sleep and progressive insomnia, 
dysarthria, ataxia and memory impairment. The disease usually 
manifests at 40-60 years of age and the duration varies between 7-18 
[2] 
months (reviewed in Gambetti et al., 1993). FF1 has been recently 
transmitted to mice (Tateishi et al., 1995). 
1.3 Diversity in neuropathology of TSEs 
One of the most important criteria by which these diseases are 
classified is the pathology of the CNS (reviewed in Bell and Ironside, 
1993; Fraser, 1993; Fraser et al., 1986). Generally it consists of non-
inflammatory, degenerative vacuolation of neurons and spongiform 
change of the neuropil, usually confined to the grey matter. The disease 
progresses with neuronal loss, gliosis and hypertrophy of astrocytes. 
Formation of cerebral plaques due to extracellular deposits of amyloid 
are an inconsistent feature, related to some forms of TSEs. The pathology 
is influenced by the genetic differences of the host and variations in the 
origin of the infectious agent. Aggregates of PrPSC purified from diseased 
brain homogenates, designated "scrapie-associated fibrils" (SAF) (Merz et 
al., 1981), are usually part of the molecular pathology of the disease and 
regardless of their significance, their presence has been useful for 
confirming TSE cases (Gibbs et al., 1985; Hope et al., 1988). The detection 
of PrP5C, the protease-resistant, disease-associated isoform of PrPc, which 
is thought to have a central role in the etiology and pathogenesis of the 
disease, can also serve as a diagnostic marker. Assays developed to detect 
PrP5c and distinguish between PrPSc and PrPc could result in providing a 
more reliable diagnostic method (Tateishi and Kitamoto, 1993, reviewed 
in Bell and Ironside, 1993). 
In neurons, PrP5c has been detected in synaptic structures 
(Kitamoto et al., 1991), dendrites and terminal axons (DeArmond et al., 
1987), in contrast to PrPc which is detected in the cell bodies (Kitamoto et 
al., 1991). PrP5c usually accumulates on the plasmalemma of neurons, 
diffusing from the cell surface to extraneuronal space and dense 
accumulation of PrPSC is associated with disruption of the neuropil and 
vacuolation (Jeffrey et al., 1994a; Jeffrey et al., 1994b). PrPSc can also be 
detected in astrocytes (Diedrich et al., 1991). The site of PrP 5 c 
accumulation in astrocytes and microglial cells is thought to be the 
lysosomes (Jeffrey et al., 1994c). 
In naturally occurring TSEs of animals, neuropathology appears 
generally similar (reviewed in Fraser, 1993; Fraser et al., 1986). Most 
prominent features are the vacuolation of neurons in the spinal cord; 
medulla, pons and midbrain, while the cerebrum is usually unaffected. 
Spongiform degeneration in the neuropil occurs in the brain stem, 
septum and hypothalamus (Zlotnik, 1958) and pathology is accompanied 
by astrocytic hypertrophy. Some animals affected with TME, CWD and 
FSE show cerebral cortical spongiform lesions and in a few cases of 
scrapie and CWD severe cerebrovascular amyloidosis has been observed 
(Willoughby et al., 1992; Williams and Young, 1980; Wyatt et al., 1991; 
Hatsough and Burger, 1965; Wood and Done, 1992). 
Human TSEs manifest with a wide range of neuropathology 
(reviewed in Bell and Ironside, 1993; Lantos, 1992). Spongiform change 
in the cerebral cortex, grey matter and cerebellum, accompanied by 
proliferation and hypertrophy of the astrocytes, is evident in all kuru 
cases, but the most striking feature is the presence of amyloid plaques, 
mainly in the cerebellum, in approximately 70% of the cases (Gajdusek, 
1990; Bell and Ironside, 1993). 
In most CJD cases cortical atrophy has been described and in a few 
cases cerebellar atrophy is also prominent (Bell and Ironside, 1993). 
Characteristic histological findings include spongiform degeneration of 
the neuropil, neuronal loss, astrocytosis and sometimes amyloid plaque 
formation. Additionally, spongiform change in the cerebral white matter 
is observed in some cases. However, these neuropathological changes 
are not consistent and the severity and distribution of lesions differ 
substantially from case to case (Bell and Ironside, 1993; Lantos, 1992). 
Histopathology in GSS cases is dominated by accumulation of 
amyloid plaques throughout the cerebrum and cerebellum, with 
spongiform change in the cerebral cortex occurring only in some cases 
(Bell and Ironside, 1993; Masters et al., 1981a). 
The most prominent feature of FF1 is thalamic atrophy. Neuronal 
loss, gliosis and spongiosis have also been observed in the thalamus, 
cerebral cortex, and cerebellum (Gambetti et al., 1993). 
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1.4 The nature of the infectious agent 
Contradictory views have been presented concerning the nature of 
the TSE infectious agent. Although most scientific evidence to date 
argues against the requirement for a conventional virus or viroid, the 
possibility of a nucleic acid component cannot be excluded. Early studies 
demonstrated that infectivity was resistant to heating, treatment with 
acetylethyleneimine, ultra-violet and ionizing radiation (Stamp et al., 
1959; Alper et al., 1966; Alper et al., 1967). Further investigations showed 
that the agent was resistant to treatment with DNase, RNase, formalin, 
ether, pepsin and high salt concentrations (Pattison and Millson, 1961; 
Pattison and Millson, 1960; Mould and Smith, 1995). These findings were 
confirmed and extended when a range of procedures that inactivate, 
degrade, or modify nucleic acids appeared to have little effect on 
infectivity (Gajdusek, 1977; BellingerKawahara et al., 1987a; 
BellingerKawahara et al., 1987b). Although the possibility of a nucleic 
acid being part of the agent was not completely eliminated, it would 
have to be quite small and well protected. Other researchers have 
questioned the methodology used to produce these results and have 
presented evidence suggesting that the infectious agent resembles a 
virus both in size and in susceptibility to inactivating procedures 
(Rohwer, 1984). 
Subsequent physicochemical studies suggested that this putative 
nucleic acid would have to be very small (approximately 100 bp or less), 
very efficient (low molecule to infectivity ratio) and heterogeneous in 
size (Meyer et al., 1991; Kellings et al., 1992). In contrast, other 
investigators have been able to identify nucleic acids (500-6000 bp length) 
in infectious preparations (Sklaviadis et al., 1990; Akowitz et al., 1990), 
which appeared to be similar to nuclease protected viral cores 
(Sklaviadis et al., 1990; Akowitz et al., 1990). A small single-stranded D-
loop mitochondrial DNA fragment has been shown to be enriched in 
highly infectious preparations (Aiken et al., 1990; Aiken and Marsh, 
1990) and retroviral-like sequences present in these preparations have 
been cloned (Murdoch et al., 1990; Akowitz et al., 1993). Also, small 
virus-like particles (Ozel and Diringer, 1994), single-stranded DNA 
associated with proteins (Narang et al., 1988; Narang, 1990) and 
multimeric mitochondrial DNA (Narang, 1990) have been visualised by 
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electron microscopy in highly infectious fractions. The contribution of 
any of these molecules to the infectious agent has not yet been 
established. However, subtractive hybridisation and cloning 
methodologies have failed to identify a nucleic acid (Aiken and Marsh, 
1990; Duguid and Dinauer, 1990; Duguid et al., 1989; Duguid et al., 1988; 
Diedrich et al., 1987), but the sensitivity of these techniques has been 
questioned (Aiken and Marsh, 1990). 
The unusual properties of the agent and the identification of a 
hydrophobic protein that copurified with infectivity (Prusiner, 1982) led 
to the proposal of the term 'prion' (Prusiner, 1982) in order to 
distinguish the particles from viruses and viroids. Although this 
protein, designated PrP, is now generally accepted to be the main 
component of the agent, there are contradictory views on its association 
with infectivity (Sklaviadis et al., 1990; Manuelidis et al., 1987; Bolton et 
al., 1982; Prusiner et al., 1982). Different hypotheses on the nature, and 
replication of the agent will be further discussed in (1.13). 
1.5 PrP gene 
Partially purified infectious fractions demonstrated that the 
infectious agent was likely to be hydrophobic, had a tendency to 
aggregate and was sensitive to phenol, chaotropic ions and denaturing 
detergents, suggesting the possibility of a protein component (Prusiner et 
al., 1980a; Prusiner et al., 1978). Further purification revealed the 
existence of a hydrophobic protein, designated PrP 27-30, which was 
partially resistant to proteinase K digestion and had molecular weight of 
27-30 kD (Prusiner et al., 1981; Prusiner et al., 1980b; Prusiner et al., 1982; 
McKinley et al., 1983). Once the sequence of PrP 27-30 was determined 
(Prusiner et al.,' 1984), oligonucleotides corresponding to that sequence 
were synthesised and used to identify a PrP cDNA (Oesch et al., 1985; 
Chesebro et al., 1985). Southern blotting with PrP cDNA revealed a 
single-copy chromosomal gene that gave the same restriction patterns 
when infected and normal brain samples were compared (Basler et al., 
1986). 
Since the isolation of hamster PrP sequences (Oesch et al., 1985;. 
Basler et al., 1986; Chesebro et al., 1985; Robakis et al., 1986; Lowenstein et 
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al., 1990), PrP genes from other species, including human (Puckett et al., 
1991; Liao et al., 1986; Kretzschmar et al., 1986b), mouse (Locht et al., 1986; 
Westaway et al., 1987), sheep (Goldmann et al., 1990), cattle (Goldmann 
et al., 1991b) and mink (Kretzschmar et al., 1992) have been characterised. 
The PrP gene has also been cloned from a bird (chicken) (Gabriel et al., 
1992; Harris et al., 1991) and a marsupial (possum) (Windl et aL, 1995). 
PrP-related sequences have been identified in Drosophila melanogaster, 
Caenorhabditis elegans and yeast (Westaway and Prusiner, 1986), but 
attempts to prove the existence of a PrP-like protein in these species 
have failed. Attempts to clone the C. elegans PrP gene that hybridised 
with the hamster PrP cDNA resulted in the identification of an 
unrelated gene (a novel heterologous nuclear ribonucleoprotein gene) 
(Iwasaki et al., 1992). These results suggest that the PrP gene is confined 
to mammals and some other vertebrates. The conservation of the open 
reading frame (ORF) between mammals is over 81% at the nucleic acid 
level and over 85% at the amino acid level (Kretzschmar et al., 1992; 
Goldmann, 1993). The similarity of the amino acid sequence between 
mouse and chicken is 33% (Laplanche et al., 1993). PrP shows almost no 
homology to other known proteins (Goldmann, 1993). 
The human PrP gene (PRNP) was shown to be located on 
chromosome 20 (Puckett et al., 1991; Liao et al., 1986; Sparkes et al., 1986) 
and the mouse PrP gene (Prn-p) on chromosome 2 (Sparkes et al., 1986). 
The PrP ORF is contained within a single exon, eliminating the 
possibility of alternative splicing, and this exon is separated from an 
upstream PrP exon by a 10 kb intron (Basler et al., 1986; Puckett et al., 
1991). The PrP ORF has a similar length (approximately 760 bp) in all 
mammals. Examples of the PrP gene and mRNA structure are given in 
Figure 1.1. 
The promoter of the PrP genes has not been well defined. Sequence 
data have revealed that there is no typical consensus TATA box for 
transcription initiation. A prominent feature is a high content of G and 
C nucleotides, particularly around the transcription start site (Puckett et 
al., 1991; Westaway et al., 1987; Basler et al., 1986). The promoter of the 
PrP gene contains consensus sequences for the binding of ubiquitous 
transcription factors such as Spi and AP-1 and hence resembles 
housekeeping gene promoters. 
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Figure 1.1 Structure of PrP gene and transcription products 
The hamster PrP gene consisting of two exons and the hamster PrP mRNA. 
The sheep PrP gene consisting of 3 exons. Two different size transcripts are probably 
a result of the use of an additional poly(A) addition site (Goldmann, 1993). 
The 5' leader sequence of the PrP transcript is encoded by one exon 
in hamster and man and by two exons in mouse and sheep (Puckett et 
al., 1991; Basler et al., 1986; Westaway et al., 1987; Goldmann, 1993). 
Differences in the length of the 5' leader sequence have been observed in 
mouse and hamster PrP mRNA, due to multiple transcription initiation 
sites while, in human, only one major initiation site has been detected 
(Puckett et al., 1991; Basler et al., 1986; Westaway et al., 1987). 
A conserved feature of the PrP ORF is that it contains a GC rich 
region in the 5' half, organised usually in 24 bp repeats coding for almost 
identical octapeptides (Oesch et al., 1985; Liao et al., 1986; Goldmann et 
al., 1990; Goldmann et al., 1991b; Locht et al., 1986; Kretzschmar et al., 
1992). 
The 3' untranslated region (3' UTR) of PrP mRNA is quite long and 
conserved between humans, rodents and sheep, apart from two sheep-
specific insertions (Goldmann et al., 1990). In particular, there is a AT-
rich domain upstream of the poly(A) addition signal and near the end of 
the mRNA, that is highly homologous between species (Goldmann, 
1993; Goldmann et al., 1990). Two mRNA transcripts are present in 
sheep, thought to be produced through alternative use of poly(A) 
addition signals in the sheep 3' UTR (Hunter et al., 1994; Horiuchi et al., 
1995). 
1.6 PrP expression 
PrP mRNA in mouse is detected mainly in the brain and the 
highest expression was shown to be in the brainstem, hippocampus, 
thalamus, cortex and cerebellum (Manson et al., 1992a; Mobley et al., 
1988). In situ hybridisation has revealed that PrP is expressed in mouse 
embryos after 13.5 days throughout the developing neural tube and after 
16 days in non-neuronal cells, with high levels observed in specific 
kidney cells and tooth buds (Manson et al., 1992b). In neonatal mice PrP 
mRNA has been shown to be developmentally regulated; it increases at 
different rates in various brain regions (McKinley et al., 1987). During 
the first 20 days after birth PrP mRNA increases four-fold and remains at 
that level throughout adult life (Lazarini et al., 1991). It continues to be 
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expressed at high levels in most, if not all, neurons in the adult brain, as 
well as in ganglia and peripheral nerves (Kretzschmar et al., 1986a; 
Manson et al., 1992b; Manson et al., 1992a). Expression in many non-
neuronal cells, including astrocytes, pericytes and ependymal, epithelial 
and endothelial cells, has also been reported (Brown et al., 1990). PrP 
mRNA has been detected in smaller amounts in many other tissues 
tested, such as heart, lung, kidney, intestine, skeletal muscle, spleen, 
adrenal gland, lymph node, ovary and testis, but not in liver (Chesebro 
et al., 1985; Horiuchi et al., 1995; Caughey et al., 1988a; Bendheim et al., 
1992; Oesch et al., 1985; Brown et al., 1990; Robakis et al., 1986). It has been 
observed that PrP mRNA expression can be induced by nerve growth 
factor (NGF) (Mobley et al., 1988). There is no change in the level, size, or 
localisation of PrP mRNA during the course of the disease (Chesebro et 
al., 1985; Manson et al., 1992a). 
The human PrP mRNA is 2.7 kb, the bovine is 4.5 kb (same as in 
sheep and goats), the hamster 2.1 kb and the mouse 2.3 kb. 
1.7 PrP protein 
1.7.1 Primary structure and post-translational modifications of PrP 
PrP2730, which was identified as the most abundant component in 
the infectious preparations (Prusiner et al., 1982; Prusiner et al., 1984), is 
an isoform of a normal cellular protein, PrPc, encoded by the PrP gene of 
the host (Oesch et al., 1985; Basler et al., 1986). When PrPC was isolated 
from normal brain it appeared as a soluble, protease sensitive protein of 
molecular weight 33-35 kD (Oesch et al., 1985; Meyer et al., 1986; Barry et 
al., 1986; Bendheim ° et al., 1988). In the purified infectious preparations, 
the disease-associated form, PrPSc, is insoluble after detergent extraction 
and tends to aggregate (Oesch et al., 1985; Prusiner et al., 1981). It shows, 
though, the same molecular weight as PrPc, 33-35 kD, which is reduced 
to 27-30 kD (PrP 2730) after proteinase K digestion (Prusiner et al., 1984; 
Hope et al,. 1986; Turk et al., 1988; Prusiner et al., 1982). This partial 
proteinase K resistance is a feature widely used for diagnosis of TSEs. 
The primary structure of PrPSc has been shown to be identical to 
that predicted for PrPc, by amino acid sequencing and mass spectrometry 
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(Stahl et al., 1993; Baldwin et al., 1993). The charge and size heterogeneity 
observed with electrophoretic separation techniques indicates extensive 
post-translational modifications for both isoforms (Meyer et al., 1986; 
Hope et al., 1986). 
Amino acid sequences of the PrP protein from different species 
have been deduced from genomic and cDNA sequences and some have 
been confirmed by protein sequencing (Puckett et al., 1991; Basler et al., 
1986; Locht et al., 1986; Goldmann et al., 1990; Goldmann et al., 1991b; 
Kretzschmar et al., 1992; Prusiner et al., 1984; Hope et al., 1986; Turk et al., 
1988). PrP proteins of different species exhibit above 85% similarity and 
the structural characteristics are conserved. The length of the predicted 
precursor protein is 253 amino acids for human PrP, 254 for hamster and 
mouse, 257 for mink and 256 for sheep. The structure of the PrP protein 
(hamster) 'is presented in Figure 1.2. 
A series of studies (Hope et al., 1986; Basler et al., 1986; Goldmann et al., 
1990; Puckett et al., 1991; Kretzschmar 'et al., 1992; Prusiner et al., 1984; 
Turk et al., 1988; Locht et al., 1986; Bazan et al., 1987; Goldmann et al., 
1991b) have shown that the amino-terminal 22 amino acids (24, in 
sheep, cattle, mink) form the signal peptide, which is cleaved off after 
guiding the protein into the endoplasmic reticulum. PrP of all species 
contains 2 hexapeptide repeats and usually 5 glycine-rich octapeptide 
repeats (codons 51 to 90). In cattle, the most common allele contains 6 
octarepeats (Goldmann et al., 1991b). Two further tandem repeats 
(codons 148 to 159 and 161 to 171) and an overlapping aromatic 
palindrome (codons 147 to 163) (Sulkowski, 1992) are also present in the 
PrP sequence. Although these repeats appear to be unique to PrP, the 
core of the octapeptide repeats is similar to motifs found in keratin 
(Oesch et al., 1985). No function has been assigned to these motifs. 
However, it has been postulated that the palindromic sequences could 
play a role in dimerisation of PrP, or binding of other proteins to PrP 
(Goldmann, 1993). In man, insertions of integral numbers of the 
octapeptide repeats are linked to inherited TSEs (discussed in section 1.8), 
but data from experiments using cell culture systems have indicated that 
the deletion of that region or the addition of extra octarepeats does not 
influence the conversion of PrPC to PrP 5C (Rogers et al., 1993). Also, it 
was recently demonstrated that introduction of PrP transgenes carrying 
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Precursor PrP protein. 
Post-translationally modified PrP protein 
octapeptide repeat deletions into PrP null mice conferred susceptibility to 
the disease, but the levels of PrPsc were much lower than those observed 
in infected wild type mice (Fischer et al., 1996). 
A hydrophobic, transmembrane a-helix domain (codons 113 to 135) 
and amphipathic a-helix (codons 157 to 177) were proposed to cross the 
lipid bilayer. This idea was supported by secondary structure predictions 
through computational analysis (Bazan et al., 1987) and by in vitro 
translation studies (Yost et al., 1990; Lopez et al., 1990; Hay et al., 1987a). 
However, it is now well established that PrP is attached to the cell 
membrane by a glycosyl-phosphatidylinositol phospholipid (GPI) anchor 
and can be detached by enzymatic digestion with phosphatidylinositol-
specific phospholipase C (PIPLC) (Stahl et al., 1987; Stahl et al., 1990c; 
Stahl et al., 1990a). The GPI anchor attachment signal, formed by the 
hydrophobic carboxy-terminal 23 amino acids (codons 232 to 254), is 
removed prior to the GPI attachment. The site of the anchor attachment 
is serine 231 (Stahl et al., 1990b; Stahl et al., 1990a). The structure of the 
GPI moiety appears to be heterogeneous (2-2.5 kD), with 30% of the 
carbohydrate structure consisting of sialic acid, but no differences have 
been observed between the GPI anchors of PrPc and PrP 5c (Stahl et al., 
1992; Stahl et al., 1990a). Furthermore, cell culture experiments have 
demonstrated that the presence of the GPI anchor is not required for the 
conversion of PrPc to PrPSc (Rogers et al., 1993; Kocisko et al., 1994). 
However, when a C-terminal truncated (including the GPI addition site) 
PrP transgene was introduced into PrP null mice no PrP protein was 
produced, suggesting that the protein may have been secreted and 
degraded rapidly (Fischer et al., 1996). A secreted form of PrP has been 
reported in cerebrospinal fluid (Tagliavini et al., 1992), in cell-free 
translation systems (Lopez et al., 1990; Yost et al., 1990) and Xenopus 
oocytes (Hay et al., 198Th), but its significance is not known. 
Two cysteine residues (codons 178 and 213) are linked by an 
intramolecular disulfide bond, which creates a loop including two 
asparagine-linked glycosylation sites (codons 181 and 197) (Turk et al., 
1988; Bazan et al., 1987). However, PrP is not always glycosylated at these 
sites; the existence of unglycosylated, monoglycosylated and 
diglycosylated isoforms has been confirmed directly (Somerville and 
Ritchie, 1990) and by cell culture experiments (Caughey et al., 1989). The 
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size heterogeneity of the unglycosylated form (observed on SDS-PAGE 
electrophoresis), is due to variations in the GPI anchor and in vivo 
proteolysis (Stahl et al., 1992; Somerville and Ritchie, 1990; Hope et al., 
1988c; Hope and Hunter, 1988). Structural analysis of the asparagine-
linked sugar moieties performed on PrPSc demonstrated over 400 
different oligosaccharide combinations (Endo et al., 1989). Whether this 
is true for PrPc  and whether it is important for the formation and 
diversity (strains) of the infectious agent remain to be established. 
However, it has been demonstrated, that the conversion of PrPc to PrPSc 
is still possible when glycosylation is inhibited (Rogers et al., 1990). 
Another modification that occurs in both PrPc and PrP 5 C is the 
conversion of two arginine residues (codons 25 and 37) to citrulline 
(Hope, 1993). Although PrP has 2 threonine phosphorylation sites 
(codons 183 and 192), a tyrosine phosphorylation site (codon 155, not 
present in human PrP) and a tyrosine sulphation motif (codon 145, not 
present in rodent PrP) their utilisation has not been experimentally 
demonstrated (Goldmann, 1993). 
These data suggest that there are no obvious covalent differences 
between PrPc and PrP 5C, although an amino acid substitution or a post 
translational modification occurring in a very small fraction of PrP 5  c 
could be covered by the general heterogeneity observed, or could have 
escaped the detection methods. 
1.7.2 Secondary structure and conformation of PrP 
The secondary structure of PrPC is predominantly a-helical, (42%) 
with little content in I-sheet (3%) (Pan et al., 1993). In contrast the g 
sheet content of PrPSc is high (34% 1-sheet, 20% a-helix, 46% L-turns and 
random coil). Characterisation of PrP 2730 also showed a high content in 
I-sheet (43% I.-sheet, no a-helix, 57% g-turns and random coil) (Safar et 
al., 1993). Furthermore, treatments that were found to reduce infectivity, 
such as high pH and SDS denaturation, also reduced the 1-sheet content 
of PrP2730 (Gasset et al., 1993). This finding is not surprising since it is 
known that amyloids generally contain proteins with L-sheet 
conformation. Whether this conformational change is related to the 
pathogenesis of the disease still remains to be established. 
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It was proposed that PrP has four regions of a-helices. When these 
were synthesised as peptides, three of them formed a I-sheet 
conformation in vitro (Gasset et al., 1992). These peptides were also 
shown to be neurotoxic (Forloni et al., 1993). It was therefore 
hypothesised that PrP has a three-dimensional conformation, consisting 
of four regions of a-helices (Huang et al., 1994) and some of them could 
undergo a conversion into g-sheets spontaneously, or through 
mutations in the PrP primary sequence, or triggered by the interaction 
with the infectious agent (Goldfarb et al., 1993; Huang et al., 1994; 
Sulkowski, 1992). 
1.8 Genetics of TSEs 
Following experimental transmission of scrapie to mice (Chandler, 
1961) a series of studies involving different inbred mouse strains 
produced evidence supporting the influence of a single autosomal gene, 
designated Sinc, on scrapie incubation periods (Dickinson et al., 1968). 
Further characterisation of this gene led to the suggestion that there 
were two alleles in mice, termed Sinc 7 and SincP 7, that controlled the 
incubation periods after infection with the different scrapie-agent strains 
(Dickinson and Meikie, 1971). 
Studies on the Pm-p genes (PrP genes) of mice that exhibited short 
and long incubation periods, demonstrated a genetic linkage between a 
gene thought to modulate the incubation periods, designated Pm-i, and 
a restriction fragment length polymorphism of Pm-p (Carlson et al., 
1986; Carison, 1991). Following the cloning of the mouse PrP gene, two 
alleles were identified, Pmnpa and Prnpb, which differed by two amino 
acids, at codon 108: Leu or Phe and at codon 189: Thr or Ala, respectively 
(Locht et al., 1986; Westaway et al., 1987). It was demonstrated that Prnpa 
segregated with the Sinc 7 and Prnpb with the SincP 7 allele (Carlson et 
al., 1986; Carlson et al., 1988; Carlson et al., 1991). 
Other researchers have confirmed the linkage between Pm-p and 
Prn-i/Sinc, but it has not been unequivocally proven that they are 
congruent (Carlson et al., 1986; Carlson et al., 1988; Hunter et al., 1992). 
The incubation period gene for experimental scrapie in Cheviot 
sheep, termed Sip, was also shown to be linked to PrP gene restriction 
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fragment length polymorphisms (Hunter et al., 1989). It was 
subsequently demonstrated that four PrP protein variants were 
associated with the short (sA) and prolonged (pA) incubation period 
alleles (Goldmann et al., 1991a). Further studies with different strains of 
agent supported the correlation between dimorphisms in codons 136 and 
171 of the ovine PrP gene and the modulation of the incubation period 
and disease incidence (Goldmann et al., 1994; Westaway et al., 1994b). 
In humans, a genetic contribution was recognised when 
approximately 10% of CJD cases were found to be familial (Masters et al., 
1981b). Genetic linkage studies in mice and the discovery of the human 
PrP gene (see section 1.5) led to a search for mutations that might feature 
in human hereditary disease. Since a point mutation at codon 102 (Pro 
->Leu) was shown to be linked to GSS, many other pathogenic 
mutations and non-pathogenic polymorphisms have been identified 
(Prusiner, 1994b; Prusiner and DeArmond, 1994; Smith and Collinge, 
1995; Prusiner and Hsiao, 1994; Gajdusek, 1993; Prusiner, 1994a), 
summarised in Table 2 and Figure 1.3. The polymorphism at codon 129 
can determine the phenotype of the disease when the 178 Asp-> Asn 
mutation is present. The 129 Met 178 Asn combination was shown to 
segregate with FF1, whereas 129 Val 178 Asn segregated with CJD. Studies 
involving many normal individuals and sporadic CJD cases have 
revealed that homozygosity at the 129 codon predisposes to the disease 
(Palmer et al., 1991; De Silva et al., 1994; Windl et 'al., submitted). Other 
researchers have reported that 129 Val influences the pathological 
features of sporadic CJD (Miyazono et al., 1992) and in familial GSS 198 
Phe->Ser, 129' Val homozygosity is responsible for early onset of the 
disease (Dlouhy et al., 1992). 
The availability of these genetic markers has facilitated the study of 
the remarkably heterogeneous phenotypes of inherited TSEs and the 
recognition of cases that were not considered previously to be TSE. 
1.9 Pathogenesis of TSEs 
Because the infectious agent has not been unequivocally identified, 
the spread and the dynamics of infectivity have been studied only with 
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Table 2. Pathogenic mutations and non-pathogenic polymorphisms of 
the human PrP gene. 
pathogenic mutations disease references 
octapeptide Owen et al., 1990; Owen et al., 
repeat familial CJD 1991; Goldfarb et al., 1991a; 
insertions  Goldfarb et al., 1993 
aa 102 Pro->Leu familial GSS Hsiao et cii., 1989; Kretzschmar et 
al., 1991 
aa 105 Pro->Leu familial GSS Kitamoto et al., 1993b 
aa 117 Ala->Val familial GSS DohUra et al., 1989 
aa 145 Tyr->stop familial GSS Kitamoto et al., 1993a 
aa 178 Asp->Asn 129 Val familial CJD Goldfarb et cii., 1991c 
aa 178 Asp->Asn 129 Met familial FF1 Goldfarb et al., 1992; Medori et 
al., 1992; Gambetti et al., 1993 
aa 180 Val->Iso sporadic CJD Hitoshi et al., 1993; Tateishi and 
Kitamoto, 1995 
Diouhy et al., 1992; Tagliavini et 
aa 198 Phe->Ser familial GSS al., 1994; Hsiao et cii., 1992; 
Tagliavini et al., 1991 
aa 200 Glu->Lys familial CJD Goldfarb et al., 1990; Goldfarb et 
al., 1991b; Bertoni et al., 1992 
aa 210 Val->Iso familial CJD Pocchiari et al., 1993; Ripoll et al., 
1993 
aa 217 Gln->Arg familial GSS Hsiao et al., 1992; Tagliavini et 
al., 1994 




aa 117 (no aa change)  Gajdusek, 1993 
aa 129 Met->Val see text Palmer et al., 1991; De Silva et al., 
1994 
octapeptide repeat Palmer et al., 1993; Pocchiari et 
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Figure 1.3 Pathogenic mutations and polymorphisms of PrP 
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great difficulty. Experimental studies on the pathogenesis of TSEs have 
been facilitated by the use of scrapie in rodents as a model. The 
incubation period and the time course of the disease can vary 
substantially depending on four main factors: the dose and the site of 
infection, the genotype of the mouse, and the strain of the infectious 
agent. 
There is a different effective dose for each route of infection and the 
incubation period varies considerably with the, dose of the agent 
(Kimberlin and Walker, 1979b; Kimberlin and Walker, 1978). 
Administration of the agent directly to the CNS - intraspinal (i.s.) and 
intracerebral (i.c.) injection - is more effective than the peripheral routes 
of infection - subcutaneous (s.c.), intraperitonial (i.p.) and intravenous 
(i.v.) (Kimberlin et al., 1987b; Kimberlin and Walker, 1988a). The relative 
efficiencies of infection are i.v.>i.p.>s.c. The difference between i.v and 
s.c. is approximately 3,500-fold and between s.c. and i.c. 10,000-fold 
(Kimberlin and Walker, 1989a; Kimberlin and Walker, 1979b). 
The peripheral routes of infection have been used to establish the 
dynamics of agent replication in different tissues before the invasion of 
the central nervous system. The involvement of the lymphoreticular 
system (LRS) was established in the 1960s, when it was demonstrated 
that following subcutaneous (s.c.) injection the first tissue to become 
infected is the spleen. The agent spreads to other tissues of the LRS, 
including the lymph nodes, thymus and submaxillary salivary glands 
(Eklund et al., 1967). Subsequent studies confirmed this observation and 
demonstrated that in natural scrapie of sheep, the infection of the LRS 
precedes neural infection (Hadlow et al., 1982). 
The importance of the spleen was demonstrated in splenectomised, 
or genetically asplenic mice, by the prolongation of the incubation 
periods after intraperitonial (i.p.) injection (Fraser and Dickinson, 1970; 
Fraser and Dickinson, 1978; Kimberlin 1989a). However, the absence of 
the spleen did not affect all peripheral routes. When mice were infected 
by the oral route (intragastrically), neuroinvasion was proposed to occur 
through nerve endings in the gut or through Peyer's patches and the 
incubation period was shown to be unaffected by splenectomy 
(Kimberlin and Walker, 1989b). Upon s.c. infection of mink with TME 
the peripheral spread was confined to the lymph nodes and infectivity 
was detected in the rest of the LRS only after establishment of infection 
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in the CNS (Hadlow et al., 1987). The efficiency of the s.c. route depends 
on the exact site of injection (Kimberlin and Walker, 1979b). 
Intravenous (i.v.) injection is the most effective peripheral route, 
producing the shortest incubation periods, but there is no evidence 
supporting a direct infection of the CNS by a haematogenous route 
(Kimberlin and Walker, 1978). Capillary endothelial cells and liver show 
relatively high levels of infectivity immediately after i.v. infection, but 
they do not appear to sustain the infectious agent (Milison et al., 1979; 
Diringer, 1984). 
Although peripheral routes seem to have different efficiencies of 
infection with a specific scrapie strain (139A) the dose-response curves 
are similar, suggesting that pathogenesis follows common pathways 
(Kimberlin and Walker, 1978; Kimberlin and Walker, 1979b). Irradiation 
of mice had no effect on the pathogenesis, indicating that the cells of the 
LRS involved in the infectious process are probably long-lived and non-
dividing (Fraser and Farquhar, 1987; Scott, 1993). Infectivity spreads from 
spleen and visceral lymph nodes along visceral autonomic nerves to the 
mid-thoracic cord (Kimberlin and Walker, 1988a). Direct spreading 
through nerve endings is also possible in the gut (Kimberlin and 
Walker, 1989b) and probably the skin, after scarification prior to contact 
with the infectious agent (Scott, 1993). 
Once the agent has invaded the thoracic cord, there is a spread of 
the infection in the brain to specific, yet uncharacterised areas, termed 
clinical target areas (CTA) (Kimberlin and Walker, 1983). It has been 
shown that direct inoculation of the spinal cord produces shorter 
incubation periods than i.c. injection. This finding suggests that 
infectivity can target quicker the CTA by the spinal cord inervasions, 
than inoculation at a specific site in the brain (Kimberlin et al., 1987b). 
This finding suggests that there are restrictions on the spread of the 
agent, depending on the different types of connecting neurons 
(Kimberlin and Walker, 1988a; Kimberlin and Walker, 1988b). 
Stereotaxic injection into various regions of the brain with different 
scrapie strains demonstrated differences in the incubation periods and 
lesion profiles, supporting the idea that infection in the CNS is restricted 
to specific neuroanatomical pathways (Kim et al., 1987; Kim et al., 1990b; 
Kim et al., 1990a). Furthermore, ocular inoculation has demonstrated 
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that both pathology and infectivity can be targeted to neuroanatomical 
projections of the retina (Fraser and Dickinson, 1985). 
The spread of infection depends on the site of entry of the 
infectious agent, which determines the pathway by which the CTA are 
reached, probably involving complex neuron-to-neuron steps 
(Kimberlin, 1990b). Splenectomy does not effect the i.c. route (Kimberlin 
and Walker, 1988a). The rate of the spread of infectivity in the CNS was 
estimated to be about 0.5-2 mm/day, which is much slower than that of 
conventional slow 'neuronal' viruses but similar to slow intra-axonal 
transport of cytoskeletal proteins (Kimberlin and Walker, 1988a; 
Kimberlin and Walker, 1988b). The suggestion that the number of 
scrapie permissive cells, or CTA, is limited is supported by the 
competition between strains after i.c. or i.p. coinjection (Dickinson et al., 
1972; Dickinson and Outram, 1979). 
1.10 Strain variation and mutatipn of TSE agents and interaction 
with the host 
Experimental transmission of scrapie to goats produced the first 
evidence that there were distinct strains of the infectious agent (Pattison 
and Millson, 1961; Pattison and Millson, 1962). Since then, over 20 
strains have been isolated in experimental animals (mainly mice and 
hamsters) by serial passage of infectious agent from different sources, 
including a sheep, goats, cattle and mink (Bruce, 1993; Bessen and Marsh, 
1992). The strains are distinguishable primarily on the basis of their 
incubation periods, in mice of a defined genotype. This discrimination is 
confirmed by the type, distribution and severity of neuropathological 
changes (Kascsak et al., 1991; Bruce and Fraser, 1991). The pattern and 
degree of vacuolar degeneration of the neuropil is scored from coded 
sections in nine grey matter and three white matter brain areas to 
construct a 'lesion profile', characteristic for each strain (Fraser and 
Dickinson, 1973; Bruce and Fraser, 1991; Bruce, 1993). The strains also 
differ in other respects, such as the extent of cerebral amyloidosis 
produced, their neuroinvasiveness after peripheral infection, their 
clinical characteristics and their ease of transmission between species. 
Apart from the distinct phenotypic properties, the strains differ in 
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biochemical and molecular properties including resistance to thermal 
inactivation, the morphology of SAF, the sensitivity of PrPSC to 
proteinase K digestion and the molecular weight of PrPSC (Bruce and 
Dickinson, 1987; Kascsak et al., 1991; Bruce and Fraser, 1991; Bessen and 
Marsh, 1992). For example, the two strains of TME, hyper (HY) and 
drowsy (DY), exhibit differences in certain properties of PrP 5C, (PrPTME), 
such as, sedimentation rate in the presence of N-laurylsarcosine, 
sensitivity to proteinase K digestion, solubility in detergent solutions, 
electrophoretic migration and immunoreactivity (Bessen and Marsh, 
1992). 
The differences in the pattern of degeneration in the brain between 
the strains (established in mice) suggests that they have different abilities 
to recognise and spread in particular sets of neurons (Bruce, 1993; 
DeArmond et al., 1993; Hecker et al., 1992). Apart from the characteristic 
'lesion profile', the differences in 'pathology between strains can be 
demonstrated more clearly by the regional distribution of PrP 5 C. 
Immunostaining for PrP 5c can reveal differences even within a certain 
brain region, for example, strains 87V, 79A, ME7 and 22A induce 
completely different distributions of PrP 5c in mouse hippocampus 
(Bruce, 1993). The detection of PrP 5c in brain sections, as well as the 
kinetics and patterns of its accumulation, were facilitated by the histoblot 
method (Taraboulos et al., 1992a; DeArmond et al., 1993; Hecker et al., 
1992). In these studies it was shown that Sc237 (or 263K), 139H and ME7H 
strains show distinct - although overlapping at some regions - patterns 
of PrP 5c accumulation, suggesting that some neurons are capable of 
supporting replication of different strains, or, the same region might 
contain neurons with different susceptibilities to different strains 
(Hecker et al., 1992; DeArmond et al., 1993). 
When a strain is passaged under standard conditions of dose and 
route of infection, it appears to have always. a reproducible incubation 
period in each of three Sinc genotypes. For example, 22A strain has a 
shorter incubation period in SincP 7 than in Sinc 7; in heterozygotes the 
incubation period is even longer. For the ME7 strain, the incubation 
period is shorter in Sinc 7 than SincP 7 homozygotes, but in 
Sinc 7 /SincP7 heterozygotes the incubation period falls between those 
observed for the homozygous genotypes (Bruce, 1993; Bruce and Fraser, 
1991; Bruce et al., 1991). 
9.01 
Some strains, such as 139A and 22C, retain the same properties 
when passaged through different host Sinc genotypes, while others, for 
example 22A, change. This change does not always happen at the first 
passage to the new genotype. With some strains, a gradual, reproducible 
selection of a new strain with a shorter incubation period has been 
observed after passage to a new Sinc genotype (Bruce and Dickinson, 
1987; Bruce and Fraser, 1991). Other strains, for example 87A, are stable 
when passaged at a low dose in the same genotype, but mutate if 
passaged at a higher dose. The new strain, which exhibits shorter 
incubation periods, retains its characteristics, even when passaged at a 
high dose (Bruce and Dickinson, 1987; Bruce and Fraser, 1991). 
The strains also appear to behave differently when transmitted to 
different species (Kimberlin et al., 1989; Kimberlin et al., 1987a; Bruce, 
1993). Some remain completely unchanged, some are modified giving 
rise to new strains that remain stable in subsequent passages, while some 
change only after passage through certain species. 
In summary, different strains are characterised by differences in 
pathogeneisity and host pathology. The Sinc genotype of the mouse host 
affects the incubation time of different strains in different ways, and in 
some cases brings about changes in the properties of the strain. Similar 
effects are observed on passage through different species. 
1.11 The species barrier 
When the infectious agent is passaged initially to a new species, a 
prolonged incubation period (usually accompanied by variations in the 
symptoms and histopathology) is observed, a phenomenon termed the 
species barrier (Pattison, 1965; Dickinson, 1976; Kimberlin and Walker, 
1979a). However, the infectious agent can overcome the species barrier 
and on subsequent passages the incubation .period decreases, until it 
stabilises for that species. Differences in the pathogenesis between the 
first and subsequent passages have commonly been observed. Usually 
the incubation period is longer after i.p. infection than after i.c. (see 
section 1.9), but in some interspecies passages the incubation periods for 
the two routes are similar (Bruce, .1993). 
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Passage of the infectious agent to a new species always results in an 
(initially) prolonged incubation period, even when the strain properties 
remain the same (Kimberlin et al., 1987a; Kimberlin et al., 1989; Bruce, 
1993). This observation suggests that the host genome has a definite 
influence on the incoming agent. Experimentation involving transgenic 
mice has provided more evidence on this issue (see section 1.12.1). 
1. 12 In vivo and in vitro models of TSEs 
1.12.1 In vivo models of TSEs 
Studies with transgenic mice have elucidated the role of the PrP 
gene in several aspects of the disease. Transgenic mice harbouring 
various numbers of copies of the hamster PrP cosmid clone (cosHaPrP) 
were shown to be susceptible to hamster-adapted scrapie (Sc237 strain, of 
the same origin as 263K), while non-transgenic mice were resistant (Scott 
et al., 1989). Tg(cosHaPrP)81 mice containing 30-50 copies of the cosmid 
transgene showed an incubation period similar to that observed in 
hamsters (70-75 days). Tg(cosHaPrP)71 mice, containing 4-8 copies were 
also susceptible, but exhibited longer incubation periods (170 days). 
Neuropathology in these transgenic mice was characteristic of that 
observed in hamsters and hamster PrPsc was present in their brains. 
Both transgenic and non-transgenic mice were susceptible to mouse-
adapted scrapie (Rocky Mountain Laboratory (RML) strain). However, 
problems were encountered with breeding transgenic lines generated 
with a minigene construct (based on the hamster PrP open reading 
frame) and the only established colony failed to express hamster PrPc 
(HaPrPC) (Scott et al., 1989). The production of more Tg(cosHaPrP) lines 
established an inverse correlation between the incubation period and the 
amount of HaPrPC produced (Prusiner et al., 1990). The titres in the 
brains of the transgenic mice were independent of the incubation 
periods. Inoculation of these mice with the RML strain produced mouse-
adapted scrapie that could be passaged to mice but not to hamsters; 
neuropathology was characteristic of mice. Inoculation with the Sc237 
strain produced hamster-adapted scrapie that could be transmitted to 
hamsters but not mice. Furthermore, when these Tg(cosHaPrP) mice 
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were inoculated with different strains of hamster-adapted scrapie (Sc237, 
139H and ME7I-I), the properties of the particular strains were retained 
(Hecker et al., 1992; DeArmond et al., 1993) (see also section 1.10). These 
experiments demonstrate the importance of the PrP gene in controlling 
the incubation period, susceptibility and species barrier of the disease. 
Transgenic mice carrying the mouse PrP transgene (Prn-p 1 allele) 
modified to contain the GSS mutation (codon 102 Pro-> Leu in human, 
codon 101 in mice) have been generated (Hsiao et al., 1991). High-
expressing transgenic Tg(GSSPrP) lines, or Tg(MoPrP-P1O1L)H, showing 
approximately 8-fold overexpression of the transgene, developed 
spontaneous neurodegeneration and pathology indistinguishable from 
mouse-scrapie, but detection of PrPSC was very rare (Hsiao et al., 1991; 
Hsiao et al., 1994). A low expressing line (2-fold higher than non-
transgenic mice), designated Tg(GSSPrP)196, failed to develop 
spontaneous disease (Hsiao et al., 1994). Subsequently, some Tg196 mice 
inoculated with brain homogenates from symptomatic Tg(MoPrP -
P101L)H mice developed neurologic dysfunction between 226 and 716 
days and the infectious agent from these mice was shown to be 
transmitted again to 83% of inoculated Tg196. Diseased Tg196 showed 
characteristic spongiform changes in the brain but no PrPS C 
accumulation. The agent from Tg(MoPrP-P1O1L)H symptomatic mice 
was also transmissible to hamsters but not to Swiss CD-i mice and PrP 5c 
was detected in some of the infected hamster brains. These experiments 
suggest that there are other factors apart from the PrP gene itself 
influencing the susceptibility and the course of the disease. 
Two different strategies were used to disrupt the PrP gene by 
insertion of the neomycin resistance gene (Bueler et al., 1992; Manson et 
al., 1994). These mice, designated Pm-p 0 ! 0 (or PrP null), had normal 
development and no obvious abnormal phenotype (Bueler et al., 1992; 
Manson et al., 1994). It was shown that they were resistant to infection by 
mouse-adapted scrapie, but became susceptible to hamster-adapted 
scrapie after introduction of hamster PrP transgenes (Bueler et al., 1993; 
Prusiner et al., 1993). These findings further demonstrated the 
importance of the PrP protein in disease susceptibility. Subsequent 
studies, based on electrophysiological techniques, revealed that PrP null 
mice have impairments in long term potentiation (LTP) and weakened 
GABAA (y-aminobutyric acid type A) receptor-mediated fast synaptic 
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inhibition in the hippocampus (Collinge et al., 1994). This phenotype 
was rescued by high, but not low, expression of a human PrP trangene 
(Whittington et al., 1995). This deficit was not observed by another group 
(Lledo et al., 1996), but has been independently reproduced (Manson et 
al., 1995). 
Studies with transgenic mice expressing chimeric PrP transgenes 
where different regions of the mouse PrP ORF were replaced with 
hamster equivalents (Scott et al., 1992), demonstrated that a few amino 
acid changes in the primary sequence of the PrP protein produced by the 
transgene influence the susceptibility of the host to mouse- or hamster-
adapted scrapie (Scott et al., 1993). Tg(MH2M PrP) mice, in which mouse 
amino acids 94 to 188 were replaced with the hamster sequence (5 
hamster specific amino acid substitutions) were susceptible to both RML 
and Sc237. Tg(MHM2 PrP) mice, with only two hamster specific 
substitutions between amino acids 94 and 131, were susceptible to RML 
only. Terminal infection of Tg(MH2M PrP) mice was associated with the 
deposition of chimeric MH2M PrPSc in the brain and subsequent 
transmission of infectivity was more efficient in transgenic Tg(MH2M 
PrP) mice, but also possible in both non-transgenic mice and hamsters. 
These studies support the idea that an hornophilic interaction between 
PrPc of the host and PrP 5c of the inoculum is necessary for efficient 
infection. 
Trangenic mice generated with a chimeric PrP gene, where mouse 
amino acids 96 to 167 were replaced by the human sequence (9 human 
specific amino acid substitutions), designated Tg(MHu2M PrP), were 
susceptible to inoculation with infectious brain homogenates from CJD 
patients, but only approximately 10% of transgenic mice expressing the 
human PrP, designated Tg(HuPrP) and non-transgenic mice developed 
neurologic dysfunction (Telling et al., 1994). However, when the HuPrP 
transgene was combined with the homozygous mouse PrP null 
mutation, the mice became susceptible to human infectious agent, 
suggesting that the inhibition of transmission observed previously was 
due to the endogenous mouse PrPc (Telling et al., 1995). The 
susceptibility of Tg(MHu2M) was only ,  slightly increased (Telling et al., 
1995). These findings led to the hypothesis that another molecule, a 
putative protein X, binds to a region of PrPc (probably the C-terminal) 
and facilitates the interaction with PrPSc, while the central region of PrPC 
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(including codons 96 to 167) interacts directly with PrPSc. The binding of 
this protein X to PrPC would be promoted when the two proteins are 
from the same species. Therefore, in Tg(HuPrP) transgenic mice, the 
endogenous mouse PrPc would interact with the mouse protein X 
inhibiting its binding to human PrP produced by the transgene and 
subsequently to PrPSC in the inoculum (Telling et al., 1995). 
However, two lines of the Tg(HuPrP) mice were reported to be 
susceptible to a single isolate of CJD and to two inherited TSEs (one with 
a 144-base pair insertional mutation in PRNP and FF1) by another 
research group (Collinge et al., 1995), but the incubation periods were 
longer than those observed in mice expressing only human PrP (null 
background). These mice were shown to produce human PrPSC. 
Therefore, their ability to produce human PrP 5C after challenge with the 
BSE infectious agent was assessed. In the Tg(HuPrP) mice (carrying also 
the endogenous MoPrP gene) only mouse PrPsc was detected, but 
confirmation that these mice are not producing any human PrP 5C, by 
inoculations of brain homogenates into mice expressing only HuPrP, are 
still in progress. In mice expressing only the human PrP, no human 
PrPSc production was detected at 264 days after inoculation (Collinge et 
al., 1995). However, it is too early to conclude that these mice are not 
susceptible to the BSE infectious agent. 
Two PrP gene alleles, Prnpa  and  Prnpb,  have been correlated with 
short and long incubation periods respectively, following infection with 
different strains, suggesting that the PrP sequence of the host influences 
susceptibility to mouse scrapie (see section 1.8). When heterozygous 
mice Prnpa/Prnp 1) were inoculated with the Chandler scrapie strain the 
incubation periods were longer than those observed in homozygous 
Prnpa mice (Carlson et al., 1986; Carlson et al., 1989). Homozygous Pm-
p a mice carrying several copies of a Pmn-p 1 transgene exhibited 
unexpectedly shorter incubation periods than non-transgenic controls 
(Westaway et al., 1991). In an attempt to elucidate these observations, 
three different scrapie strains were tested in conjuction with a range of 
host genotypes expressing different ratios of Prnpa  and  Prnpb  alleles 
(Carlson et al., 1994). Congenic mice, PrP null mice (Bueler et al., 1992) 
and transgenic mice carrying various copies of the Prnpb  allele as well 
as Fl hybrids between the different mouse strains were used in these 
experiments. It was revealed that the level of PrPc produced by the Pm- 
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pa allele (MoPrP-A) was responsible for the incubation periods produced 
with the RML strain. Incubation periods were inversely related to the 
amount of MoPrP-A. Increase of MoPrP-B also resulted in shortening of 
the incubation periods, but to a lesser extent. In contrast, MoPrP-A 
expression had an inhibiting effect on transmission of the 22A and 87V 
isolates. Increasing MoPrP-A was related to increase of incubation 
periods, while the reverse correlation was observed with MoPrP-B. 
MoPrP-A expression conferred resistance to the 87V strain, regardless of 
MoPrP-B expression. These results suggest that allotypic interactions 
between PrPc of the host and PrPSc of the inoculum influence the 
efficiency of transmission and the incubation period. Furthermore, the 
neuropathological features and PrPsc accumulation were characteristic 
for each isolate. However, differences observed in mice with the same 
Pm-p genotype inoculated by the 87V isolate suggested that a genetic 
locus distinct from Pm-p could be involved. 
The transgenes used in all the transgenic experiments were based 
on cosmid clones (the mouse or the hamster), which were modified 
appropriately to contain cloning cassettes so as to permit the replacement 
of different ORF fragments. Because other DNA sequences apart from 
PrP gene were included in these transgenes, the involvement of other 
genetic factors in controlling several aspects of the disease could not be 
ruled out. This possibility was not further investigated since attempts to 
generate transgenic mice by using a hamster PrP ORF based construct 
(minigene) failed, suggesting possible absence of sequences necessary for 
appropriate PrP expression (Scott et al., 1989). 
In all the transgenic experiments, the mice contained multiple 
copies of the transgene and sometimes exhibited high levels of PrPc 
expression. Spontaneous disease developed in some older animals 
nd 60 copies of the Syrian hamster cosmid transgene, 36 carrying 120 a  
and 31 copies of the Prnpb mouse cosmid transgene and high copy 
number of a sheep PrP cosmid transgene. Disease was not observed in 
animals with low transgene copy number (Westaway et al., 1994a). The 
pathogenic changes included necrotising myopathy of the skeletal 
muscle, demyelination of the sciatic nerve and spongiform degeneration 
of the CNS. Low levels of proteinase K resistant PrP detected in a few 
samples, but were also detected in some young animals without any 
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symptoms of the disease, suggesting that the neuromyopathy was not 
due to TSE. 
1.12.2 In vitro models of TSEs 
Cell culture models of TSEs have provided information on the 
biosynthesis and metabolism of PrPC and PrPSc, the conversion of PrPC to 
PrPSC, agent replication, species specificity and strain variation. 
A rat pheochromocytoma cell line (PC12) was shown to be able to 
sustain scrapie replication (strain 139A) when differentiated by addition 
of nerve growth factor (NGF) (Rubenstein et al., 1984). NGF-treated PC12 
cells develop a neuron-like morphology, stop dividing and show an 
induction of PrP mRNA expression (Wion et al., 1988), but the difficulty 
of maintaining them has limited their use. Dose-dependent decrease of 
cholinergic enzyme activities (but not adrenergic) was demonstrated in 
139A-infected PC12 cells (Rubenstein et al., 1991). Strain variation was 
also shown in PC12 cells (Rubenstein et al., 1992; Rubenstein et al., 1994). 
Agent replication was much higher with the 139A strain than with ME7 
(both mouse-adapted strains). No replication of the hamster-adapted 
263K strain nor, paradoxically, of the rat-adapted 139R was observed. 
Infection of a mouse neuroblastoma cell line (N2a) with mouse-
adapted scrapie led to the establishment of persistently infected cells 
(Race et al., 1987; Butler et al., 1988). However, it was demonstrated that 
infectivity could be lost, especially under conditions of stress (Butler et 
al., 1988). Another persistently infected cell line was established, 
designated HaB, derived from infected hamster brain (Taraboulos et al., 
1990b). Study of the biosynthesis and metabolism of PrPC and PrPSc was 
based on these cell lines and uninfected N2a. It was shown that PrPc 
acquires its glycophosphatidylinositol anchor in the endoplasmic 
reticulum, as well as high mannose glycans which are converted to 
more complex glycans in the Golgi apparatus (Caughey et al., 1989). 
Mature PrPc is attached to the membrane by a glycophosphatidylinositol 
moiety and can be released by treatment with proteases or PIPLC 
(Caughey et al., 1990). The half life of PrPc was shown to be 
approximately 3-6 hours (Caughey et al., 1989). In contrast, PrPSc was 
shown to be proteinase K and PIPLC resistant and exhibited a very slow 
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turnover (half life over 15 hours) (Caughey et al., 1989; Caughey et al., 
1990). It was demonstrated that the conversion of PrPC to PrPSC is a post-
translational change that probably occurs on the plasma membrane or at 
the endocytic pathway before exposure to lysosomal enzymes 
(Taraboulos et al., 1992b; Borchelt et al., 1992). An N-terminal truncation 
of PrP5c was observed after exposure to endosomal or lysosomal 
proteases (Caughey et al., 1991). The site of accumulation of PrPSc 
appeared be in the cytoplasm (Taraboulos et al., 1990b). In subsequent 
studies it was proposed that PrP 5c accumulated in lysosomes (Taraboulos 
et al., 1992b). No differences in the biosynthesis of the two isoforms has 
been detected (Caughey, 1993; Caughey et al., 1989). 
Several studies involving expression of recombinant PrP molecules 
in cell culture facilitated the study of the role of PrP mutations in PrP 
biosynthesis. Also, the importance of certain regions and mutations of 
PrP for the conversion and the species barrier was investigated. A series 
of different constructs was generated for this purpose; expression was 
carried out in insect cells and a range of mammalian cells (Scott et al., 
1988; Rogers et al., 1991; Caughey et al., 1988b; Scott et al., 1992; Rogers et 
al., 1993; Priola et al., 1994; Chesebro et al., 1993; Borchelt et al., 1993; 
Priola et al., 1995). Neuronal cell lines (especially mouse neuroblastoma 
cells) are used regularly for PrP expression and detection of PrP protein is 
done usually by immunoprecipitations. In the constructs used no PrP 
regulatory sequences were included (ORF-based constructs) and the 
expression of PrP was driven usually from strong viral promoters. The 
use of these constructs did not aid the exploration of the significance of 
untranslated and flanking regions of the PrP gene. Initial experiments 
showed that very high PrP mRNA expression was necessary to generate 
detectable levels of PrPc. The use of recombinant vaccinia virus 
expression systems, retroviral vectors and stable transfections in 
conjunction with the use of immunoprecipitation to detect PrP made it 
possible to overcome this problem. Furthermore, it was noted that PrP 
processing can differ depending on the cell line (Scott et al., 1988). 
In order to investigate the regions that feature in the conversion of 
PrPc to PrPsc, modified constructs based on the chimeric mouse PrP gene 
MHM2 (Rogers et al., 1991; Scott et al., 1992) were generated (Rogers et al., 
1993; Chesebro et al., 1993; Taraboulos et al., 1990a). MHM2 PrP protein 
contains a hamster specific epitope that can be recognised by the 
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monoclonal antibody 3F4 (Rogers et aL, 1991; Scott et al., 1992). It can 
therefore be distinguished from endogenous mouse PrPC and P rPSC 
produced in uninfected and infected N2a cells. It was shown that this 
chimeric PrP could undergo conversion to the proteinase K resistant 
form when expressed in scrapie infected N2a cells,, while another 
chimeric PrP produced from the H3M construct, in which codons 50 to 
188 of the mouse PrP are replaced by the hamster sequence, could not 
(Scott et al., 1992). This result facilitated the identification of regions 
important for species specificity. Several modified MHM2 constructs 
were made and their ability to produce PrPC that could be converted to 
PrPSc was tested in infected N2a cells. Deletion of amino acids 23 to 88, 
deletion of the octapeptide repeat region, addition of 1, 2, 4 and 6 
octapeptide repeats and deletion of the GPI anchor did not affect the 
conversion of PrP to a proteinase K resistant state (Rogers et al., 1993). In 
addition, removal of the glycosylation sites did not affect conversion 
(Taraboulos et al., 1990a). Cell lines expressing mutant hamster PrP (GSS 
102 mutation) did not cause conversion to PrPsc and expression of 
hamster PrP in N2a cells did not confer susceptibility to the hamster-
adapted 263K stain (Chesebro et al., 1993), in contrast to the results 
obtained from transgenic experimentation. 
Initial attempts to convert PrPc to the proteinase K resistant 
isoform in cell-free systems failed (Raeber et al., 1992). Recently it was 
demonstrated that this conversion is possible after partial denaturation 
of PrPc in guanidine-HC1 and incubation with PrP 5c (Kocisko et al., 1994). 
The two strains of hamster-adapted TME that exhibit different proteinase 
K profiles (see 1.10), were shown to retain this strain specificity in a cell-
free conversion reaction (Bessen et al., 1995). Furthermore, the 
conversion was shown to be influenced by the species barrier between 
mouse and hamster (Kocisko et al., 1995), consistent with the results 
from the in vivo studies. 
Studies in cell culture have demonstrated that sulfated polyanions 
can inhibit PrPSC accumulation (Caughey, 1993; Caughey and Raymond, 
1993). For example, Congo red (a disulfonated polyanion) has been 
shown to inhibit proteinase K-resistant PrP formation in scrapie-infected 
neuroblastoma cells (Caughey and Raymond, 1993; Caughey et al., 1993; 
Caughey and Race, 1992). It has also been suggested that endogenous 
highly sulfated glycosaminoglycans (GAGs) are involved in the 
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conversion of PrPC to PrPSC (Priola and Caughey, 1994; Caughey and 
Raymond, 1993; Caughey, 1993). Possibly GAGs guide and stabilise the 
interaction between PrPC and PrP. Therefore, it has been hypothesised 
that sulfated polyanions bind to PrPc and/or PrPSc and inhibit an 
interaction with cellular GAGs, which is crucial for the conversion of 
PrPc to PrPSc (Caughey, 1993; Caughey and Raymond, 1993; Priola and 
Caughey, 1994). These findings suggest that sulfated glycans could 
potentially provide means of therapeutic intervention in human TSEs 
(Caughey, 1993; Caughey and Raymond, 1993). 
1.13 Hypotheses on the nature and replication of the TSE infectious 
agent 
It has been proposed that the infectious agent is devoid of nucleic 
acid and that it consists of a proteinaceous infectious particle, termed 
'prion' (Prusiner, 1982) (see also section 1.4). The 'protein only', or 
'prion hypothesis' is supported by a series of findings: PrP 5c is the major 
component of the infectious agent and it is related to infectious titres, no 
nucleic acid has been identified and infectivity is resistant to procedures 
that modify, mutate, or destroy nucleic acids (section 1.4). Also, the 
importance of PrP in all aspects of the disease has been proved through 
genetic studies and the use of in vivo and in vitro models (sections 1.8, 
1.12). It was therefore suggested that the infectious agent consists of an 
abnormal monomeric prion protein (PrPSc) which combines with a 
normal host protein (PrPc) to generate an heterodimer. This would lead 
to the conversion of the normal protein to the abnormal form, followed 
by separation of the proteins and formation of monomeric infectious 
particles that could convert more normal protein (Prusiner, 1982; 
Prusiner, 1991). Another model suggests that disease depends on a 
nucleation mechanism where PrPSc is a 'seed' for a polymerisation 
reaction by which new PrPc molecules are recruited and converted in 
more PrP5c molecules (Kocisko et al., 1994). This reaction has been 
observed in amyloid fibril formation by other proteins (Jarrett and 
Lansbury, 1993), but it is known that TSEs are not always associated with 
the formation of PrP5c and amyloid plaques (sections 1.2, 1.12.1). 
0. 
However, the existence of a wide variety of infectious agent strains 
that can retain their characteristics through passaging in different hosts 
and can 'mutate' when passaged in the same host (Bruce et al., 1991; 
Bruce and Fraser, 1991) (see also section 1.10) brought about an 
alternative theory (the 'virino hypothesis'), which proposes that the 
infectious agent has its own genome and PrPc could act as a protector 
or/and a receptor (Hope and Baybutt, 1991; Aiken and Marsh, 1990; Bruce 
and Dickinson, 1987; Bruce and Fraser, 1991). Reasons why the putative 
nucleic acid has not yet been identified could be that it is possibly 
extremely small in size, well protected, of very low abundance, or host 
encoded. 
A model attempting to combine the controversial features of the 
different hypotheses has been proposed (Weissmann, 1991). This model 
suggests that the infectious agent (holoprion) consists of two 
components: PrPSc (apoprion), which could transmit the disease and 
initiate the pathogenic process itself and a genetic component (coprion), 
which could modulate the properties of PrPsc and determine the strain 
specific characteristics. 
Strain diversity has also been proposed to reflect variations in the 
PrP protein due to different glycosylation patterns (Endo et al., 1989; 
Prusiner and DeArmond, 1994; Weissmann et al., 1993) or different 
structural conformations (Huang et al., 1994; Stahl et al., 1993; Prusiner, 
1991; Prusiner, 1993b) (section 1.7.2), possibly combined with a selective 
permissiveness of various cell types to certain PrP isoforms (Hecker et 
al., 1992; Prusiner and DeArmond, 1994; Weissmann et al., 1993). These 
theories are currently being tested. 
Recently, it has been proposed that another protein might be 
necessary for the interaction between PrPc and PrPSc (Telling et al., 1995). 
This protein X, encoded by the host, would interact with a region of PrPc. 
A different part of PrPc would interact with PrPSc and the formation of 
the complex would promote the conversion of PrPc to PrPSc  (section 
1.12.1). 
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1.14 Aims and objectives 
Previously, PrP transgenic animals were employed to demonstrate 
that a 40 kb cosmid clone, comprising of the entire hamster PrP gene and 
flanking sequences, could confer susceptibility to hamster TSE and 
model all aspects of the disease, including the incubation periods and 
lesion profiles produced by different strains (Scott et al., 1989; Prusiner et 
al., 1990; Hecker et al., 1992) (section 1.12.1). Hamster PrP expression was 
driven by its own promoter and therefore directed to all tissues in which 
PrP is normally expressed. Investigation of the role of limited and 
specific PrP expression in controlling susceptibility, pathogenesis, and 
the species barrier, can be achieved only by directing expression of a PrP 
transgene to neurons in the brain and furthermore, to restricted areas of 
the brain. Also, in order to eliminate the contribution of any flanking 
sequences present in previously tested transgenes to the disease process, 
the use of the hamster PrP open reading frame (HaPrP ORF) as a 
minigene was considered for generation of transgenic mice. The main 
questions to be addressed were whether the PrP ORF could confer 
susceptibility, whether brain specific neuronal expression could confer 
susceptibility and whether region specific expression could confer 
region-specific susceptibility to the disease. 
A previous attempt to express a PrP minigene had failed, but it was 
not clear whether that was due to the absence of adequate regulatory 
sequences, the influence of the integration site, or possible methylation 
of the transgene (Scott et al., 1989) (see also section 1.12.1). Generation of 
multiple transgenic lines, together with the use of a characterised 
heterologous promoter and polyadenylation signal sequence, could help 
overcome that problem. 
It was decided to use the neuron specific enolase (NSE) promoter 
for neuron specific expression and to further restrict expression to 
dopaminergic and adrenergic pathways by using the tyrosine hydroxylase 
(TH) promoter (section 2.2). 
Apart from neurons, some PrP expression is detected in glial cells 
and it has been demonstrated PrP 5c also accumulates in astrocytes and 
microglial cells, suggesting a possible role of these cells in the 
pathogenesis of the disease. Also, propagation of infectivity in the 
lymphoreticular system and particularly in the spleen seems to be 
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important for the establishment of the disease (section 1.9). Therefore, 
neuron-specific expression of hamster PrP could possibly be inadequate 
for replication of the hamster agent, or for PrP 5C accumulation in the 
brain. It would be interesting to test whether glial cells are crucial for 
PrPsc formation and whether infectivity would be detected in the spleen 
after infection with the hamster agent. Also, the effectiveness of 
different routes of infection (direct injection in the central nervous 
system, or peripheral inoculation) could be determined. It is suspected 
that intracerebral, intrasciatic, or intraocular injection might overcome 
resistance to infection by peripheral routes. 
In transgenic mice with hamster PrP expression in restricted 
regions of the brain some insight may be gained into the behaviour of 
the infectious agent and its interaction with PrPC produced from the 
transgene. If the hamster agent was introduced stereotactically into the 
brain in a non-susceptible area (no hamster PrP expression), the ability of 
the agent to cross that area and target susceptible areas could be assessed. 
Introducing the agent into a susceptible area by stereotactic injection 
would test whether it would remain in that area or whether it would 
spread to unsusceptible areas. Also, if HaPrPsc spread to areas of the 
brain in which HaPrPc was not expressed it would be interesting to see 
whether these areas would degenerate. If degeneration were to occur in 
regions that do not express hamster PrP but express endogenous mouse 
PrP, the rate of degeneration might differ in comparison to susceptible 
parts of the brain. This suggestion is supported by previous studies 
showing that the species barrier can be crossed (section 1.9, 1.10) and 
degeneration can occur, but only after very prolonged incubation periods 
(section 1.10). Another question that could be addressed is whether the 
lesion profiles of different hamster-adapted strains are affected by the 
restricted expression of hamster PrPc. 
If pathology appeared to be restricted to susceptible areas only, these 
areas would become effectively ablated. The role of the ablated brain 
regions could be investigated by phenotype analysis. This experiment 
could have more general application. The PrP gene could be linked to 
different promoters giving different expression patterns. Regions 
expressing PrP could be ablated by inoculation with the agent. One 
advantage of this approach is that the ablation could be at any chosen 
point in development. 
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CHAPTER 2 
Generation and analysis of transgenic mice 
expressing the hamster PrP gene 
2.1 Transgenic technology 
Transgenic mice were first generated in the early 1980's; since then 
their use in biological research has increased exponentially (Aguzzi et 
al., 1994). This technology has been used to create animal models of 
human diseases and assess the role of specific genes (or parts of genes) in 
vivo (Palmiter and Brinster, 1986; Aguzzi et al., 1994). Transgenic mice 
are generated by microinjection of a DNA construct into the pronuclei of 
fertilised eggs, which are then reimplanted into a foster mother and 
allowed to develop to term (Palmiter and Brinster, 1986). The DNA 
generally integrates at a single, random chrornosomal site and, when 
multiple copies integrate, they usually form a tandem head-to tail array. 
In most cases this foreign DNA (transgene) is stably transmitted to the 
offspring. Transgenic technology is now applicable to a wide range of 
species including rat, rabbit, sheep, goat, cattle, fish and insects (Lathe 
and Morris, 1994). 
The gene of interest can be introduced as a transgene either under 
the control of its own regulatory elements or those of a foreign gene. To 
assess the elements required for high-level and correct expression, 
different putative control regions of a gene are used to drive the 
expression of a reporter gene. Tissue specific transgenes can be expressed 
correctly if they carry all necessary elements, but expression can be 
influenced by the site of integration: abnormal expression patterns are 
often detected depending on the sensitivity of the promoter to the 
chromosomal context (Palmiter and Brinster, 1986). Integration near 
specific enhancer sequences might cause ectopic expression, while some 
transgenic constructs do not express at all, probably due to integration 
into heterochromatic regions. Some constructs fail to express because of 
interference from vector sequences, other constructs may contain 
inappropriate (and often unknown) binding sites for negative regulatory 
factors, or may lack sequences such as topoisomerase binding sites, 
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nuclear matrix-attachment sites, or origins of replication (Palmiter and 
Brinster, 1986). Expression levels sometimes correlate with the copy 
number of the transgene but other times not, indicating that many 
transgene constructs lack distal elements (e.g. locus control regions 
(LCRs)), necessary for copy-number dependent gene expression. 
Constructs that are functional in tissue culture do not always 
express reliably in transgenic mice. This might be due to developmental 
regulation of the transgene, or the influence of the integration site 
(Palmiter and Brinster, 1986). It has also been shown that a larger 
fragment of DNA than that used in tissue culture may be necessary for 
in vivo expression (Palmiter and Brinster, 1986). 
Generally, large transgene constructs are recommended for 
position-independent gene expression. Such constructs are likely to 
include more regulatory elements of the selected gene. For this reason 
cosmid clones (inserts up to -40 kb), recombinant P1 bacteriophage (up 
to 100 kb), yeast artificial chromosomes (YAC5) (usually -300-500 kb, >1 
Mb possible) and bacterial artificial chromosomes (BACs) (up to 350 kb) 
can be used (Lathe and Mullins, 1993). Alternatively a defined promoter 
can be used in conjuction with the isolated coding region of the gene of 
interest. The expression of these constructs is however more likely to be 
affected by the site of integration and it is possible that elements usually 
necessary for the expression of the gene will be accidentally excluded. It 
has been also shown that the presence of introns can enhance expression 
of certain genes (Brinster et al., 1988). Other approaches applied in order 
to achieve high level, specific and site-independent expression include 
co-integration strategies and the use of LCRs, or matrix-attachment 
regions (MARs) (Lathe and Mullins, 1993). 
Transgenic mice carrying foreign PrP genes have provided insights 
into the role of PrP in susceptibility and incubation period, interspecies 
transmission and pathogenesis of TSEs (section 1.12.1). The study 
presented in this chapter was an attempt to expand and further test 
previous findings by using transgenic technology (section 1.14). 
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2.2 The choice of promoter - 
The 5' flanking sequences of the rat neuron specific enolase (NSE) 
gene and the rat tyrosine hydroxylase (TH) gene were chosen to drive 
hamster PrP expression to specific areas of the brain in transgenic mice. 
The 5' regulatory elements of each of these genes had been characterised 
in a transgenic context and were readily available. 
2.2.1 Neuron specific enolase (NSE) promoter 
Neuron-specific enolase (NSE) is one of the three types of isozymes 
of enolase (2-phospho-D-glycerate hydrolase), an enzyme involved in 
glycolysis. Each isozyme is composed as a homodimer. The a a 
homodimer is the non-neuronal enolase (NNE) expressed in glial cells, 
the JR9 isozyme is localised in mature muscle and the yy isozyme is 
expressed in terminally differentiated neurons and neurbendocrine cells 
(Sakimura et al., 1987). 
Studies on rat and monkey have demonstrated that NSE and NNE 
are developmentally regulated (Schmechel et al., 1980; Marangos et al., 
1980). In embryonic and early postnatal brain NNE levels are high and 
NSE levels very low. NSE expression appears after neurogenesis starts, 
increases as neurons mature functionally and morphologically and 
slowly reaches adult levels, resulting in NSE being one of the most 
abundant proteins of the brain. NNE levels decrease when NSE 
expression begins and then increase again to adult levels. 
The rat NSE cDNA has been isolated and the developmental 
expression has been characterised (ForssPetter et al., 1986). The rat NSE 
gene has been isolated and its structure has been analysed (Sakimura et 
al., 1987). In vitro expression studies indicated that about 1.5 kb of 5' 
flanking sequence contains elements able to drive efficient transcription 
of NSE (Sakimura et al., 1987). A sequence that resembles the TATA box 
(TCTATAGG) has been identified at positions -142 to -135 and an 
enhancer core-like sequence (GGGTTATTA) has been identified at 
position -350 in respect to the transcription initiation sites, upstream 
exon one. A typical CAAT box was absent. The region immediately 
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upstream of the cap site contains many GC-box like sequences thought to 
be important in regulation of transcription. 
A transgene containing 1.8 kb of the rat NSE 5' flanking sequence 
fused to the s-gal reporter gene was created to test whether these 
sequences could direct tissue-specific expression (ForssPetter et al., 1990). 
The analysis of the transgenic mice generated demonstrated that the cis-
acting regulatory sequences of the NSE promoter could confer neuron 
specific expression although some ectopic expression was detected in the 
testis. It was shown that c-gal mRNA expression was developmentally 
regulated in a similar way to that of the endogenous NSE mRNA, but in 
some lines the levels of transgene RNA were much lower than that of 
the endogenous gene. 
Recent experiments using different fragments of the rat NSE 5' 
flanking sequence fused to the CAT gene demonstrated that the cis-
acting regulatory elements responsible for enhanced CAT expression in 
neuronal cell lines and primary cultures were localised in the region of 
-190 bp to -1500 bp upstream the transcription initiation site and also in a 
500 bp portion of intron 1 (Sakimura et al., 1995). Enhanced expression 
was detected only when both intron 1 and 5' flanking sequences were 
used. 
For the generation of transgenic lines that would express hamster 
PrP specifically in neurons in the brain, the 1.8 kb rat NSE fragment was 
used, since it had been demonstrated that it was adequate to drive 
neuron-specific expression in the brain in a transgenic model. If ectopic 
expression was observed in any of the lines created, its effect on the 
course of the infection could be further investigated by experimenting 
with different routes of infection. 
2.2.2 Tyrosine hydroxylase (TH) promoter 
TH catalyses the oxidation of tyrosine to L-dihydroxyphenylalanine 
(L-DOPA) (Kandel et al., 1991). This is the first and rate limiting step in 
the synthesis, of catecholamines: dopamine, noradrenaline, and 
adrenaline. The expression of TH is limited to discrete populations of 
cells in the central and peripheral nervous systems. In the central 
nervous system (CNS), TH-expressing neurons include adrenergic and 
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noradrenergic cells of the brainstem, dopaminergic cells of the midbrain 
(containing the ventral tegmental area and the substantia nigra), the 
diencephalon (periventricular and hypothalamic nuclei), retinal 
amacrine cells and dopaminergic cells in the olfactory bulb (Banerjee et 
al., 1992). TH-expressing neurons in the brain are involved in such 
functions as motor, neuroendocrine, biorhythm, feeding, mating, 
emotion, learning and memory, and sleep-wake cycle regulation 
(Kaneda et al., 1991; Grima et al., 1987). In the peripheral nervous system 
(PNS), TH expression is mainly limited to sympathetic ganglia and the 
adrenal medullary chromaffin cells. It is involved in the sympathetic 
function of PNS (Banerjee et al., 1992; Kaneda et cii., 1991). 
Long term alteration of TH activity is due to transcriptional 
stimulation of the TH gene. Glucocorticoid, cAMP, nerve growth factor 
and epidermal growth factor have been reported to increase TH activity 
through transcriptional regulation of the TH gene , (Lewis et cii., 1987; 
Gizang-Ginsberg and Ziff, 1990; Lewis and Chikaraishi, 1987). 
Highly conserved regions, likely to play an important role in the 
regulation of TH gene expression, were identified by comparison of the 
5' flanking regions of human and rat TH genes, (Le Bourdelles et al., 
1988). 
Expression studies involving deletions and site directed 
mutagenesis on the 5' flanking sequence of the rat TH gene have 
revealed that sequences from -205 to -182 comprise an APi motif and a 
partially overlapping 20 bp dyad symmetry element which contains an E 
box core (CANNTG). These elements are required both in vivo and in 
vitro for efficient and cell specific expression of TH (Sung Ok and 
Chikaraishi, 1992). 
Transgenic mice generated with 4.8 kb of the 5' flanking sequences 
of the rat TH gene linked to the CAT reporter gene predominantly 
exhibit correct tissue-specific expression in the CNS and to a lesser extent 
in the periphery. This study was based on one transgenic line of 4 lines 
analysed as only one expressed the transgene. Transgene expression was 
measured by CAT enzyme activity assay of dissected brain regions. CAT 
activity was detected in all the expected areas containing TH-positive 
cells, although some ectopic but low level expression was detected in 
other areas such as the striatum, anterior olfactory nucleus and cortex. 
The highest expression was observed in the olfactory bulb, which 
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contains the majority of the CNS TH-expressing cells. Also, 
developmental expression of CAT was found to parallel the postnatal 
rise in endogenous TH in the olfactory bulb (Banerjee et al., 1992). 
Several transgenic mouse lines generated with a 5.3 kb fragment of 
the rat TH promoter driving the thymidine kinase (TK) gene exhibited 
different expression patterns of TK in the brain, demonstrated by in situ 
hybridization and immunocytochemistry, probably depending on the 
site of integration of the transgene. Some lines showed the expected 
expression in the nigrostriatal pathway, including the ventral tegmental 
area, substantia nigra and locus ceruleus, but additional expression in 
non-catecholaminergic regions (frontal cortex, colliculi, cerebellum) was 
detected. Other lines showed only low level ectopic expression 
(cerebellum, anterior cortex) and some did not express at all (Dr R.Al-
Shawi, personal communication). 
In recent studies 0.15 kb, 2.4 kb, and 9.0 kb fragments of 5' flanking 
sequence of the rat TH gene were fused to the E. coli lacZ (f-
galactosidase) reporter gene in order to identify TH promoter elements 
that could confer in vivo tissue specific expression. Transgenic mice 
bearing 9.0 kb, but not the smaller constructs with either 2.4 kb or 0.15 kb 
of 5' flanking sequence, displayed specific expression of f-galactosidase at 
levels equivalent to the endogenous TH, in the I  central 
catecholaminergic cells and, to a lesser extent, in the adrenal gland (Mm 
et al., 1994). 
To achieve region-specific expression in the brain of transgenic 
mice, the 5.3 kb fragment of the TH promoter was chosen, since it was 
the most thoroughly characterised at the time and immediately 
available. The fact that the expression patterns in the brain produced by 
using this fragment were different between transgenic lines was 
considered to be an advantage, since the main aim was to achieve region 
specific expression without having preferences about the exact regions. 
Transgenic lines expressing the hamster PrP in discrete, but different 
areas of the brain provide more options for testing the participation of 
certain cell types in the course of disease. If any of the transgenic lines 
generated expressed PrP only in the catecholaminergic pathways of the 
brain, it would be the only region that would degenerate after infection 
with the agent. 
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2.3 DNA constructs for the generation of transgenic mice 
The following sections describe the cloning strategies used to link 
the promoter regulatory elements of either the NSE or TH genes to the 
HaPrP ORF and the Simian virus 40 (SV40) polyadenylation (poly(A)) 
sequences. 
Two constructs, pNSE HaPrP and pTH HaPrP, were generated by 
several cloning steps and were used for the production of transgenic 
mice (Tg). 
The plasmid vector pBluescriptllKS- (Stratagene, appendix 2) was 
used as a basis for the constructs. pBluescriptllKS- was chosen because 
the entire transgene construct can be excised from the multiple cloning 
site (MCS) by a single digest using a rare restriction endonuclease, 
BssHII. Also, pBluescriptll KS- contains the lacZ gene downstream of the 
MCS, which is useful for selection of recombinants. 
2.3.1 Cloning of the HaPrP cDNA: generation of pBluescript HaPrP 
The HaPrP was chosen for generation of Tg mice because 
information gained from previous transgenic studies could be exploited. 
Infection by different strains of infectious agent has been studied and the 
incubation periods and lesion profiles have been characterised. Also, the 
fact that hamster-specific, anti-PrP antibody is available, facilitates 
detection of the transgene-encoded PrP protein. 
A 1.9 kb HaPrP cDNA was obtained from pHG327[Sst]/fl-QB 
expression vector (Dr N. Robakis, unpublished vector, appendix 2). The 
HaPrP cDNA clone was excised by BamHI restriction endonuclease 
digestion and subcloned into the BamHI site of pBluescriptllKS- for 
further characterisation. Attempts to sequence that fragment with the T3 
and T7 sequencing primers (appendix 1) flanking the pBluescriptllKS-
polylinker failed because of nucleotide repeats around the cloning sites 
of the HaPrP cDNA. That was probably due to the terminal transferase 
tailing procedure used for the initial cDNA cloning (Old and Primrose, 
1985). Subsequently, internal sequencing primers, 569G, 241V, 325S, 324S, 
164N (appendix 1), corresponding to nucleotides 303-288, 526-490, 263-
281, 556-573, 755-725 respectively (numbers according to the start of the 
HaPrP cDNA; number 1=10th nucleotide upstream of the initiating 
ATG) were used to overcome that problem and the complete sequence 
of the cDNA was determined. 
In order to avoid the repeats at either end of the cDNA and most of 
the 3' UTR sequence, PCR primers were, designed including convenient 
restriction sites for subcloning. The expected size of the amplified 
fragment is 900 bp and it contains the HaPrP ORF and 168 bp of the 3' 
UTR. The forward primer, 485W (appendix 1), included a Hindlil 
restriction site and was designed to match the 15 first nucleotides (10 nt 
upstream of the initiating ATG and 5 nt of HaPrP ORF) of the 5' end of 
the cDNA starting just beyond the polyG repeat sequence present in the 
HaPrP cDNA clone. The reverse primer, 484W (appendix 1) included 
sequences matching the 3' UTR at an internal position, 153-168 nt distal 
to the TGA stop codon and introduced an EcoRI site. The PCR product 
was gel purified (section 7.6.2) and cloned between the Hindlil and EcoRI 
sites of pBluescriptllKS-, generating the construct pBluescript HaPrP 
(Figure 2.3.1). The insert in pBluescript HaPrP was sequenced and 
'confirmed to be free of any mutations which may have been introduced 
during the PCR procedure. 
2.3.2 Generation of pNSE HaPrP construct 
The rat NSE promoter (1.8 kb fragment) was derived from the 
pNSE lacZ construct (ForssPetter et al., 1990, appendix 2). That was used 
to generate pNSEPrP.3 construct (Dr 0. Windl and Dr P. Estibeiro, see 
appendix 2). The HuPrP ORF fragment of pNSEPrP.3 was replaced by the 
HaPrP fragment (derived from pBluescript HaPrP, see Figure 2.3.1) to 
generate pNSE HaPrP (Figure 2.3.1, appendix 2). 
2.3.3 Generation of modified pBluescriptllKS- vector 
(pBluescript PS.N.A.) 
• The polylinker of pBluescriptllKS- was modified by deletion of a 
part of the MCS (PstI-SacI) and insertion of a Hindlil-Noti-EcoRI (HNE) 
adaptor, to generate pBluescipt APS.N., as shown in Figure 2.3.2. The two 
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Figure 2.3.1 Generation of pNSE HaPrP construct 
pNSEPrP.3 and pBluescript HaPrP constructs were cleaved by EcoRI restriction endonuclease digest. 
TheEcoRl-EcoRl lacZ-SV40 poly(A) fragment was subcloned into pBluescript HaPrP. Correct orientation was tested 
by Barn HI digest, which should give a 750 bp SV40 fragment and a 4350 bp vector fragment. 
The HindIII-BamHI fragment of pBluescript HaPrP pA construct, carrying the 900 bp HaPrP fragment and 550 bp 
fragment including SV40 and lacZ sequences was cloned into pNSEPrP.3, which was previously digested with HindlIl 
and BamHI. This cloning step resulted in the substitution of the HindIII-BamHI fragment of pNSEPrP.3 containing the 
human PrP fragment with the equivalent fragment from pBluescript HaPrP pA, to create the construct pNSE HaPrP, used 
for the generation of transgenic mice. 
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figure 2.3.2 Generation of 'cloning' vector pBluescriptLWS.N.A. 
The Pst I-Sac I fragment of the polylinker was deleted (LWS vector) so that the sites in that region would not 
interfere with subsequent doning steps. 
A HindIII-EcoRJ adaptor including a NotI site (pre-annealed FINE I and FINE II oligos), was inserted between 
the existing HindIli and Ecoffi sites (IPS.N. vector). 
The SV40 polyadenylation signal was inserted between the KpnI and the XhoI site (APS.N.A. vector). 
oligos used to create the HNE adaptor were HNEI and HNEII (appendix 
1). 
PCR amplification of a 250 bp fragment containing only SV40 
poly(A) sequences from pUC19-SV40 vector, using primers containing 
appropriate restriction sites was then used. pUC19-SV40 vector is based 
on pUC19 (New England Biolabs) and contains SV40 sequences 
including the poly(A) addition sites (between the BamHI and BclI sites of 
SV40). The forward primer, 076X (appendix 1), contained an XhoI site 
and included SV40 sequences immediately downstream of the BclI site. 
The reverse primer, 487W (appendix 1), contained a KpnI site and 
included SV40 sequences just upstream of the BamHI site. The 250 bp 
SV40 fragment was cloned as a XhoI-KpnI fragment into pBluescipt 
APS.N. to generate the construct pBluescript LWS.N.A. (Figure 2.3.2, 
appendix 2). After cloning, the fragment was sequenced in order to 
confirm that no mutations had been introduced by PCR amplification. 
2.3.4 Cloning the rat TH promoter in pBluescript LWS.N.A. 
The cloning steps necessary for subcloning the rat TH promoter 
from the pTH 5 kb CAT construct (gift from Dr J.Mallet, unpublished 
construct, appendix 2) into the APS.N.A. vector are presented in Figures 
2.3.3 and 2.3.4. pUC19 (New England Biolabs, appendix 2) was used for 
intermediate cloning steps. An EcoRI oligonucleotide linker (EcoRl 1. 
oligo, appendix 1) was used for cloning steps (1) and (5). By using this 
linker sequence, the SalT site at the 5' end of the promoter is retained, 
but the SmaT site of the polylinker of pUC19 is destroyed. The completed 
construct, pBluescript LPS.N.A.TH, is shown in Figure 2.3.4 (6). 
2.3.5 Generation of the pTH HaPrP construct 
The Hindlil-EcoRl HaPrP fragment was excised from pBlüescript 
HaPrP (Figure 2.3.1) and subcloned into pBluescript APS.N.A.TH (Figure 
2.3.4) after the addition of Hindlil linkers (HindIll I. oligo, appendix 1), as 
demonstrated in Figure 2.3.5. 
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Figure 2.3.3 Subcloning of TH 5.3 kb fragment 
TheTH promoter was excised from the pTH 5 kb CAT construct by a 
Sail and EcoRI restriction digests and EcoRl linkers were added. 
The TH promoter and a small fragment remaining from the CAT 
gene were subcloned into the EcoRl site of pUC19. The orientation of the 
fragment was tested by BamHI restriction digest (unique site in the TH 
promoter and in the polylinker Of pUC19). Correct orientation should 
give an 800 bp fragment, containing the CAT fragment and a fragment 
of the TH promoter and a 7500 bp fragment containing the large TH 
fragment and vector sequences. 
The remaining Kpiil-EcoRI fragment of the CAT gene was removed 
by KpnT digest. The pUC19 TH vector, still carrying 4400 bp of the 
promoter sequence was recircularised. The 900 bp KpnI-KpnlI fragment 
of the TH promoter, which was removed by the KpnI digest, was 
subsequently used for subcloning into pUC19 TH. 
(continuing in Figure 2.3.4) 
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Figure 2.3.4 Subcloning of TH 5.3 kbfragment 
(continuing from Figure 2.3.3) 
The 900 bp Kpn I- Kpn I TH promoter fragment was subcloned 
into pUC 19 TH. The orientation of the fragment was determined by 
double digest,with Xho I (unique site in the 900 bp fragment of TH) 
and Sma I (in the polylinker of pUC19). Correct orientation gave a 
820 bp fragment containing most of the small TH fragment and a 7200bp 
fragment containing the rest of the TH promoter and vector sequences. 
The TH promoter was cleaved with Eco RT and Sma I and Eco RI 
linkers were added. 
The TH promoter was cloned into the Eco RI site of pBluescript II KS- 
APS.N.A. and the orientation was determined by restriction digest with 
Xho I (unique site in TH promoter and in the polylinker of LPS.N.A.) 
which should give an 850 bp TH fragment and a 6700 bp fragment, 
containing the rest of the TH promoter and vector sequences. 
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Figure 2.3.5 Generation of pTH HaPrP construct 
The HaPrP Hindlil-EcoRl fragment was excised from pBluescript HaPrP construct and Hindlil linkers were, added. 
The HaPrP fragment was cloned into the Hindlil site of pBluescript APS.N.A., generating the construct pTH HaPrP (3). 
The orientation was tested by a BglI restriction digest, which cleaves pBuescriptll KS - twice, TH promoter twice and 
HaPrP twice. The correct orientation should give: a 2400 bp fragment containing HaPrP, SV40 and vector sequences, a 240 bp 
fragment of HaPrP, a 300 bp fragment containing HaPrP, TH and polylinker sequences, a 3000 bp TH promoter fragment, 
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Figure 2.3.6 pNSE HaPrP and pTH HaPrP constructs. 
NSE HaPrP and TH HaPrP fragments used for the generation of transgenic mice, are produced 
by a single BssHII digest from pNSE HaPrP and pTH HaPrP constructs. 
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ly(A)  
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By addition of the Hindlil linker the EcoRI site on the 3' of the 
HaPrP fragment was retained. 
After completion of all cloning steps, both pNSE HaPrP and pTH 
HaPrP constructs (appendix 2) were sequenced to confirm integrity and 
orientation of constituent fragments. 
With a BssHII restriction endonuclease digest each of these 
constructs gave the fragment used for microinjection into fertilised 
mouse eggs (schematically presented in Figure 2.3.6), for the generation 
of transgenic animals. 
2.4 Generation of transgenic mice 
Purified TH HaPrP and NSE HaPrP BssHII fragments (Figure 2.3.6) 
were microinjected into fertilised mouse eggs (by Dr P. Estibeiro) to 
generate transgenic (Tg) mice as described in section 7:31.2. Mice carrying 
the transgene were identified either by PCR (section 7.6.11), or by dot blot 
(section 7.15) of DNA recovered following tail, or ear, biopsy (section 
7.7.1). The dot blot method gave more reproducible results, it was easier 
to perform for large numbers of samples and the blots could be used for 
hybridisation with different probes. 
In using PCR to identify Tg founder mice, the forward primer, 
HaP1 (appendix 1), was located in the HaPrP ORE, 540 bp downstream of 
the initiating ATG. The reverse primer, tgSV40.1 (appendix 1), was 
located upstream of the BamHI site in the SV40 sequence. These primers 
could be used for identifying Tg mice generated with both constructs. 
The expected size of the PCR fragment is 910 bp in the NSE HaPrP 
transgenic mice and 630 bp in the TH HaPrP transgenic mice, as 
presented in Figure 2.4.1. 
Founder mice were crossed to non-transgenic Fl mice and the 
transgene was maintained in an heterozygous state. Four Tg lines were 
generated with the NSE HaPrP transgene (Tg NSE 14, 17, 20, 23) and 3 Tg 
lines with the TH HaPrP transgene (Tg TH1, 10, 15) (Table 2.4.1). Tg NSE 
23 founder did not give rise to any transgenic progeny, indicating that 
probably it was chimeric. 
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Figure 2.4.1 Identification of Tg founder mice by PCR amplification. 
PCR amplification (section 7.6.11) from mouse genomic DNA (section 
7.7.1) and schematic presentation of the expected PCR products. The PCR 
products were electrophorised on a 1% agarose gel (section 7.5). 
The size of the PCR product is 910 bp in the Tg NSE mice. 
Identification of the founder Tg NSE 14 (lane 7) is shown here. 
The size of the PCR product is 630 bp in the Tg TH mice. 
Identification of the founder Tg TH 1 (lane 2) and Tg TH 10 (lane 11) is 
shown here. 
Lower intensity PCR products of other than expected sizes were 
considered as artefacts. Lane 1 in both gels is the 1 kb ladder. 
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Transgenic offspring generated were analysed for copy number by 
dot blot and Southern blot analysis. The BssHII fragment used for 
generation of transgenics (Figure 2.3.6) was used as a copy number 
control on the dot blots and sometimes on the Southern blots. The 
amount of transgene fragment used was estimated as described in 7.31.3. 
Dot blots (examples shown in Figure 2.4.2) were usually probed with 
fragments containing the SV40 sequence present only in the transgene, 
so as to avoid the hybridisation signal produced by the endogenous PrP 
gene. Hybridisation of DNA samples from Tg NSE HaPrP lines gave a 
higher signal when the EcoRI-BamHI SV40-lacZ fragment (Figure 2.3.1) 
was used, while the TH HaPrP lines gave better results with the KpnI-
XhoI 5V40 fragment (Figure 2.3.5), because the probe had greater 
homology to the respective transgene sequence. The amount of genomic. 
DNA used for the dot blots was variable and therefore, the signal was 
not always of the same intensity between Tg mice of the same line, 
sometimes creating problems with copy number estimation and 
identification of positive Tg mice. For this reason the dot blots were 
often repeated, or hybridised with different probes and any further 
ambiguity was resolved by Sçuthern blot analysis. Copy numbers are 
summarised in Table 2.4.2. 
The integrity of the transgene was investigated by Southern blot 
analysis (Figures 2.4.3 and schematic presentation Figure 2.4.4). Southern 
blots were hybridised with the 900 bp Hindlil-EcoRl HaPrP ORF-
containing fragment (Figure 2.3.5). The HaPrP ORF is 90% homologous 
to the MoPrP ORF and therefore this probe hybridised with the 
endogenous, single copy, MoPrP gene. Comparison of the intensity of 
the endogenous MoPrP band with the transgene band would give an 
approximate estimation of copy number. EcoRI digest of genomic DNA 
from the Tg NSE HaPrP transgenic lines showed the expected 2.8 kb 
fragment containing the transgene and a Hindlil digest showed the 
expected 4 kb fragment containing the transgene (schematically 
presented in Figure 2.4.4A). In the Tg TH HaPrP lines, both EcoRI and 
HindlIl digests revealed the expected 0.9 kb fragment containing the 
transgene (schematically presented in Figure 2.4.4A). EcoRI digest 
revealed the expected 2.1 kb fragment and the Hindlil digest the expected 
2.6 kb fragment of the endogenous MoPrP gene. Control digests of NSE 
HaPrP poly(A) and TH HaPrP poly(A) BssHII fragments (transgenes) 
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mixed with non-Tg genomic DNA, usually showed bands of the same 
size as those obtained from digests of transgenic mouse DNA (transgene 
concatamers). Hindlil digest of the NSE HaPrP poly(A) BssHII transgene 
fragment showed the expected 2.3 kb fragment (Figure 2.4.3B lane 11) 
which is different from the 4 kb fragment obtained from the Tg NSE 
•HaPrP genomic DNA due to transgene concatamerisation (see Figure 
2.4.4Ab). Fainter bands evident in Tg NSE 20, Tg TH 1, Tg TH 10 and Tg 
TH 15 at unexpected sizes are probably result of transgene 
rearrangements and/or interrupted coding sequences, which are not 
expected to interfere with transgene expression since there are also 
copies of the transgene that are intact. The restriction patterns were the 
same for the founder mice and their progeny, the copy numbers were 
constant and the transgene was transmitted in a Mendelian fashion. 
These data are consistent with observations suggesting that the 
transgene is integrated as a tandem "head to tail" array into a single 
autosomal site (Palmiter and Brinster, 1986) in lines Tg NSE 14 and Tg 
NSE 17, but aberrant copies could also be present in the rest of the lines. 
The results of the generation of transgenic lines are summarised in 
tables 2.4.1 and 2.4.2. 
Table 2.4.1 Generation of transgenic mice 
construct eggs injected eggs implantec mice born transgenic 
pNSE HaPrP 252 214 26 4 
pTHHaPrP 163 147 16 3 
Table 2.4.2 Characterisation of transgenic lines 
construct line copy number transmission integrity 
pNSE HaPrP 
14 2 + + 
1 7 1-2 + 
 
+ 
20 15 + + 
23 1 - -. 
pTHHaPrP 
1 1 + + 
10 1-2 + + 
15 15 + + 
Figure 2.4.2 Dot blot analysis of transgenic mice 
Blots A and B were probed with the SV40 EcoRI-BamHI fragment. 
Blots C and D were probed with the SV40 KpnI-XhoI fragment. 
Each line represents different litters from different generations of Tg 
mice. 
Dot blot A 
line 1: litter of Tg NSE 14 
line 2: litter of Tg NSE 20 
line 3-4: litter of Tg NSE 17 
line 5: - 
line 6 (6a-6c): control NSE fragment: 10, 5, 0 copies 
Dot blot B 
line 1: litter of Tg NSE 14 
line 2-3: litter of Tg NSE 17 
column j : control NSE fragment: 1, 5, 10 copies 
Dot blot C 
line 1 (lc-le): control TH fragment 1, 2, 5 copies 
line 2: litter of Ig TH 1 
line 3-4: litter of Tg TH 10 
line 5: litter of Tg TH 1 
line 6: litter of Tg TH 15 
Dot blot D 
line 1-3: litter of Tg TH 1 
line 4-5: litter of Tg TH 10 
line 6: litter of Tg NSE 14 
line 7: litter of Tg NSE 20 
For example in dot blot A positive (transgenic) mice were considered 



























7i• I. . 
8J ••• •s• 
figure 2.4.2 
Figure 2.4.3 Southern blot analysis of transgenic mice 
A. EcoRI digests of genomic DNA revealed a 2.1 kb fragment 
corresponing to the endogenous MoPrP, a 2.8 kb NSE-HaPrP transgene-
derived fragment (in Tg NSE mice, schematically represented in Figure 
2.4.4Aa) and a 0.9 kb HaPrP transgene-derived fragment (in Tg TH mice, 
schematically represented in Figure 2.4.4Ba) after hybridisation with the 
HaPrP Hindlil-EcoRl fragment (see text). 
1 kb ladder 
Tg TH 1 (litter 2) 
Tg TH 10 (litter 1) 
Tg TH 1 (litter 3) 
control TH HaPrP poly(A) transgene fragment, 1 copy (see text) 
Ig TH 1 (litter 4) 
non-Tg littermate of Tg TI-I 1 (litter 4) 
Tg TH 1 (litter 2) 
Tg NSE 14 (litter 4) 
non-Tg littermate of Tg NSE 14 (litter 4) 
Tg NSE 17 (litter 1) 
1 kb ladder 
B. Hindlil digests of genomic DNA revealed a 2.6 kb fragment 
corresponing to the endogenous MoPrP, a 4 kb NSE-HaPrP transgene-
derived fragment (in Tg NSE mice, schematically represented in Figure 
2.4.4Ab) and a 0.9 kb HaPrP transgene-derived fragment (in Tg TH mice, 
schematically represented in Figure 2.4.4Bb) after hybridisation with the 
HaPrP Hindlil-EcoRl fragment (see text). 
1 kb ladder 
non-Tg littermate of Tg TH 10 (litter 3) 
non-Tg littermate of Tg TH 10 (litter 2) 
Tg TH 10 (litter 2) 
non-Tg littermate of Tg TH 15 (litter 2) 
Tg TH 15 (litter 2) 
non-Tg littermate of Tg TH 15 (litter 2) 
control TH HaPrP poly(A) transgene fragment, 1 copy (see text) 
Tg NSE 20 (litter 4) 
non-Tg littermate of Tg NSE 20 (litter 4) 
control NSE HaPrP poly(A) transgene fragment, 1 copy (see text) 
non-Tg littermate of Tg NSE 20 (litter 4) 
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Figure 2.4.4 Schematic presentation of EcoRI and Hindlil digests of genomic 
DNA from Tg NSE and Tg TH mice 
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2.5 Expression of transgene in Tg NSE HaPrP lines 
The Tg NSE HaPrP lines were analysed for transgene expression by 
Northern blot analysis (sections 7.16 and 7.18). Total RNA was isolated 
from various tissues of Tg and non-Tg littermates (section 7.8). 
Hybridisation of brain RNA with the HaPrP ORF fragment revealed a 2.3 
kb mRNA species corresponding to the endogenous MoPrP transcript 
and a 1.7 kb mRNA species corresponding to the transgene mRNA 
(Figure 2.5.1A and 2.5.1C). Similar results were obtained when the 
MoPrP ORF was used as a hybridisation probe (Figure 2.5.11)). When the 
SV40 poly(A) fragment was used as a probe only the mRNA produced by 
the transgene gave a hybridisation signal, although some faint bands, 
probably background hybridisation, were observed in all brain samples 
(Figure 2.5.113). Phosphorimager detection and quantification analysis 
(Molecular Dynamics software package), was used to estimate the levels 
of mRNA. Total hamster brain RNA was used as a positive control 
(Figure 2.5.1C) and other mouse tissues were included in the analysis 
(Figures 2.5.1A,B,D). In the highest expressing line, Tg NSE 20, the 
expression of the transgene was approximately 15% of that of the 
endogenous MoPrP gene. Tg NSE 14 showed approximately 25% 
expression in comparison to Tg NSE 20 (2-5% in comparison to the 
endogenous). Tg NSE 17 did not show any expression of the transgene 
which could be due to the site of integration, or methylation state of the 
transgene. Endogenous MoPrP mRNA was detected in other tissues 
apart from brain (see also section 1.6). Quantification of PrP mRNA from 
various tissues, normalised against ubiquitously expressed ribosomal 
protein (S26) mRNA revealed that heart PrP mRNA was approximately 
25-30%, lung 25%, kidney 15%, spleen 10%, muscle 10% and liver 0-1% 
in comparison to brain PrP mRNA. However, HaPrP mRNA produced 
from the line Tg NSE 20 transgene was present only in the brain (Figure 
2.5.1A,B,D). 
2.6 Expression of HaPrP protein in Tg NSE HaPrP lines 
To study PrP protein expression, several tissues from Tg NSE 20 
and Tg NSE 14 mice and non-Tg littermates, as well as hamster brain 
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Figure 2.5.1 Northern blot analysis of Tg NSE HaPrP lines 
A. Probed with HaPrP ORF fragment. 
B. Probed with EcoRI -BamHI SV40 fragment. 
The same samples in the same order were used for blots A and B 
1-5 brain samples 
Tg NSE 20 (litter 3) 
Tg NSE 14 (litter 2) 
Tg NSE 17 (litter 1) 
non-Tg littermate of Tg NSE 20 (litter 3) 
non-Tg littermate of Tg NSE 14 (litter 2) 
Tg NSE 20 spleen (litter 3) 
Tg NSE 20 liver (litter 3) 
C. Probed with HaPrP ORF fragment. 
hamster brain 
hamster brain 1:10 dilution of sample 1 in sterile water 
hamster brain 1:20 dilution of sample 1 in sterile water 
Tg NSE 20 brain (litter 4) 
Tg NSE 20 brain (litter 4)1:10 dilution in sterile water 
Tg NSE 20 brain (litter 4) 1:20 dilution in sterile water 
(samples 2 and 3 were partially degraded) 
D. Probed with MoPrP ORF fragment. 
Control hybridisation with S26 (mouse ribosomal protein coding 
fragment) is also presented. 
Fl mouse brain 
Fl mouse heart 
Fl mouse liver 
Fl mouse lung 
Tg NSE 20 (litter 5) brain 
Tg NSE 20 (litter 5) heart 
Tg NSE 20 (litter 5) muscle 
Tg NSE 20 (litter 5) liver 
Tg NSE 20 (litter 5) spleen 
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protein samples, were analysed by Western immunoblotting (section 
7.21.6). 
Brain protein samples from Tg NSE HuPrP line 42 (one of the Tg 
1ine carrying the HuPrP ORF generated by Dr. P. Estibeiro and Dr. 0. 
Windl), shown to express HuPrP mRNA in the brain (Dr. P. Estibeiro 
and Dr. 0. Windi personal communication) were included in the 
analysis. The antibodies (ab) used were the monoclonal 3F4 (Kascsak et 
al., 1987), which reacts with hamster and human, but not mouse PrP and 
the polyclonal 1133 and 1A8, which react with PrP produced from 
different species, including mouse hamster and man (Farquhar et al., 
1989). From all samples tested, only the endogenous mouse or hamster 
PrP protein was detected in the brain samples (Figures 2.6.1 and 2.6.2). 
Endogenous PrP protein can be detected in other tissues apart from 
brain, but larger amounts of tissue and more sensitive detection 
methods are necessary in order to achieve this (Horiuchi et al., 1995). To 
test the sensitivity of the method used here, serial dilutions of hamster 
brain protein were used (Figure 2.6.213,C). It was revealed that PrP 
protein could be detected in samples containing 5% (1:20 dilution) of the 
amount usually used for immunoblotting (approximately 20 jig). This 
result indicated that if the mRNA produced by the transgene was 
translated as efficiently as the endogenous PrP message, the protein 
present in Tg NSE line 20 and possibly also line 14, should be detectable 
(mRNA levels 15% and 4% of the endogenous MoPrP mRNA levels). 
No HaPrP protein was detected in any brain samples from Tg NSE 
HaPrP lines. Similar results were obtained with Tg mice generated with 
a transgene carrying the HuPrP ORF (Figures 2.6.1A,B, 2.6.2A and Dr. P. 
Estibeiro and Dr. 0. Windl personal communication). Furthermore, 
these experiments provided clear evidence for downregulation of 
endogenous PrP translation in other tissues compared to brain. 
Bands present at lower molecular weight than PrP (approximately 
16 kD - 19 kD) are sometimes present in some samples (see Figure 2.6.1C 
2.6.2 and 4.6.10). These bands are not transgene-related because they are 
also present in samples from non-Tg mice. 
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Figure 2.6.1 Western blot assay of Ig NSE HaPrP mice 
A. Probed with the mouse monoclonal ab 3F4 (hamster specific). 
B. Probed with the rabbit polyclonal anti-PrP ab 1B3. 
The same saniples in the same order were used for A and B. 
size markers 
hamster brain 
Tg NSE 20 brain (litter 2) 
Tg NSE 14 brain (litter 2) 
control non-Tg mouse brain 
Tg NSE 42 brain (litter 2) carrying the HuPrP ORF 
Tg NSE 20 lung (litter 2) 
Ig NSE 20 kidney (litter 2) 
C. Probed with the mouse monoclonal ab 3F4 (hamster specific). 
size markers 
control non-Tg mouse brain 
Tg NSE 20 brain (litter 3) 
Tg NSE 20 liver (litter 3) 
Tg NSE 20 spleen (litter 3) 
hamster brain 
scrapie-infected hamster brain 
purified hamster PrP 
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45.5 kD - 
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Figure 2.6.2 Western blot assay of Ig iNSL HaFrP mice 
A. and B. Probed with the mouse monoclonal ab 31`4 (hamster specific. 




Tg NSE 20 brain (litter 4) 
Tg NSE 14 brain (litter 3) 
Fl mouse brain 
Tg NSE 42 brain (litter 3) carrying the l-luPrP ORF 
Tg NSE 14 heart (litter 3) 
Tg NSE 20 kidney (litter 3) 
B and C. The same samples were used in the same order. 
hamster brain 
hamster brain 1:10 dilution 
hamster brain 1:20 dilution 
Tg NSE 20 brain (litter 4) 
Fl mouse brain 
Tg NSE 20 heart (litter 4) 
Tg NSE 20 lung (litter 4) 
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II \pression of transgene 11_i Ig TI -I 1 laPrP lines 
In situ hybridisation (section 7.32) was performed to determine the 
hcilisation of the mRNA produced by the TH HaPrP transgene. 
Northern blot analysis and reverse transcription PCR (RT-PCR section 
7.6.12) on dissected brain regions were also performed. 
Several attempts were made to detect HaPrP mRNA by different in 
situ hybridisation protocols (sections 7.32.3 and 7.32.4). Three anti-sense 
oligos were initially chosen as probes (section 7.17.3) and the equivalent 
sense oligos were used as control probes. The oligo SV40-a (appendix 1) 
was located in the SV40 sequence directly downstream of the XhoI site in 
pTH HaPrP (Figure 2.3.5) and is therefore unique to the transgene 
sequences (SV40-s oligo is the sense equivalent). The other two oligos 
were located in the MoPrP ORF (Mo-a, appendix 1) and in the HaPrP 
ORF (Ha-a, appendix 1) in a region 50-100 nt upstream of the TGA stop 
codon that is 25% different between the two species. The Ha-a probe 
should hybridise only to HaPrP and the Mo-a only to the endogenous 
MoPrP (Mos and Ha-s were the sense oligos used, see appendix 1). A 
tyrosine hydroxylase-derived oligo, TH-a (appendix 1) was used as a 
control for endogenous TH expression. 
When tested on normal mouse brain (coronal sections of frozen 
brain) the Ha-a was expected to give no signal and the Mo-a was expected 
to hybridise to the endogenous MoPrP gene. However both probes gave 
a signal, but the hybridisation pattern was different between them 
(Figure 2.7.1). The Ha-a probe gave hybridisation signal mainly in the 
corpus callosum, the cingulum, the dentate gyrus of the hippocampus, 
the lateral geniculate nuclei and the lateral and dorsal thalamic nuclei, 
while the Mo-a probe showed endogenous MoPrP expression mainly in 
the CAl, CA2, CA3 and dentate gyrus of the hippocampus, cerebral 
cortex, mammilary nuclei, amygdaloid nuclei, cerebellum and areas in 
the thalamus and hypothalamus. This finding suggested that the Ha-a 
probe was cross-hybridising to a mouse RNA (not MoPrP mRNA) and 
therefore was not useful for detecting transgene-produced HaPrP 
Hybridisation signal was detected in the olfactory bulb and possibly 
the ventral tegmental area and the substantia nigra when the SV40-a 
probe (transgene-specific) was used on the Tg TH HaPrP brain sections 
horizontal sections of IroZen brain, Figure 2.7.2). 1 he hybridisation 
pattern was similar to that obtained by the TH-a probe in the olfactory 
bulb. Hybridisation signal was detected in the preoptic nuclei, olfactory 
tubercle, lateral olfactory tract and the olfactory nuclei. Hybridisation in 
these regions with the SV-a probe was much lower than that observed 
with the TH-a probe. In the ventral tegmental area and substantia nigra 
(Figure 2.7.3) the expression pattern obtained with the SV-a probe did 
not exactly resemble that observed with the TH-a probe. This finding 
indicated that the signal detected in that region could be due to 
background hybridisation. The SV40-s probe that was used as a negative 
control (Figure 2.7.2) did not show any hybridisation in that region, but 
hybridisation signal was detected in the cochlear nuclei and the spinal 
trigeminal nuclei. This suggested that the signal observed in these areas 
with the SV40-a, and TH-a probes was unspecific hybridisation. The Mo-
a oligo was used as a positive control showing endogenous MoPrP 
(Figure 2.7.3). 
Alternatively, a riboprobe (section 7.17.4) containing SV40 
sequences present in the transgene construct pTH HaPrP (KpnI-XhoI 
SV40 sequence, Figure 2.3.5) was used to detect transgene expression and 
the sense strand was used as a negative control (Figure 2.7.4). These 
probes were used on coronal paraffin embedded brain sections (section 
7.32.1). The MoPrP antisense riboprobe (MoPrP ORF derived, provided 
by the BBSRC Neuropathogenesis Unit, Edinburgh) was used as a 
positive control, showing endogenous MoPrP expression and the MoPrP 
sense riboprobe was used as a negative control (Figure 2.7.4). No 
transgene specific expression was detected, although the background 
produced with the riboprobes was high, not allowing detection of 
possible subtle differences. 
Using Northern blot analysis on dissected brain regions, a very faint 
signal at approximately 1.4 kb was detected with the SV40 KpnI-XhoI 
probe (Figure 2.3.5) in the olfactory bulb (Figure 2.7.5). The intensity of 
the band was only 5-10% of that present in a Tg NSE line 20 brain 
sample. RT-PCR was also performed several times on dissected regions 
of Tg TH HaPrP mouse brain. A band specific for transgene produced 
mRNA was detected in the olfactory bulb by RT-PCR, although it was 
also present, but much fainter, in the rest of brain and cortex (Figure 
2.7.5) and sometimes in other brain regions (data not shown). This could 
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Figure 2.7.1 In situ hybridisation of coronal cryostat sections of Fl mouse 
brain with 4 antisense oligo probes. 
Hybridisation with Mo-a oligo. 
Hybridisation with Ha-a oligo. 
Hybridisation with muscarinic receptor 1 derived oligo (gift from Dr 
M. Steel) revealed mainly hippocapus specific expression (used as a 
positive control). 
Hybridisation with opsin derived oligo (gift from Dr M. Steel) gave no 
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An: amygdaloid nuclei, C: cortex, CAl, CA2, CA3 regions of the Ilippocampus, cg: cingulum, Cd: caudatc nucleus, 
CPu: caudate putamen, Cb: cerebellum, cc: corpus calosurn, CThn: central thalarnic nuclei, DG: dentate gyrus 
(hippocainpus), Hi: hippocampus, Hy: hypothalamus, LThn: lateral thalamic nudei, Mn: mamrnilary nuclei, MThn: 
medial thalamic nuclei, S: septum, SN: substantia nigra, Tb: thalarnus, VTA: ventral tegmental area, VThn: ventral 
thalamic nuclei 
Figure 2.7.2 In situ hybridisation of horizontal cryostat sections of Tg TH 
15 mouse brain with 2 antisense oligo probes. 
The 4 pictures on each column are hybridised with the same probe. 
The 2 pictures on each line represent adjacent brain sections 
column 1. Hybridisation with TH-a oligo, showing endogenous TH 
expression. 
column 2. Hybridisation with SV40-a oligo, showing transgene 
expression. 
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C: cortex, Cd: caudate nucleus, Cb: cerebellum, Con: cochlear nuclei, HE  
hippocampus, Fly: hypothalamus, LOtr: lateral olfactory tract, Ob: 
olfactory bulb, On: olfactory nuclei, Otu: olfactory tubercule, Otr: olfactory 
tract, Sin: spinal trigeminal nuclei, SN: substantia nigra, Th: thalamus, 
V. ventricle, VTA: ventral tegmental area 
Figure 2.7.3 In situ hybridisation of horizontal cryostat sections of Tg TH 
15 mouse brain with 2 antisense oligo probes. 
The 4 pictures on each column are hybridised with the same probe. 
The 2 pictures on each line represent adjacent brain sections 
column 1. Hybridisation with Mo-a oligo, showing endogenous MoPrP 
expression. 
column 2. Hybridisation with SV40-s oligo, showing background 
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Figure 2.7.4 In situ hybridisation of coronal sections of Tg TH 15 paraffin 
embedded mouse brain with 4 riboprobes. 
 
The 2 pictures on each column are hybridised with the same probe. 
The 2 pictures on each line represent adjacent brain sections 
column 1. Hybridisation with SV40 sense riboprobe, showing 
background hybridisation (negative control). 
column 2. Hybridisation with SV40 antisense riboprobe, showing 
transgene expression. 
 
The 2 pictures on each column are hybridised with the same probe. 
The 2 pictures on each line represent adjacent brain sections 
column 1. Hybridisation with MoPrP sense riboprobe, showing 
background hybridisation (negative control). 
column 2. Hybridisation with MoPrP antisense riboprobe, showing 






An: amygdaloid nuclei, C: cortex, CAl, CA2, CA3 regions of the 
hippocampus, cg: cingulum, cc: corpus calosum, DG: dentate gyrus 
(hippocampus), Hi: hippocampus, Hy: hypothalamus, Mn: mammilary 
nuclei, SN: substantia nigra, Th: thalamus, VTA: ventral tegmental area, 
VThn: ventral thalarnjc nuclei 
Figure 2.7.5 
A. Northern blot analysis of Tg TH HaPrP mice 
RNA samples from dissected brain regions from Tg TH 15 (litter 2) and 
whole brain RNA samples from Fl and Tg NSE 20 (litter 5) mice, probed 
with the SV40 KpnI-XhoI SV40 fragment. 
cerebellum Tg TH 15 (litter 2) 
brain stem Tg TH 15 (litter 2) 
coliculi Tg TH 15 (litter 2) 
hippocampus Tg TI-I 15 (litter 2) 
cortex and striatum Tg TH 15 (litter 2) 
rest of brain Tg TH 15 (litter 2) 
olfactory bulb Tg TH 15 (litter 2) 
- 
Fl brain 
Tg NSE 20 brain (litter 5) 
B. RT-PCR analysis of Tg TH HaPrP mice 
PCR from Tg TH HaPrP genomic DNA sample was performed as a 
positive control revealing the expected 300 bp PCR product. Negative 
control PCR reactions were performed on genomic DNA from Fl and 
non-Tg littermates. RT-PCR was performed on dissected brain regions of 
Tg TH 15 (litter 4) brain. Reactions where the RT step, the or addition of 
RNA was ommited were also included in order to eliminate false 
positives due to DNA contamination in the RNA samples or 
contamination of the reagents. 
1 kb ladder 
Fl genomic DNA 
non-Tg littermate of Tg TH 15 (litter 4) genomic DNA 
Tg TH 15 (litter 4) genomic DNA 
cortex (no RT) 
hippcampus (no RT) 
cortex 
hippocampus 
rest of brain 
olfactory bulb 
11.rest of brain (no RT) 
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be due to cross-contamination between the brain areas during the 
dissection procedure. Nigrostriatal projections could also be present in 
different brain regions apart from the ventral tegmental area and the 
substantia nigra. Very faint bands were also sometimes detected in the 
reactions where the RT step was omitted, suggesting that there could be 
some residual DNA in the RNA samples. The primers used for the PCR 
step were two of the oligos used for the in situ hybridisation, Ha-s and 
SV40-a, in the HaPrP sequence and in the SV40 sequence respectively, 
giving a 300 bp PCR fragment. 
The transgene-specific signal detected by in situ hybridisation was 
very low in the olfactory bulb and there were indications that the signal 
observed in other regions could be background hybridisation. Northern 
blot analysis also revealed very low hybridisation signal in the olfactory 
bulb. The results obtained by RT-PCR approach were inconclusive. 
Therefore, it was decided not to pursue further the study of Tg TH HaPrP 
lines. 
2.8 Conclusions 
Analysis of the Tg NSE HaPrP lines demonstrated only low levels 
of transgene PrP mRNA expression in comparison to endogenous 
MoPrP mRNA expression. No comparison was made with endogenous 
NSE mRNA expression. However, low transgene mRNA levels, in 
comparison to endogenous NSE mRNA, were obtained in a previous 
transgenic model where the same 1.8 kb fragment containing 5 flanking 
sequences of the NSE gene was used (ForssPetter et al., 1990). The data 
presented in section 2.6 also suggest that if the mRNA produced by the 
transgene was translated as efficiently as the endogenous PrP message in 
the brain, the protein produced should be detectable by the method 
applied here in, at least, Tg NSE line 20 (the amount of transgene-
produced mRNA is 15% in comparison to endogenous MoPrP). No 
HaPrP protein was detected in any of the brain samples tested from Tg 
NSE HaPrP lines. Similarly, in unpublished studies in which the HuPrP 
ORF was under the control of the 1.8 kb NSE promoter fragment mRNA 
expression but no protein was detected (Figures 2.6.1, 2.6.3 and Dr. P. 
Estibeiro and Dr. 0. Windl personal communication). Also, results 
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obtained from transgenic studies where the sheep PrP ORF was used 
under the control of the Thy-i promoter suggested that possibly the 
sheep PrP ORF was not sufficient for PrP protein expression (Dr J. Hope 
and Dr H. Baybutt, personal communication). It should be noted that the 
sheep PrP would be detected only if the signal produced was high 
enough to be distinguished over the signal produced by the endogenous 
MoPrP, since there was no sheep specific anti-PrP monoclonal antibody 
available. 
Another attempt to generate transgenic mice with a construct that 
contained only the HaPrP ORF had failed, but the reasons for this were 
not clear (Scott et al., 1989). A fragment containing putative PrP 
promoter sequences that had not been characterised was used to drive 
HaPrP expression; no RNA data were presented. 
One interpretation of these results was that there could be a block at 
the level of translation due to the use of the isolated PrP ORF. It was 
hypothesised that the 5' and 3' untranslated sequences of PrP might 
contain important regulatory sequences. 
Because the analysis of the TH HaPrP lines involves complicated 
techniques, and the analysis of the Tg NSE lines indicated that there 
could be a problem with the use of the PrP ORF fragment in the 
transgenic constructs, analysis was restricted to one of the three TH 
HaPrP transgenic lines generated. In situ hybridisation and Northern 
blot analysis indicated that there was probably extremely low PrP mRNA 
expression in at least some of the catecholaminergic neurons (olfactory 
bulb). Therefore, it was decided that the TH HaPrP lines would not be 
pursued and no more transgenic lines would be generated with either 
construct. Recent experiments (Min et al., 1994) demonstrated that a 9 kb 
fragment of the 5' flanking sequence of the rat TH gene is necessary to 
drive high-level, specific expression of a reporter gene (lacZ) in 
transgenic mice. 
Although the data presented here suggested that the open reading 
frame alone could be insufficient for PrP protein expression and other 
elements of the PrP gene (missing from constructs previously tested) 
could be necessary for adequate translation and translocation of the 
mRNA, several studies demonstrated that PrP ORF containing 
constructs appeared to produce PrP protein in cell culture, though 
sensitive detection methods were necessary (section 1.12.2). However, in 
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some cases PrP mRNA, but no PrP protein, was detected (Scott et al., 
1988). The role of the 5' and 3' untranslated sequences of PrP has not 
been addressed; all successful transgenic models were generated with 
cosmid-based constructs and constructs used in cell culture contained 
only the PrP ORF (section 1.12). PrP intron sequences could also be 
important for PrP protein expression. Apart from influencing 
transcription efficiency, intron sequences could be important for RNA 
routing. Also, splicing could contribute to the stability of PrP mRNA. 
In retrospect, there are two trivial reasons that account for the 
failure to express PrP protein in the Tg NSE HaPrP transgenic mice: 
The polylinker that lies between the NSE cap-site and the PrP reading 
frame contains an ATG start codon. Since this is out of frame relative to 
the PrP sequence, polypeptides initiated at this site will not react with 
anti-PrP sera. 
The PrP cDNA sequence (Oesch.et a!, 1985) employed in the constructs 
lacks the first 32 nucleotides, including the initiator ATG codon and 
consequently any protein translated from it would lack the first 14 N-
terminal aminoacids (initiation at the second ATG, 42 nucleotides 
downstream the first ATG). In effect the signal peptide would be reduced 
in length from 22 to 8 aminoacids. This could effect PrP protein levels 
through a variety of routes, such as translation efficiency of mRNA and 
altered stability of mRNA and/or protein, either intrinsic to the 
molecule or due to an altered cellular distribution. The same PrP 
fragment was used also in the TH HaPrP construct. 
To investigate possible effects of the 5' and 3' UTR of HaPrP and the 
presence of an intron on translation efficiency, a series of constructs was 
tested in cultured cells. At the same time the effect of the N-terminus 
truncation of the HaPrP fragment on protein levels was assesed. 
CHAPTER 3 
The influence of the 3' and 5 untranslated 
regions of hamster PrP on the translation of 
lacZ 
3.1 Eukaryotic mRNA regulation-control of translation 
3.1.1 Mechanisms that influence initiation of translation 
The regulation of mRNA translation is recognised to be one of the 
crucial steps for modulating gene expression. There are several features 
that can influence the initiation of translation, pre-mRNA processing 
and mRNA stability, subcellular localization and degradation. 
In eukaryotes the initiation of translation is modulated by the 
phosphorylation-dephosphorylation of the translation initiation factors 
(Sonenberg, 1994; Merrick, 1992; Jackson, 1993) and five features of the 
mRNA: the 5' m7G cap structure, the primary sequence (context) around 
the initiating AUG codon, the position of the AUG codon (whether it is 
the first AUG in the mRNA), the secondary structure upstream and 
downstream from the AUG codon and the length of the leader sequence 
(Kozak, 1991a; Kozak, 1991b). 
The 5' cap structure is present in most eukaryotic mRNAs and 
there is strong evidence suggesting that ribosomes bind at, or near the 
cap and 'scan' the mRNA in a linear 54 fashion, until they encounter 
an AUG initiator (in the right context, see below) (Kozak, 1991a; Kozak, 
1991b). Cap-independent, internal initiation of translation can also occur. 
Uncapped mRNAs of picornaviruses and several vertebrate and 
invertebrate cellular mRNAs contain internal ribosomal entry sites 
(reviewed in Sonenberg, 1994, Kozak, 1991a, Jackson, 1993). It has been 
demonstrated that ribosomes can bypass a segment of the 5' UTR 
(mosaic virus mRNA) suggesting an alternative mechanism to the 
linear scanning model (Sonenberg, 1994). The cap structure is also 
important for mRNA stability and transport (reviewed in Sachs, 1993, 
Kozak, 1991b). 
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Comparison between eukaryotic mRNAs and mutagenesis of the 
nucleotides surrounding the initiator AUG codon revealed that the 
most common sequence for initiation of translation is 
GCCA/GCCAUGG ('strong', or favourable context) (Kozak, 1991a; Kozak, 
1991b; Kozak, 1989). The most conserved nucleotide is a purine (usually 
A) at position -3 (3 nucleotides upstream of the AUG) and G at +4 (the A 
of the AUG being defined as position +1). The contribution of the other 
positions (-1, -2, -4, -5 ,-6) is more obvious when nucleotides at positions 
-3 and +4 are unfavourable (Kozak, 1989). In that case nucleotides even 
further upstream of the AUG (-7 to -9) can contribute to the efficiency of 
translation (GCCGCCA/GCCAUGG, optimal consensus), but those closer 
to the AUG have greater influence. Also, these nucleotides enhance 
translation only when they occur together and at a precise distance from 
the AUG (Kozak, 1987; Kozak, 1989). The translation of mRNAs that do 
not have a 'strong' consensus sequence is regulated and therefore 
usually they encode regulatory proteins (Kozak, 1991a) presumably 
because they are required only at low levels. 
According to the scanning model the first AUG in the mRNA 
sequence is the initiator AUG, when it is in a 'strong' context. However, 
there are several cases (mainly in viral mRNAs) where two proteins are 
produced from the same mRNA. This occurs when the context of the 
first AUG is unfavourable, causing 'leaky' scanning and initiation from 
a second AUG. In vertebrates, promoter switching or alternative splicing 
is usually necessary to produce two mRNAs and (possibly) two proteins 
from the same gene (Kozak, 1991a; Kozak, 1991b; Geballe and Morris, 
1994). Evidence from yeast suggest that the first AUG in the mRNA 
sequence is the initiator codon, even if translation is very weak due to 
unfavourable context (reviewed in Kozak, 1989). These data indicate that 
the existence of upstream AUG would inhibit translation from 
downstream AUG in eukayotic mRNAs (apart from viral mRNAs). 
However, when the ORF following the first AUG is very short the 
ribosomes can reinitiate translation at a downstream AUG (Kozak, 
1991b; Kozak, 1987a; Geballe and Morris, 1994). The intercistronic length 
is important for the efficiency of the reinitiation by eukaryotic ribosomes 
(Kozak, 1987b; Geballe and Morris, 1994). 
The secondary structure surrounding the initiator AUG is also 
crucial. Extensive secondary structure upstream of the AUG has an 
inhibiting effect on translation efficiency. Impairment of translation 
depends on the distance between the structure and the cap (inhibition is 
stronger when the secondary structure is nearer to the cap) and the free 
energy of the structure. In contrast, secondary structure downstream of 
the AUG may assist recognition of the initiator codon, perhaps by 
slowing ribosome scarming, contributing to the fidelity of translation 
initiation. This may sometimes compensate for an unfavourable AUG 
context (Kozak, 1991a; Kozak, 1991b). Presence of secondary structure 5' 
to an AUG codon might enhance initiation from upstream AUG codons 
or even from cryptic non-AUG codons (Kozak, 1991a). 
Apart from the structure of the 5' leader sequence, its length is also 
crucial. If the AUG is positioned too close to the cap (less than 20 (Kozak, 
1991b) or 40 (Geballe and Morris, 1994) nucleotides) and there is no 
substantial secondary structure downstream of that AUG, bypassing is 
thought to be favoured, increasing initiation from a downstream AUG. 
Further lengthening of the leader sequence has a dramatic increase on 
translation efficiency. Generally, long, unstructured leader sequences 
(low G content) preceding the AUG codon appear to be necessary for 
high levels of translation (Kozak, 1991a; Kozak, 1991b). 
3.1.2 The influence of 3' and 5' untranslated regions (UTR) on 
mRNA regulation and control of translation. 
Translation of the mRNA can be regulated by sequences in the 5' 
and 3' untranslated regions (UTRs) involving protein-mRNA 
interactions. In eukaryotes when the mRNA is regulated by 5' UTR 
motifs, the most important aspect is the distance from the cap (reviewed 
in Jackson, 1993). The regulation of ferritin mRNA by iron has served as 
a model for studying the inhibition of translation by specific structures 
in the 5' UTR (reviewed in Sonenberg, 1994; Jackson, 1993). Regulation 
depends on a stem-loop structure, the iron responsive element (IRE) 
which lies within 40 nucleotides of the cap structure. A protein termed 
iron regulatory factor (IRF), or IRE-binding protein (IRE-BP) binds to the 
IRE when iron levels are low and inhibits ferritin mRNA translation. 
There is evidence suggesting that changes in availability of iron involve 
changes in the iron-sulfur cluster in the IRF, which alter the RNA- 
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binding activity of the protein (Haile et a! 1992). It has also been 
demonstrated that nitric oxide inhibits ferritin translation by increasing 
binding of IRF to the IRE either through chelation of iron, or by affecting 
the iron-sulfur cluster (Sonenberg, 1994). The IRE has to be close to the 
cap, whereas the distance between the IRE and the initiator AUG is not 
significant (Stripecke et a! 1994; Jackson, 1993). Another IRE has been 
identified in the 5' UTR of the mRNA of erythroid 5-aminolevulinic 
acid-synthase (rate limiting enzyme of heme biosynthesis) (Dandekar et 
a! 1991), indicating that iron might regulate several mRNAs that are 
involved in iron metabolism pathways. 
Autoregulation of translation by repressor protein binding to the 5' 
UTR has been reported in the case of thymidylate synthase, which binds 
to its own mRNA downstream of the cap at a sequence that includes the 
initiator AUG (reviewed in Sonenberg, 1994; Stripecke et al 1994). 
Dihydrofolate reductase also binds at the 5' of its own mRNA, inhibiting 
translation (cited in Sonenberg, 1994). 
In vitro studies have indicated that inhibition of translation of a 
family of seven related Drosophila mRNAs during spermatogenesis 
depends on repressor protein binding to a 12 nucleotide motif located 28 
nucleotides downstream of the cap (reviewed in Jackson, 1993). 
Several examples of the involvement of 3' UTR sequences in the 
regulation of translation have been reported. 
A 60 nt motif has been found in the extreme 3' of protamine 
mRNA in mice which is thought to be necessary for temporal regulation 
(inhibition) of translation in the developing spermatides. The proteins 
that bind to this motif are homologous to RNA-binding proteins found 
in Xenopous oocytes and are found only in cells where protamines are 
not translated (reviewed in Jackson, 1993). 
The synthesis of the sex determination protein of C. elegans tra-2 is 
negatively regulated by a 28 nücleotide direct repeat element in the 3' 
UTR of the mRNA (reviewed in Sonenberg, 1994). 
Synthesis of rabbit erythroid 15-lipoxygenase is negatively regulated 
by the binding of a 48 kD protein to a region of 10 tandem repeats of 
similar pyrimidine-rich 19 nucleotide motifs in the 3' UTR (Ostareck-
Lederer et a! 1994). 
It has been demonstrated that part of the 3' UTR of a-tropdmyosin 
mRNA suppresses tumor formation (Rastinejad et a! 1993) and also that 
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the 3' UTRs of troponin I, tropomyosin and a-cardiac actin mRNAs are 
trans-acting regulators that inhibit cell division and promote 
differentiation (Rastinejad and Blau, 1993). 
The utilisation of two alternative polyadenylation sites in the 3' 
UTR of the amyloid precursor protein (APP) mRNA provides another 
example of control of translation by 3' UTR sequences (De Sauvage et al., 
1992). The longer mRNA that uses the second polyadenylation site was 
shown to be translated more efficiently in vitro than the shorter one. 
Furthermore, the sequence between the two sites increased translation of 
reporter genes (chicken lysozyme and chloramphenicol 
acetyltransferase) when cloned downstream of their coding regions to 
produce chimeric mRNAs. 
Sequences in the 3' UTR have also been shown to influence 
mRNA stability and degradation. AU-rich motifs (consensus AUUUA), 
in the 3' UTRs of granulocyte-macrophage colony stimulating factor, 
lymphokine and protooncogene mRNAs are thought to make them 
unstable (reviewed in Jackson, 1993, Sachs, 1993). c-myc and c-fos 
mRNAs have destabilising elements in the ORF and destabilising AU-
rich elements in the 3' UTR, responsible for the high turnover of their 
mRNAs. Stimulation of degradation by AU-rich elements requires 
translation of the mRNA (reviewed in Sachs, 1993). Binding of two 
proteins to AU-rich elements in the 3' UTR of c-myc has been shown to 
promote degradation (cited in Jackson, 1993). 
In the 3' UTR of the transferrin receptor mRNA there are five 
secondary structure elements resembling the IRE in the 5' UTR of 
ferritin mRNA. Binding of the IRF protein to these structures under 
conditions of iron starvation appears to stabilise the mRNA (Koeller et 
a! 1989). 
Sequences in the 3' UTR can also be responsible for correct 
localization of mRNAs in the cell. Examples are the oskar and bicoid 
mRNAs in Drosophila eggs that need to be localised to the posterior and 
the anterior end respectively. Transport and retention in the final 
location are achieved through RNA-protein interactions that involve 
binding of imperfect, but extended double-stranded mRNA sequences to 
the RNA-binding protein, staufen (reviewed in Jackson, 1993). Specific 
localization of a-actin and g-actin mRNAs in the differentiating 
myotubes requires a 63 nucleotide region (including a 12 nucleotide 
motif) in the 5' end of the 3' UTR of the mRNAs that probably interacts 
with an as yet unidentified RNA-binding protein (reviewed in Jackson, 
1993). 
Other important signals present in the 3' UTR are motifs known as 
cytoplasmic polyadenylation elements (CPEs) in Xenopus, or adenylation 
control elements (ACE) in the mouse, which control shortening of the 
poly(A) tail when the mRNA is masked at the first stages of oogenesis 
and the lengthening of the poly(A) during maturation, when the 
mRNA is translated (reviewed in Sàchs, 1993). All mRNAs contain a 
polyadenylation addition signal, AAUAAA in the 3' UTR. Evidence 
mainly based on studies in yeast demonstrate that deadenylation might 
be a prerequisite for mRNA degradation (reviewed in Kozak, 1987b). 
Apart from contributing to the mRNA stability, the poly(A) tail appears 
to enhance translation through interactions with the 5' cap structure 
(reviewed in Sonenberg, 1994). The poly(A) tail increases translation of 
capped mRNAs only and the 5' cap promotes translation of poly(A)+ 
mRNAs much better than poly(A)- mRNAs. Other studies suggest that 
interactions between sequences in the 3' UTR and sequences in the 5' 
UTR stimulate translation. Whether this involves direct interaction 
between these sequences or interaction with another protein, which 
could be a component of the translation initiation machinery, is not 
clear. A poly(A)-binding protein (PAB), that could mediate this 
interaction has been characterised in yeast. Interaction between the 5' 
and 3' UTR is also supported by electron microscopy studies (reviewed 
in Sonenberg, 1994). 
3.2 The 5' and 3' UTR of PrP mRNA 
The importance of 5' and 3' UTR sequences on mRNA regulation 
and translation was discussed in section 3.1. Data obtained using the 
transgenic mice generated with constructs that did not contain 5' or 3' 
UTR sequences of HaPrP, or intron sequences, indicated that these 
sequences were possibly involved in controlling PrP translation (section 
2.8). Investigating their role could possibly also give some insight into 
the function of PrP, since there is evidence suggesting that tightly 
regulated genes are usually regulatory proteins such as cell surface 
receptors, growth factors, transcription factors and cytokines, or 
protooncogenes, or proteins involved in development and 
differentiation (Sonenberg, 1994; Kozak, 1991a; Geballe and Morris, 1994). 
A remarkable feature of the PrP genes is that the 3' UTR sequence is 
conserved between mammals. Comparison of the 3' UTR of PrP mRNA 
of sheep with that of man and rodent (hamster and mouse) revealed 
certain regions that were up to 90% homologous (Goldmann et al., 1990, 
personal observations). Figure 3.2.1 shows the approximate regions of 
homology. The length of the most conserved regions was estimated 
through sequence alignments done with 'pileup' GCG7, University of 
Wisconsin Genetics Computer Group software package. The 
approximate length for each region was: A=180 bp, B=320 bp, C=240 bp, 
D=520 bp, E=440 bp, F=1440 bp G=160 bp. There are two sheep specific 
insertions (D and F regions, Figure 3.2.1), region B is not present in 
rodent PrP and region C is not present in human PrP. Because these 
comparisons revealed high conservation between certain regions, 
secondary structure analysis was performed in order to identify possible 
similarities in the structure of these regions ('fold' and 'squiggles' 
programs, of the software package mentioned above, were used). No 
conserved motif was found in any of the regions that showed homology 
on the primary sequence level. Also there was no similarity to known 
regulatory motifs (section 3.1). Primary sequence comparison between 
more PrP sequences in addition to those previously studied, including 
bovine, mink and rat PrP, revealed that only shorter regions within the 
regions previously defined exhibited over 50% homology. For example, 
in the 5' end of region B there is a 55 nucleotide stretch ('region B1) that 
shows 60% homology between the seven PrP sequences. Again, 
secondary structure analysis of these highly conserved regions failed to 
reveal a conserved secondary structure motif, although some structures 
exhibited similarity. Furthermore, the secondary structure analysis data 
showed that the same sequence would appear to have a different 
structure if different parts of the surrounding sequences were included 
in the analysis. Therefore, no conclusions could be drawn. A more 
informative approach would be to test whether the 3' UTR (and 
subsequently specific regions of the 3' UTR) are important for mRNA 
regulation and translation and then try to identify secondary structure 
motifs in these sequences. 
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Figure 32.1 Comparison of 3' UTR PrP mRNA sequences of man and rodent with the sheep. 
The different hatching represents different percentage of homology with the sheep sequence. 
This figure is based on (Goldmann eta! 1990, Figure 6). 
The 5' UTR of PrP is not well defined for most species and primary 
sequence comparison between known 5' UTR sequences revealed less 
than 50% homology. The existence of two upstream exons (i.e. in mouse 
PrP) contributes to the diversity of the 5' UTR PrP sequences. These 
features did not assist predictions as to whether any of these sequences 
could be involved in regulating translation by secondary structure 
inhibition or by regulatory proteins binding to certain motifs. The best 
approach would be to test the effect of different parts of the 5' UTR on 
translation efficiency. 
In some previous experiments, the initiation of translation and 
leader sequence of HaPrP were replaced with the 'optimal' consensus 
sequence (see Figure 3.5.2) and the human cytomegalovirus 5' leader 
sequence from pEE6hCMV vector (appendix 2), in order to obtain high 
level PrP protein production (Dr L. Wightman and Dr A. Bennett, 
personal communication). The HaPrP fragment (consisting of the ORF 
only) with the altered initiation of translation sequence, had been cloned 
in the polylinker of pEE6hCMV as a Hindlil-EcoRl fragment. Once this 
construct became available, it was used in cell culture in parallel with 
other constructs containing different parts of 5' UTR of HaPrP (see 
sections 3.5.1 and 4.2 and 4.5). 
3.3 Investigation of the role of the 5' and 3' UTR of HaPrP on 
translation 
To resolve the issues concerning PrP translation and possible 
presence of regulatory elements in the 5' and 3' UTR of PrP, the effect of 
these sequences on the translation of a reporter gene (lacZ) and on HaPrP 
was determined. lacZ would provide an easy and accurate assay system, 
but any regulation due to specific interactions between PrP sequences 
would be revealed only when 3' and 5' UTR PrP sequences are used 
together with the PrP ORF. 
Sequences investigated were the 3' UTR of HaPrP, the 5' UTR of 
HaPrP in exon 2 and the complete HaPrP 5' UTR (exon 1 and small part 
of exon 2). Also, the effect of changing the initiation of translation 
consensus sequence and changing the leader sequence together with the 
addition of a generic intron was investigated. Intron sequences are 
known to regulate transcription and their presence has been shown to be 
important both in vivo and in vitro (section 2.1). Although there is no 
clear evidence demonstrating that introns can positively regulate 
translation of mRNA (though when introns are not removed by splicing 
they can inhibit translation (Kozak, 1991a)), it would be interesting to 
investigate whether the presence of an intron can influence PrP 
translation. 
The effect of of these sequences on the translation of lacZ is 
presented in this chapter and the effect on the translation of HaPrP is 
presented in chapter 4. 
3.4 The effect of the HaPrP 3'UTR on lacZ translation efficiency 
3.4.1 Generation of pCEP1acZ and pCEP1acZ3'UTR constructs 
In order to identify possible translational control elements in the 3' 
UTR of HaPrP, the effect of the addition of the 1.2 kb 3' UTR of the 
HaPrP at the 3' end of the coding region of lacZ was investigated. 
The expression vector used for cloning of the different fragments 
was pCEP4 (Invitrogen, appendix 2), which has the human 
cytomegalovirus (hCMV) promoter and an SV40 poly(A) sequence at 
either side of the polylinker. The lacZ gene was derived from pSV-1-
galactosidase (pSV--gal) vector (Promega, see appendix 2). The 3287 bp 
Hindil-EcoRl lacZ fragment was excised from pSV--galactosidase vector 
and cloned into the polylinker of pSP72.polyl vector (appendix 2). 
pSP72.polyl was used as an intermediate vector for the cloning of lacZ 
because pCEP4 does not have an EcoRI site in the polylinker. 
pBluescriptll KS- could not be used because it already contains a portion 
of the lacZ gene, and cloning the lacZ gene could cause recombination 
between homologous parts and instability. The 320 bp lacZ fragment was 
PCR amplified with primers containing appropriate sites. The forward 
primer lacZ.1 (appendix 1) included the EcoRI site (present in the lacZ 
gene) and lacZ sequence beyond this site and the reverse primer, lacZ.2 
(appendix 1) included the sequence at the end of the lacZ gene, and 
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Figure 3.4.1 Generation of 12CEP1acZ construct 
The Hindill-EcoRl fragment containing lacZ sequences was sucloned into pSP72.polyl, to generate pSP72.polyl+lacZl 
PCR with appropriate primers gave the remaining 320 bp of lacZ, which was subcloned (3) into pSP72.polyl+lacZl 
as a EcoRI-NotI fragment to give pSP72.polyl+lacZ. 
(4) The entire lacZ fragment was subcloned into pCEP4 as a Hindill-Noti fragment to generate pCEP1acZ.b. 
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figure 3.4.2 Generation of pCEP1acZ3'UTR construct 
PCR with appropriate primers (introducing an XhoI and a BamHI site, see text) of the 1185 bp HaPrP 
3' UTR fragment. 
Subcloning of the 1185 bp fragment into pCEP1acZ construct to generate the pCEP1acZ3'UTR construct (3). 
of the polylinker of pSP72.polyl where the 3287 bp lacZ fragment had 
already been cloned (Figure 3.4.1). The 320 bp fragment and the regions 
around the cloning sites were fully sequenced to confirm that no 
mutations had been introduced by PCR. The whole Hindlil-Noti 
fragment was cloned into the polylinker of pCEP4 to generate the 
construct pCEP1acZ (Figure 3.4.1). 
The 3' UTR of PrP was PCR amplified from pHG327[Sst]/fi-QB 
vector (see also section 2.3.1, appendix 2). The forward primer, 3'UTR.1 
(appendix 1) corresponded to HaPrP sequences immediately beyond the 
HaPrP TGA stop codon and included a XhoI site and the reverse primer, 
3'UTR.2 (appendix 1) was located beyond the poly(A) addition signal, 
1185 nucleotides downstream the stop codon and included a BamHI site 
(Figure 3.4.2). pCEP1acZ3'UTR was generated by cloning the XhoI-BamHI 
HaPrP 3' UTR fragment downstream of the lacZ in pCEP1acZ (Figure 
3.4.2). 
3.4.2 Expression of lacZ-HaPrP 3' UTR fusion constructs 
The effect of the HaPrP 3' UTR on the translation of lacZ was 
determined by measuring L-gal enzyme activity in protein extracts from 
cos7 cells (monkey kidney cells) transfected with the lacZ constructs. 
Cells were transfected by calcium phosphate method (section 7.29.5) with 
pSV--gal in parallel with the two constructs described above (section 
3.4.1). Transfection with pCEP4 vector, (not containing lacZ sequences), 
as well as co-transfection of each construct with pCAT-control vector 
(Promega), containing the chloramphenicol acetyltransferase reporter 
gene, were always performed. RNA was extracted from one portion of 
the harvested cells and protein from the remainder. Northern blot 
analysis was performed with RNA from the transfected cell lines and the 
result was quantified by phosphorimager (chapter 7, introductory 
paragraph). The probe used was the Hindill-EcoRl fragment of lacZ 
(Figure 3.4.1). The transcript produced from pSV--gal and pCEP1acZ 
construct is 3.7 kb and from pCEPlacZ3'UTR 4.9 kb. CAT and a-gal 
activity assays were performed on the protein extracts of harvested cells 
(sections 7.27, 7.28). CAT activity assay served as a 
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Tables 3.4.1 and 3.4.2 Translation efficiency of lacZ-HaPrP 3' UTR 
constructs in transiently transfected cos7 cells 
(Co-transfections with pCAT construct) 
Table 3.4.1 
The ratio of I-Ga1 activity to lacZ mRNA indicates translation efficiency. 









construct a b b/a 
pCEP1acZ 0.68 0.25 0.29 1.16 
pCEP lacZ3'UTR 0.95 0.63 0.55 0.87 
pSV--Gal 1 1 1 1.00 
pCEP(control) 0.89 0 —0 
Table 3.4.2 
Data from three experiments. 
translation efficiency relative to pSV-1-gal 
construct 1 2 3 average 
pCEPlacZ 1.16 0.95 1.21 1.1 
pCEP lacZ3'UTRI 0.87 0.91 1.15 0.9 
pSV-I-Gal 1 1 1 1 
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control for transfection efficiency levels. Measurements of s-gal mRNA 
levels, CAT and s-gal enzyme activity were first expressed in relation to 
the values obtained in parallel by co-transfection with pSV-R-gal and 
pCAT. The ratio of f-gal activity to lacZ mRNA would give the 
translation efficiency for each construct. 
One experiment is presented in detail as an example (Table 3.4.1, 
Figure 3.4.3) and the average of three experiments is presented in Table 
3.4.2). The 1-gal mRNA levels presented in table 3.4.1 were estimated on 
the Northern blot shown in Figure 3.4.3. 
The results obtained demonstrated that pCEP1acZ and 
pCEP1acZ3'UTR had a small insignificant difference in translation 
efficiency. 
3.4.3 Conclusions 
The results presented here indicate that the HaPrP 3' UTR does not 
have a significant effect on the translation of lacZ in cos7 cells, 
suggesting that it is not likely to contain any elements necessary for 
translation regulation. However, the possibility that the HaPrP 3' UTR 
has an effect only when combined with the HaPrP ORF, or an interaction 
between the 3' HaPrP UTR and the 5' HaPrP UTR cannot be excluded. 
Constructs containing different parts of the HaPrP gene would give an 
insight to this issue. Results considering constructs containing different 
HaPrP sequences are presented in chapter 4. 
The effects of different 5' UTR portions of the HaPrP gene on the 
translation of lacZ were assessed by generating a series of 5' UTR HaPrP-
lacZ fusion constructs and testing them in cell culture as presented in 
section 3.5. 
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Figure 3.4.3 Northern blot analysis of transiently transfected cos7 cells 
Probed with the lacZ Hindill-EcoRl fragment. 







Figure 3.5.4 Northern blot analysis of transiently transfected cos7 cells 
Probed with lacZ Hindlil-EcoRl fragment. 
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3.5 Comparison of translation efficiency between 5' UTR HaPrP-
lacZ fusion constructs 
3.5.1 Generation of 5' UTR HaPrP-lacZ fusion constructs 
Three different HaPrP 5' UTR-lacZ constructs were generated. Each 
contained a different 5' UTR sequence and the entire HaPrP ORF region 
fused to the lacZ gene. The stop codon of HaPrP and the first codon of 
lacZ were deleted (Figure 3.5.1), but the reading frame was preserved so 
as to create a functional HaPrP-lacZ fusion protein. This was possible by 
using PCR with appropriate primers for the HaPrP fragments prior to 
cloning in pgeo vector (appendix 2). The sequence of pgeo around the 
NruI cloning site at the beginning of the lacZ gene is shown in Figure 
3.5.1. The three different 5' UTR sequences used were: 
the 5' UTR sequence of HaPrP in exon 2 (10 nucleotides). 
the complete 5' UTR HaPrP sequence including exon 1 (60 nucleotides) 
and the 5' UTR of exon 2 (10 nucleotides). 
the 'optimal' initiation of translation consensus sequence directly 
upstream of the initiation codon of HaPrP. 
The 'optimal' consensus sequence has been used previously in 
conjunction with the HaPrP ORE and has been demonstrated to produce 
high HaPrP expression in cell culture (Dr A. Bennett and Dr L. 
Wightman, personal communication). The sequence of the three 
different 5' regions are presented in Figure 3.5.2. 
Genomic DNA from hamster brain was used to amplify by PCR a 
portion of HaPrP exon 2, containing the 5' UTR and the HaPrP ORE. RT-
PCR on hamster brain RNA was applied in order to obtain the complete 
HaPrP 5'UTR (consisting of exon 1 and portion of exon 2) and the HaPrP 
ORF. The plasmid pEE6hCMVneoHaPrP (appendix 2) was used to 
amplify by PCR the HaPrP fragment with the 'optimal' consensus 
sequence. The reverse primer used for all three HaPrP fragments was 
3'HalacZ (appendix 1, Figure 3.5.1) and included lacZ sequences up to the 
NruI site (including the NruI site and two more nucleotides, Figure 
3.5.1). The forward primer for exon 2 was 5'ex2.a (appendix 1), for exon 1 
was 5'exl.a (appendix 1) and for the 5' 'optimal' consensus, 5'Ko 
(appendix 1). 
p8geopo1y1inker 	I lacZ 
51 Sail 	 NcoI 	NruI 
GTC GAC CTG CAG GAG CCC CCC 	GCT CGC GAT CCC * 
51
HaPrP ORF (3') 
c-rc ATC UC CTG ATG CTG GGA@ 




HaPrP ORF (3') I lacZ51 	 3, fusion I 
gene 	CTC ATC TFC CrC ATC CTG GGA 1 CCT CCC CAT CCC 
Figure 3.5.1 Fusion of 3' of HaPrP ORF with the lacZ (doned in pl3geo vector) 
The polylinker of pf3geo . The Sail and the NruI sites were used for doning 
the •HaPrP PCR fragments. 
The 3' end of HaPrP ORF was fused in frame to the lacZ gene. This was 
achieved by using as a reverse primer to PCR amplify the HaPrP fragment, 
3'HalacZ oligo, which induded HaPrP and lacZ sequences (containing the 
NruI site). 
The stop codon of PrP and the initiation codon of lacZ have been deleted 
to generate an in frame HaPrP-lacZ fusion. 
complete 
5' UTR of 
HaPrP 51 
exon 1 CCGGCGTCCGACCAGCACACCGAGAAGGCA 
(60 bp) CATCGACTCCACFCCTCGCGTCGCTCGCAG 
exon 2 ATCA CCC A TdG 
(lObp) # I 	3' 
5 	 I 
ATCA CCC A T4G HaPrP exon 2 
'optimal' 
consensus GCC CCC A CCK)G 
for initiation I 





of translation 	CCC CCC A/C CC 
(Kozak 1987b) 
consensus sequence 
for initiation 	 CCC A/C CC 
of translation 
(Kozak 1991a, 1991b) 
—. 	 - 	r1 	.1 	 . ,-, Trr'ys - - - -- --- -- - - L_TT 	 1__7 
Three different 5' UTR sequences were used upstream of the HaPrP ORF. 
These 5' UTR-HaPrP ORF PCR fragments were fused to the lacZ gene in 
p9geo (see Figure 3.5.1) to generate the three lacZ-HaPrP ORF fusion 
constructs presented in Figure 3.5.3. 
The sequence surrounding the initiator AUG in each of the constructs is 
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Figure 3.5.3 Generation of 5' UTR HaPrP ORF-lacZ fusion constructs 
The 5' UTR of pE2HaPIgeo consists of exon 2 sequences. pE1,2HaP8geo includes exon 1 (complete 5' UTR 
of HaPrP). In pKoHaPLgeo construct, the 5' UTR of HaPrP has been replaced with the 'optimal' consesnsus 
sequence (see text and Figure 3.5.2). 
The three forward primers included a Sail site. After the PCR step, each 
of the three HaPrP fragments was cloned as a SalI-NruI fragment in 
pIgeo vector to generate the constructs pE2HaP9geo, pE1,2HaPLgeo and 
pKoHaPgeo as shown in Figure 3.5.3. The HaPrP fragment in each 
construct was fully sequenced, using internal HaPrP oligos, to ensure 
that no mutations had been introduced by the PCR step (the 
proofreading DNA polymerase UlTrna (Perkin Elmer) was used) and the 
junction between HaPrP and lacZ was sequenced to confirm that the 
fusion was in frame. 
3.5.2 Expression of 5' UTR HaPrP-lacZ fusion constructs 
The two constructs containing different 5' ends of the HaPrP gene, 
pE2HaP1geo (including the 5' UTR of exon 2) and pE1,2Ha1geo 
(including the 5' UTR of exon 1 and exon 2) and the construct made with 
the 'optimal' consensus sequence, pKoHaLgeo, were tested for 
translation efficiency after transfection in cos7 cells. As before the cells 
were co-transfected with the pCAT vector. The dark blue colour of 
transfected cells after X-Gal staining indicated that the lacZ gene was 
functional in all three constructs. Measurements of lacZ mRNA levels, 
CAT and f-gal enzyme activities are shown relatively to the values 
obtained by co-transfection with pE2HaP1geo and pCAT constructs 
(Table 3.5.1). The amounts of RNA presented in Table 3.5.1 were 
estimated by phosphorimager analysis based on the Northern presented 
in Figure 3.5.4. The Northern was probed with the Hindill-EcoRl lacZ 
fragment (Figure 3.4.1) and the transcript size is similar for the three 
constructs (5 kb). The ratio of a-gal activity to 1-gal mRNA levels 
represents the translation efficiency for each construct. An example of 
the calculations is shown in Table 3.5.1 and the average of three 
experiments is shown in Table 3.5.2. 
Tables 3.5.1 and 3.5.2 Translation efficiency of HaPrP 5' UTR-lacZ fusion 
constructs transiently transfected in cos7 cells 
(Co-transfections with pCAT construct) 
Table 3.5.1 
The ratio of g-Gal activity to lacZ mRNA indicates translation efficiency. 









construct a b b/a 
pE2HaPgeo 1 1 1 1.00 
pE1,2HaP1geo 1.25 1.12 1.95 1.74 
pKoHaPIgeo 1 	0.69 0.74 1.16 1.57 
pCEP (control) 1 0.8 	1 0 1 	-0  
Table 3.5.2 
Data from three experiments. 
translation efficiency relative to pE2HaPgeo 
construct 1 2 3 average 
pE2HaPgeo 1 1 1 1 
pE1,2HaP1geo 1 	1.74 1.68 1.97 1.79 
pKoHaPRgeo 1 1.57 1.62 1.73 1.64 
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3.5.3 Conclusions 
The HaPrP-lacZ fusion constructs produced a functional lacZ gene 
when tested in cell culture, as demonstrated by X-Gal staining of 
transfected cells and I-gal activity assays. Apart from having an intact 
coding sequence, lacZ protein should be intracellular to be active. In the 
HaPrP-lacZ fusion proteins produced here, we assume that the HaPrP 
region of the protein was extracellular, attached to the membrane either 
by a GPI anchor, as normally expected (see 1.7) or, in case the GPI 
addition reaction was inhibited by the presence of lacZ in the fusion 
protein, by the short transmembrane sequence that serves as the signal 
for GPI addition. The lacZ part of the protein should remain 
intracellular, maybe attached to the membrane by the transmembrane 
part of PrP, or released as a soluble protein in the cell (by unknown 
mechanism) and therefore active. This fact enabled the comparison of 
translation efficiency between the constructs. 
The results shown here suggest that there are no major differences 
in translation efficiency produced by the use of the different 5' UTR 
fragments. However, pE1,2HaP1geo appears to translate slightly better 
than the other two constructs and the construct that has only 10 
nucleotides of HaPrP exon 2 as a 5' UTR, translates worse. Any increase 
or decrease in translation efficiency observed is less than 2-fold. 
These data suggest that even if exon 1 cOntains some regulatory 
elements they are probably rather weak, because the differences in 
translation efficiency are not significant. 
The possibility that regulatory elements in the 5' UTR are active 
when HaPrP sequences alone are present, or an interaction between 5' 
and 3' HaPrP UTR is crucial for regulation of translation, cannot be 




The effect of 3' and 5' untranslated sequences 
on the translation of hamster PrP 
4.1 Introduction 
The role of 3' UTR sequences on translation was discussed in 
section 3.1. Although it has been postulated that the HaPrP 3' UTR 
might have an effect on the translation efficiency of HaPrP, it does not 
appear to have a significant effect on lacZ translation (section 3.4.3). 
Similar observations were obtained when the effect of different 5' UTR 
sequences of HaPrP on lacZ translation was tested (section 3.5.3). 
It was decided that the effect of these sequences on the translation 
of HaPrP should be investigated. Three constructs based on 
pBluescriptllKS- were initially generated (section 4.2) and tested in an in 
vitro translation system in order to assess whether these HaPrP 
fragments were translatable and whether there were significant 
differences in the amounts of protein produced (section 4.3). These 
fragments were subcloned into the vector pCEP4 (appendix 2) and used 
for expression experiments in cell culture. Problems with the production 
and/or the detection of HaPrP protein were encountered (section 4.4.1). 
The use of different cell lines and different protein analysis techniques 
was investigated. Further constructs, based on pEE6hCMV vector, were 
generated (section 4.5) and tested in cell culture (section 4.6). A construct 
containing the same HaPrP fragment as that used in the transgenic 
construct was generated and tested in parallel. Latterly a detection 
method for HaPrP protein has been established. This made possible the 
quantification of translation efficiencies of the different constructs 
(section 4.6). 
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4.2 Generation of pBluescriptllKS-HaPrP and pCEP4-HaPrP 
constructs. 
The different HaPrP fragments (Figure 4.2.1) were obtained either by 
PCR from hamster brain genomic DNA, or by RT-PCR from hamster 
brain total RNA, using the proofreading DNA polymerase UlTma 
(Perkin Elmer). All fragments were initially cloned in pBluescriptllKS-
and were fully sequenced to ensure that no mutations had been 
introduced during the PCR step. The fragment HaP contains the 5' UTR 
of exon 2 (10 nucleotides, see Figure 3.5.2) and the same 3' as the HaPrP 
fragment used for the generation of transgenics (168 nucleotides of the 3' 
UTR, see also section 2.3.1). The forward primer used to amplify by PCR 
this fragment was 5'ex.2.b (appendix 1) and introduced an XhoI site. The 
reverse primer, 3'UTR.3 (appendix 1)is similar to oligo 3'HaP, used for 
PCR amplification of the HaPrP fragment in the transgenic construct, but 
includes a BamHI site. The HaPU fragment has the same 5' end as the 
HaP fragment but includes the 3'UTR of HaPrP (1.2 kb). The forward 
primer was 5'ex.2.b (appendix 1) and the reverse primer, 3'UTR.2 
(appendix 1) introduced a BamHI site. The HaEPU fragment represents 
the complete cDNA HaPrP fragment and was obtained by RT-PCR from 
hamster brain RNA. It has the same 3' end as the HaPU fragment but 
includes exon 1 (60 nucleotides, see Figure 3.5.2) at the 5' end. The 
forward primer, S'ex.l.b (appendix 1), introduced an XhoI site. The 
reverse primer was 3'UTR.2, used also for PCR amplification of the 
HaPU fragment. The three XhoI-BamHI fragments were cloned into the 
pBluescriptllKS- (Figure 4.2.1) before subcloning into pCEP4 (Figure 
4.2.2). 
4.3 In vitro translation of HaPrP constructs 
As mentioned in section 4.1, in order to test whether the different 
HaPrP segments were translatable and to compare approximately the 
amount of protein that was produced, a rabbit reticulosyte lysate (RRL) 
in vitro translation system was used (section 7.25). RNA was prepared in 
vitro with T3 RNA polymerase (section 7.10) from the pBlueHaP, 
pBlueHaPU and pB1ueHaEPU constructs (Figure 4.2.1) after linearisation 
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Figure 4.2.1 cloning of HaPrP 1CR fragments in 
12BluescriptllKS- 
Cloning of the 940 bp HaP PCR fragment in pBluescriptllKS-
to generate pBlueHaP. 
Cloning of the 1950 bp HaPU PCR fragment in 
pBluescriptllKS- to generate pBlueHaPU. 
Cloning of the 2010 bp HaEPU PCR fragment in 
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Figure 4.2.2 Generation of 12CEP4-HaPrP constructs 
Cloning of the 940 bp HaPrP fragment in pCEP4 to generate the construct pC HaP. 
Cloning of the 1950 bp HaPrP fragment in pCEP4 to generate the construct pC HaPU. 
Cloning of the 2010 bp HaPrP fragment in pCEP4 to generate the construct pC HaEPU. 
Figure 4.3.1 In vitro translation and immunoprecipitation of 
pBluescriptllKS- HaPrP constructs 
A. Translation of pBlueHaP and pBlueHaPU constructs in the Promega 
RRL. 
500 ng of in vitro produced RNA (section 7.8) were used for each 
reaction and half of the reaction was used for SDS-PAGE (section 7.21.3). 
translation of pBlueHaP RNA 
translation of pBlueHaPU RNA 
negative control: no RNA 
B. Translation of pBlueHaP and pB1ueHaEPU constructs in the Gibco-
BRL RRL. 
500 ng of in vitro produced RNA (section 7.8) were used for the reactions 
and half of each reaction was used for SDS-PAGE (section 7.21.3) in lanes 
land 2. 
500 ng of CAT RNA (provided by the manufacturers) was used in a 
translation reaction and a quarter was used for SDS-PAGE in lane 5. 
translation of pB1ueHaEPU RNA 
translation of pBlueHaP RNA 
The remaining of the reaction shown in lane 1 (translation of 
pB1ueHaEPU) was split in two samples and each was used for 
immunoprecipitation (ip) with the 3F4 ab (lanes 3 and 4). 
ip of pB1ueHaEPU-produced HaPrP with 3F4 ab 1:500 
ip of pB1ueHaEPU-produced HaPrP with 3F4 ab 1:250 
control reaction: CAT (24 kD) 
Immunoprecipitation of in vitro translated pBlueHaPU construct in the 
Promega (C) and the Gibco-BRL (D) RRL. 500 ng of in vitro produced 
RNA (section 7.8) were used for each reaction and the whole reaction 
was used for immunoprecipitation (ip) with the 3F4 ab. 1 jig of 
luciferase, or CAT RNA provided by the manufacturers, was also 
translated and half of the reactions were used for SDS -PAGE. 
C. 	1. control reaction: luciferase (68 kD) 
negative control reaction: no RNA 
ip of pBlueHaPU-produced HaPrP with 3F4 ab 1:200 
D. 	1. ip of pBlueHaPU-produced HaPrP with 3F4 ab 1:400 
control reaction: CAT (24 kD) 
negative control reaction: no RNA 
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with BamHI (which cuts in all constructs just beyond the 3' end of the 
HaPrP fragments). After purification of the RNA produced by in vitro 
transcription and quantification, approximately the same amount of 
RNA was used from each construct for translation in the RRL. The three 
constructs appeared to produce HaPrP protein, which is unglycosylated 
and therefore 26-27 kD in size (Figure 4.3.1). The protein produced was 
also immunoprecipitated (ip, section 7.23) with the monoclonal antibody 
(ab) 31`4 (Kascsak et al., 1987) (Figure 4.3.113,C,D). Also, a translation 
reaction with control CAT, or luciferase RNA (provided by the RRL 
manufacturers, section 7.25) was sometimes performed in parallel with 
the other reactions (4.3.1C,D). The fainter bands appearing in most lanes 
above the main protein band are probably multimers of the protein and 
those bands below are presumed to be proteolytic products. 
These results demonstrate that the three different HaPrP fragments 
are able to produce HaPrP protein and there is no major difference in the 
amount produced. Immunoprecipitation of the in vitro translated PrP 
protein was performed. Establishment of this method was crucial for the 
detection of HaPrP protein in cell culture and it was used instead of 
Western blot (section 4.6). 
4.4 Translation of pCEP4-HaPrP constructs in cell culture 
4.4.1 Initial attempts: difficulties in detecting HaPrP protein 
The three pCEP4 based constructs pC HaP, pC HaPU and pC HaEPU, 
were initially tested for their translation efficiency in cos7 cells. 
Transient transfections were performed by the calcium phosphate 
method (section 7.29.5). Half of the harvested transfected cells was used 
for RNA extraction and the rest for protein extraction. The results of 
nine transfection experiments are shown in Figure 4.4.1. Northern blot 
analysis (Figure 4.4.1A) showed that it was possible to achieve 
production of substantial amounts of mRNA by the transfected 
constructs, but PrP protein was not detectable by Western blot analysis 
(Figure 4.4.1B,C). These data indicated that either the mRNA produced 
was not translated efficiently and/or that the Western blot analysis was 
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Figure 4.4.1 
A. Northern blot analysis transiently transfected cos7 cells 
The probe used was the HaP fragment (HaPrP ORF-containing 940 bp 
fragment, see Figure 4.2.1) 
cells 	construct 
1. 	cos7 pCHaP 
 cos7 pC HaEPU 
 cos7 pC HaPU 
 cos7 pCHaP 
 cos7 pC HaEPU 
 cos7 pC HaEPU 
 cos7 pC HaPU 
mouse brain 
 cos7 pCEP 
 N2a pCEP 	(underloaded) 
B and C Western blot analysis of transiently transfected cos7 cells 
Probed with the mouse monoclonal HaPrP specific ab 3F4. 
probed with the rabbit polyclonal anti-PrP ab 1B3. 








The protein extracts used in lanes 2 and 3 correspond to the RNA 
samples from transfected cell lines shown in lanes 1 and 2, respectively, 
in the Northern blot analysis (A), and the protein extracts in lanes 5 and 
6 correspond to lanes 9 and 10, respectively, in A. No Western blot 
analysis is shown for the rest transiently transfected cell lines analysed by 
Northern blot in A, because the amount of RNA produced by the 
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not sensitive enough. Also, endogenous PrP mRNA was present in cos7 
cells but PrP protein was not detectable, in contrast to N2a cells (mouse 
neuroblastoma), suggesting that the PrP protein production/detection 
problem could be due to the use of cos7 cells. Previous studies have 
shown that although cos7 are able to express PrP, the protein does not 
seem to be normally processed and substantial amounts were found to 
be secreted into the medium instead of being retained on the plasma 
membrane (Scott et al., 1988), suggesting that probably cos7 cells were not 
the best system for studying PrP expression. N2a cells are now used 
extensively for expression of PrP (section 1.12.2). The difference in 
translation efficiency regarding PrP between cos7 and N2a is possibly due 
to the fact that N2a are of neuronal origin while cos7 are kidney-derived. 
Similar observations were made with different mouse tissues: brain 
translates PrP mRNA much more efficiently than any other tissue (see 
also section 2.8). 
Several attempts to transfect N2a cells by the calcium phosphate 
method (which gave high percentage of transfected cells when 
performed on cos7 cells), failed repeatedly. Transfection using lipofectin 
was also attempted without success, although different concentrations of 
DNA and amounts of lipofectin were tried (data not shown). 
Electroporation was also applied, giving better results from the other 
methods. Table 4.4.1 presents some of the different parameters tested for 
electroporation of N2a cells. Electroporation was not without problems 
and often produced extensive cell death. It was determined that stably 
transfected lines should be generated. The fact that the pCEP4 construct 
included the gene for hygromycin resistance facilitated the production of 
stably-transfected N2a cell lines. Stable lines were also produced with 
cos7 (using the calcium phosphate method) so as to continue the 
comparison between the two cell lines. N2a cells were electroporated 
with linearised pCEP4-HaPrP constructs (using the single Clal site 
beyond the SV40 poly(A) sequence, see pCEP4 appendix 2). 72 hours after 
transfection the cells underwent selection in medium containing 
hygromycin for approximately three weeks before they were analysed. A 
titration of the amount of hygromycin that should be used was initially 
determined on both N2a and cos7 as shown in Figure 4.4.2. After the 
selection period, aliquots were harvested and used for RNA and protein 
analysis. Stable cell lines were maintained in medium containing 
PTIJ 
I' 
No media Voltage Capaci- amount of 
of cells 500 p1 (V) tance (tF) DNA —survival% —transfected% 
2X106 PBS 150 500 10 tg 60% >1% 
2X106 PBS 150 960 lOj.tg 60% >1% 
4X106 optimem 250 500 10 .'g 30% >1% 
4X106 optimem 250 960 10 pg 20% >1% 
3X106 optimem 450 500 10 pg 5% 1-5% 
3X106 optimem 450 960 10 p.g 1-5% 1-5% 
3X106 optimem 450 500 30 .'g 5% 1-5% 
3X106 optimem 450 960 30 ig 1-5% 1-5% 
2X106 PBS 450 500 10 pg 5% 1-5% 
2X106 PBS 450 960 10 tg 1-5% 5% 
3X106 PBS 450 500 30pg 5% 5% 
3X106 PBS 450 960 1 	30 tg 1-5% 5-10% 
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Figure 4.4.2 Hvromvcin selection of cos7 and N2a cells 
la. Survival of cos7 cells in 200 jig/mi hygromycin. 
lb. Survival of cos7 cells in 400 jig/mi hygromycin. 
Survival of N2a cells in 400 jig/mi hygromycin. 
Survival of N2a cells in 600 jig/mi hygromycin. 
111 
Figure 4.4.3 
A. Northern blot analysis of stable cell lines 






 cos7 pCHaP 
 cos7 pC HaEPU 
 N2a pC HaP 
 N2a pC HaPU 
 N2a pC HaEPU 
B. and C. Western blot analysis of stable cell lines 
Probed with the mouse monoclonal HaPrP specific ab 3F4 
Probed with the rabbit polyclonal anti-PrP ab 1B3 
The samples are in the same order on both blots. 
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hygromycin. No individual colonies were picked at the end of the 
selection period. In each pooi examined there were approximately 20-30 
colonies. Three N2a and three cos7 poois were made with the three 
constructs: pC HaP, pC HaPU, and pC HaEPU. The mRNA and protein 
analysis from some of the stable cell lines is shown in Figure 4.4.3. These 
data demonstrated that the stable cell lines show low mRNA expression 
and no detectable protein on a Western blot. Also, Western blot analysis 
appeared to give very high background, especially with the 31`4 antibody. 
Another construct pEE6hCMVneo-HaPrP (appendix 2, see also 
section 3.5.1) that was shown previously to express HaPrP protein in cell 
culture (Dr A. Bennett and Dr L. Wightman personal communication; 
pEE6hCMV-HaPrP was agenerous gift from Dr L. Wightman) was used 
as a positive control. This construct is based on pEE6hCMVneo construct 
(Celitech) which contains a fragment of the human cytomegalovirus 
(CMV) enhancer-promoter and includes the 5' UTR of the CMV 
immediate early gene with the leader intron. The HaPrP fragment (800 
bp) was cloned as a Hindill-EcoRl fragment in the polylinker of this 
construct and contained only the HaPrP ORF (from the ATG start codon 
to TGA stop codon) and had the 'optimal' initiation of translation 
consensus sequence upstream of the ATG (see also Figure 3.5.2). When 
this construct was tested by transient transfection in cos7 cells and was 
compared for mRNA and protein expression with the stable lines 
generated, it appeared to produce much higher amounts of mRNA and 
some HaPrP protein (Figure 4.4.4). However, the HaPrP protein 
produced did not give exactly the expected size or pattern (Figure 
4.4.4B,C, lanes 5, 6, 7) indicating that it may not be correctly processed. 
For the mRNA analysis presented in Figure 4.4.4A, hybridisation with 
the S26 sequence (mouse ribosomal protein, gift from Dr B. Davies) was 
used as a loading control, although the hybridisation signal obtained 
from N2a cells is much stronger than that from cos7, because N2a cells 
are of mouse origin. Therefore loading comparisons between N2a and 
cos7 cells are based on ethidium bromide staining. 
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Figure 4.4.4 
A. Northern blot analysis transfected cell lines 
The probe used was the HaPrP fragment (940 bp, see Figure 4.2.1) 
cells transfection construct 
 cos7 transient pCEP 
 cos7 stable pC HaP 
 cos7 stable pC HaPU 
 cos7 stable pC HaEPU 
 cos7 transient pE HaKo 
 N2a 
 N2a stable pC HaP 
 N2a stable pC HaPU 
 N2a stable pC HaEPU 
mouse brain 
B. and C. Western blot analysis of transfected cell lines 
Probed with the mouse monoclonal HaPrP specific ab 3F4 
Probed with the rabbit polyclonal anti-PrP ab 1B3 
The samples are in the same order on both blots. 
cells transfection construct 
 cos7 transient pCEP 
 cos7 stable pC HaP 
 cos7 stable pC HaPU 
 cos7 stable pC HaEPU 
 cos7 transient pE HaKo 
 cos7 transient pE HaKo 
 cos7 transient pE HaKo 
 N2a 
 N2a stable pC HaP 
 N2a stable pC HaPU 
 N2a stable pC HaEPU 
mouse brain 
From the transiently transfected cells the protein extract on lane 5 
corresponds to the RNA shown in A lane 5. No RNA data are shown 
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4.4.2 Conclusions 
The generation of the stable lines did not help in elucidating the 
problems encountered with the translation and/or detection of HaPrP 
protein because they produced very low amounts of mRNA and no 
detectable protein. 
It was postulated that the difficulty in transfecting N2a cells might 
have been specific to the N2a substrain employed. Therefore N2a cells 
were obtained from a different source (ICN) and evaluated for their 
transfection efficiency. 
The pEE6hCMVneoHaPrP construct used as a control, had a 
fragment of the human CMV that included an intron (not present in the 
human CMV promoter fragment of pCEP4). Also the HaPrP fragment in 
that construct did not have the original initiation of translation 
consensus sequence but the optimal consensus sequence (see Figure 
3.5.2). The importance of the intron and the initiation of translation 
consensus sequences have been discussed in section 3.1. It was decided 
that the effect of the hCMV intron and the different consensus sequence 
should be tested on the translation of PrP. More constructs based on 
pEE6hCMVneo were generated as presented in section 4.5. These 
constructs, together with the pCEP4-based constructs, were tested by 
transient transfection in both cos7 and N2a cells (section 4.6). 
Quantification of the translation results became possible after 
establishing an efficient transient transfection method for N2a cells and 
efficient PrP protein detection method (immunoprecipitation), (section 
4.6). 
4.5 Generation of pEE6hCMVneo-HaPrP constructs 
The pEE6hCMVneo vector (appendix 2, see also section 4.4.1) was 
used for subcloning different HaPrP fragments previously cloned in 
pCEP4 (constructs pC HaP and pC HaEPU). The HaP and the HaEPU 
fragments were cloned in pEE6hCMVneo to generate pE HaP and pE 
HaEPU constructs as shown in Figures 4.5.1 and 4.5.2. The same cloning 
strategy was followed for both fragments. The EcoRI linker used was 
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hCMV 	 HaPrP 	
SV4O
poly(A) promoter XhoI 	940 bp BarnHI 
pC HaP 
hCMV 	 HaPrP 







pE HaP (3) 
hCMV 	 SV4O  
enhancer-promoter 5'UTR 	
HdIII 	940 bp 	EcoRl 230 bp 2100 bp 	intron 	
HaPrP poly(A) 
ORF  
Figure 4.5.1 Generation of pE HaP construct 
pC HaP was digested with BamHI and EcoRI linkers were added, 
but the final digestion step with EcoRl was omitted. The fragment 
was purified through a 'Wizzard' column to avoid the remaining un 
ligated EcoRI linkers. 
The HaPrP fragment was digested with XhoI and Hindill adaptors 
were ligated. EcoRI digestion was applied to remove the EcoRl linker 
concatamers. 
HindIII-EcoRl HaPrP fragment was eventually cloned in 
pEE6hCMVneo to generate pP HaP. 
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Figure 4.5.2 Generation of pE HaEPU construct 
pC HaEPU was digested with BamHI and Ecom linker was added, but the final digestion step with 
EcoRI was ommited. The fragment was purified through a 'Wizzard' column to avoid the remaining un 
ligated EcoRI linker. 
The HaPrP fragment was digested with XhoI and Hindill adaptors were ligated. EcoRI digestion was 
applied to remove the EcoRJ linker concatamers. 
Hindill-EcoRl HaPrP fragment was eventually cloned in pEE6hCMVneo to generate pE HaEPU. 
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Figure 4.5.3 Generation of constructs tested in cell culture (a) 
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Figure 4.5.4 Generation of constructs tested in cell culture (b) 
oligo EcoRli. (appendix 1) and the Hindlil adaptors were oligos Hind.ad.1 
and Hind.ad.2 (appendix 1). 
It was also decided to subclone the HindIII-BamHI HaPrP fragment 
(800 bp) that was cloned in pEE6hCMVneoHaPrP construct, in pCEP4 to 
generate the construct pC HaKo. The PEE6hCMVneoHaPrP construct 
was renamed pE HaKo for simplicity. 
Testing the translation efficiency of the HaPrP fragment (900 bp) 
used initially for the generation of transgenics in cell culture was 
considered important. This fragment was initially cloned as a Hindlil-
EcoRI fragment in the polylinker of pBluescriptllKS-. The XhoI and 
BamHI sites of the construct (Figure 2.3.1) could be used to excise that 
fragment and clone it between the XhoI and the BamHI sites of pCEP4 to 
generate the construct pC HaPd5'. All the constructs generated are 
presented in Figures 4.5.3 and 4.5.4. 
4.6. Translation of pCEP-HaPrP and pEE6hCMVneo-HaPrP 
constructs in cell culture 
4.6.1 Comparison of translation efficiency between the constructs 
The transfection efficiency of the more recent aliquot of N2a cells 
was tested. Different transfection methods were used and compared to 
those of the N2a cells used for all previous transfections. These cells 
responded in a different way and also showed morphological differences. 
The calcium phosphate method gave higher transfection efficiency and 
less cell death than the two other methods applied, electroporation and 
lipofection (data not shown). This method enabled quick and efficient 
testing of the constructs by transient transfection and therefore helped to 
overcome the problems encountered with the stable transfections 
(section 4.4.2). 
Efforts also concentrated on establishing an efficient way for 
detecting PrP protein. Immunoprecipitations (ip, section 7.23) from 35S-
labeled (section 7.22.1), transfected cells (section 7.29.5) provided a 
solution to the detection problems encountered when Western blot 
analysis was applied. This method allowed the detection of small 
amounts of PrP protein and reduced the background. 
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Figure 4.6.1 
Immunoprecipitation of transfected cell lines with the 3F4 mouse 
monoclonal Ha PrP specific ab. 
cells transfection construct 
N2a transient pCEP 
(immunoprecipitated with the rabbit polyclonal anti-PrP ab 1A8). 
N2a transient pCEP 
N2a transient pE HaKo 
N2a transient pE HaKo 
N2a stable pC HaP 
N2a transient pC HaP 
N2a transient pC HaEPU 
cos7 transient pCEP 
cos7 transient pE HaKo 
cos7 transient pE HaEPU 
Figure 4.6.2 
Pulse-chase of transiently transfected N2a and cos7 
N2a and cos7 were transiently transfected with pC HaEPU construct and 
the protein extract was immunoprecipitated after 2 h pulse and 0, 4 and 8 
h chase. 
A. pulse-chase of N2a cells 
0 h chase 
4 h chase 
3.8hchase 
B. pulse-chase of cos7 cells 
8h chase 







PrP{ 	 1V 29.5kg 
8 	9 10 
}PrP 
18.4 kD - 
A 	2 	3 
214kD- - 
111.4 kD 






45.5 kD - 
& 
29.5kD 	 $ I PrP 
29.5 kD- '4 I Prp 
18.4 kD- 
Immunoprecipitations were performed with the monoclonal anti-
PrP antibody (ab) 3F4 (Kascsak et al., 1987) usually at 1:500 dilution, or the 
polyclonal antibodies 1B3, or 1A8 (Farquhar et al., 1989) usually 1:1000 
dilution. The 3F4 ab recognises the protein produced only by the 
constructs (HaPrP) and not the endogenous mouse or monkey PrP of the 
N2a or cos7 cells respectively. The polyclonal antibodies were used to 
show the endogenous amounts of PrP and in one experiment they were 
used for a comparison between the translation of the endogenous 
message and that produced by the constructs. The ip results could be 
quantified by phosphorimager. One of the first attempts to compare the 
amount of HaPrP protein produced by the different constructs is shown 
in Figure 4.6.1. Precise conclusions could not be made because there were 
no data on the amount of HaPrP mRNA that these transfected lines 
produced (there were insufficient cells for RNA extraction). However, 
these results suggested that there was a difference in the translation 
efficiency and the processing of HaPrP between N2a and cos7 cells. 
To investigate whether the turnover of PrP differs between cos7 
and N2a cells, the half-life of the HaPrP protein produced by one of the 
constructs (pC HaEPU) was determined. The protein extract from both 
transfected cell lines was immunoprecipitated with 3F4 ab after 4 and 8 
hours chase period following a 2 hour pulse period (section 7.22.2). The 
results of that experiment is shown in Figure 4.6.2. These data suggested 
that there is no major difference in HaPrP turnover between the two cell 
lines. 
The comparison between one of the N2a stable lines (Figure 4.6.1, 
lane 5) and the transiently transfected lines (Figure 4.6.1, lanes 3, 4, 6 and 
7) revealed that HaPrP protein levels in the transiently transfected cells 
were much higher, probably due to the higher amounts of mRNA 
achieved by this method (high transfection efficiency). In the following 
experiments, accurate quantification of the translation efficiencies 
between the different HaPrP constructs was attempted. 
Transient transfections were performed in parallel for both N2a 
and cos7 cells and control transfections were done with the pCEP4 
vector. One portion of the transfected cells was kept for RNA analysis 
and the remainder was 35 S-labeled and the protein extract 
immunoprecipitated. The Northern blots were hybridised with a HaPrP 
ORF-containing fragment (HaP 940 bp, see Figure 4.2.1) and the result 
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quantified by phosphorimager. In order to make the quantifications 
more precise, Northern blots were stripped and re-hybridised with a 
probe containing sequences from the mouse ribosomal protein S26. 
Values obtained from the phosphorimager were first expressed in 
relation to values obtained from the control transfection (N2a, or cos7 
cells transfected with pCEP4 construct). The values obtained from the 
hybridisation with HaP were normalised to control hybridisation (S26) 
values. Because cos7 are monkey cells, hybridisation with mouse S26 
would not produce as strong a signal as for N2a cells and therefore all 
comparisons between cos7 and N2a cells were done relying on ethidium 
bromide staining of the RNA gels. 
Before performing immunoprecipitations with the monoclonal 3F4 
ab or the polyclonal 1B3 (or 1A8) ab, aliquots of the protein extracts were 
kept for TCA precipitations (section 7.24). TCA precipitation values from 
cells transfected with the different constructs were expressed in relation 
to the value obtained from the control transfection. The quantification 
of HaPrP protein was done by phoshorimager analysis. The values 
obtained were first expressed in relation to the value obtained from 
control-transfected cells, and then normalised against the TCA 
precipitation values. The ratio of the final values from the 
immunoprecipitations to the final mRNA values would give the 
translation efficiency for each construct. 
Figure 4.6.4A shows a Northern blot of samples from cos7 and N2a 
cells transfected with several constructs, hybridised with HaP and S26. 
Immunoprecipitation of HaPrP protein produced by these lines is shown 
in Figure 4.6.3. After all calculations were made (Figure 4.6.5A) the 
translation efficiency of the constructs is shown as a percentage and as an 
histogram (Figure 4.6.5B). This experiment confirmed previous 
observations on the differences in PrP translation between N2a and cos7 
cells and the levels of HaPrP mRNA and protein between the stable and 
the transient cell lines. The comparison of translation efficiency between 
the constructs indicates that there are no major differences. This 
experiment shows that including quantification of the mRNA is crucial 
for the estimation of translation efficiency; major differences between 
protein levels produced from each construct might reflect only the 
differences in the levels of mRNA. Differences in the amount of mRNA 
might be due to different transcription efficiencies or different 
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Figure 4.6.3 
Immunoprecipitation of transfected cell lines with the 3174 mouse 
monoclonal Ha PrP specific ab. 
Northern blot analysis of the transfected cell lines presented here is 
shown in Figure 4.6.4A. 
cells transfection construct 
cos7 transient pE HaKo 
cos7 transient pE HaEPU 
cos7 transient pE HaP 
cos7 stable pC HaPU 
cos7 stable pC HaP 
cos7 transient pCEP 
cos7 transient pC HaKo 
cos7 transient pC HaEPU 
N2a transient pE HaKo 
N2a transient pC HaKo 
N2a transient pE HaP 
N2a transient pE HaEPU 
N2a stable pC HaEPU 
N2a stable pC HaPU 
N2a stable pC HaP 
N2a stable pCEP 
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Figure 4.6.4 
A. Northern blot analysis of transfected cell lines 
The probe used was the HaP fragment (940 bp, Figure 4.2.1) 
cells transfection construct 
 N2a transient pCEP 
 N2a transient pE HaP 
 N2a transient pE HaEPU 
 N2a transient pE HaKo 
 N2a transient pC HaKo 
 N2a transient pC HaKo 
 N2a stable pC HaP 
 N2a stable pC HaPU 
 N2a stable pC HaEPU 
 cos7 transient pCEP 
 cos7 transient pE HaP 
 cos7 transient pE HaEPU 
 cos7 transient pE HaEPU 
 cos7 transient pE HaKo 
 cos7 transient pC HaKo 
 cos7 transient pC HaKo 
 cos7 transient pC HaEPU 
Samples 5, 12 and 15 are from a previous experiment and do not 
correspond to any of the cell lines analysed by ip shown in Figure 4.6.3. 
B. Northern blot analysis transiently transfected cell lines 
The probe used was the HaPrP fragment (940 bp, Figure 4.2.1) 
cells construct 
mouse brain 
mouse brain 1:2 dilution 
 N2a pCEP 
 N2a pG HaP 
 N2a pCHaPU 
 N2a pG HaEPU 
 N2a pC HaKo 
 N2a pEHaKo 
 N2a pC HaPd5 
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In A the values shown in each column were expressed in relation to 
values obtained from the cos7 cells transfected with the pC HaEPU 
construct (the lowest ip value, line 9). The ip values (column a, based on 
Figure 4.6.3) were normalised against TCA precipitation (b) as shown in 
column c. The mRNA values obtained by hybridisation with the HaPrP 
fragment (column d, based on Figure 4.6.4A) were normalised against 
the control hybridisation values with S26 (column e, based on Figure 
4.6.4A) as shown in column f. Finally the ratio of normalised ip values 
(c) to normalised mRNA values (f) gave the translation efficiency values 
(column g, c/f) shown also as a percentage (column h, g%) and as 
histogram B (g%). 
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columrt a 	b 	c d 	e f 	g h 
cells construct ip TCA a/b mRNA con. die c/f g% 
N2a 1 	pE HaP 3.1 0.28 11.07 64 37.6 1.70 6.50 70% 
N2a 2 pE HaEPU 2.28 0.18 12.67 47 27 1.74 7.28 800% 
N2a 3 pE HaKo 5.4 0.46 11.74 4 3 1.33 8.80 100% 
N2a 141 pC HaKo 3.6 0.37 9.73 6.24 3.75 1.66 5.85 66% 
cos7 5 pE HaP 1.3 0.25 5.20 17.2 6.6 2.61 2.00 23% 
cos7 6 pE HaEPU 1.3 0.25 5.20 18.4 6.3 2.92 1.78 20% 
cos7 7 pE HaKo 4.7 1.02 4.61 5.2 3 1.73 2.66 30% 
cos7 8 pC HaKo 1.3 0.37 3.51 7.2 3 2.40 1.46 16% 













transfection efficiencies, but since that was not the issue here, it was not 
further pursued. 
In order to make the quantifications more accurate and control for 
possible mistakes in the immunoprecipitation procedure (loss of part of 
the protein extract or of the protein-A-sepharose beads, uneven loading, 
etc.) 1/10 aliquot of the protein extract was immunoprecipitated 
separately and two loadings (4/5 and 1/5) of the two final 
immunoprecipitated protein extracts were performed. Transfections 
were done in N2a cells. The constructs included in this comparison were 
pC HaP, pC HaPU, pC HaEPU pC HaKo and pC HaPd5'. Of particular 
importance for this experiment was the use of pC HaPd5' construct, 
which is the equivalent of the construct used for the generation of 
transgenic mice (N-terminal truncation of the HaPrP ORF). The 
Northern blot analysis that corresponds to this experiment is shown in 
Figure 4.6.4B and the immunoprecipitation results in 4.6.6. Calculations 
are not shown, but were done as presented in Figure 4.6.5 and the 
comparison in translation efficiencies is presented as a percentage and as 
a histogram in Figure 4.6.7. Four quantifications correspond to each 
transfected cell line because each protein extract was split in two samples 
that were immunoprecipitated, and two loadings were performed for 
each sample. The average of all four and the average of two 
(corresponding to ipi and ip2, Figure 4.6.6) of the quantifications was 
estimated and the translation efficiencies based on these estimations are 
presented in column a, and column b respectively, in Figure 4.6.7. In this 
way any major deviations due to mistakes regarding one of the four gels 
should become obvious. 
These data demonstrated again that there were no major 
differences in translation efficiency between the different constructs 
apart from pC HaPd5', where the second ATG of HaPrP was used as the 
initiating codon (the first 32 nucleotides were deleted). 
Comparison of the translation efficiency between a few of the 
constructs was repeated. Also, in order to do a comparison with the 
endogenous MoPrP protein levels, both monoclonal and polyclonal 
antibodies were used. In addition the pC HaPd5' construct (truncated 
HaORF) was tested again. The Northern blot analysis of this experiment 
is shown in Figure 4.6.8A and the two protein gels with 
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Figure 4.6.6 
Immunoprecipitation of transiently transfected cell lines with the 3F4 
mouse monoclonal HaPrP specific ab. 
The samples on each gel are in the same order. 
The RNA analysis of the transfected cell lines presented here is shown 
in Figure 4.6.4B. 
1/10 of the the protein extract that was immunopreciopitated and 
electrophorised on gel A was immunoprecipitated and electrophorised 
on gel B. Before loading 1/5 of the samples shown in A were loaded on 
gel C and 1/5 of the samples shown in B were loaded on gel D. 
cells 	construct 
1. 	N2a pCEP 
 N2a pCHaP 
 N2a pC HaPU 
 N2a pC HaEPU 
 N2a pEHaKo 
 N2a pC HaKo 
 N2a pC HaPd5' 
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cells construct a b a% b% 
N2a 1 pCEP  
N2a 2 pC HaP 22.36 33.7 86% 87% 
N2a 3 pG HaPU 21.61 30.0 83% 78% 
N2a 41 pC HaEPU 25.72 42.8 100% 100% 
N2a 5 pE HaKo 20.78 36.0 80% 99% 
N2a 6 pC HaKo 16.27 31.65 1 65% 83% 












All values in columns a and b are expressed in relation to values obtained 
from transfection with pCHaPd5 construct. 
Column a is showing the values corresponding to the translation efficiency 
of each construct when all four ip gels (figure 4.6.6) were included in the 
calculations. 
Column b is showing the values corresponding to the translation efficiency 
of each construct when ipi and ip 2 (gels A and B) were included in the 




A. Northern blot analysis transiently transfected cell lines 




cos7 pC HaEPU 
N2a pC HaEPU 
N2a pCHaEPU 
N2a pE HaKo 
N2a pE HaKo 
N2a pC HaPd5' 
N2a pC HaPd5' 
Samples 4, 7 and 9 are from a previous experiment and do not 
correspond to any of the cell lines analysed by ip shown in B and C. 
B. and C. Immunoorecinitation of transiently transfected cell lines with 
the 3F4 mouse monoclonal Ha PrP specific ab and the 1A8 rabbit 
polyclonal Anti-PrP ab. 
lls 	construct ip- 
N2a pCEP 3F4 ab 
N2a 	pCEP 1A8 ab 
N2a pC HaEPU 3F4 ab 
N2a 	pC HaEPU 1A8 ab 
N2a pE HaKo 3F4 ab 
N2a 	pEHaKo 1A8ab 
N2a pC HaPd5' 3F4 ab 
N2a 	pC HaPd5' 1A8 ab 
- 
cos7 	pCEP 1A8 ab 
cos7 pC HaEPU 1A8 ab 
Gel C represents a 1:5 loading dilution of samples shown in B. Sample 8 
on gel C was lost during the loading procedure. Quantifications shown 
in Figure 4.6.9 are based on gel B. 
The signal obtained by N2a cells transfected with pCEP construct and 
immunoprecipitated with the 3F4 ab is due to background hybridisation 
(lane 1 gels B, C). 
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Figure 4.6.9 
A. Comparison of translation efficiency between different constructs 
All values were expressed in relation to values obtained from N2a cells 
transfected with pC HaPd5' construct (the lowest ip value). 
The ip values in column a, were estimated on the samples 
immunoprecipitated with the 3F4 ab: lanes 3, 5, 7, gel B.ip, Figure 4.6.8. 
These values were normalised against TCA precipitation (b) as shown in 
column c. The mRNA values obtained by hybridisation with the HaP 
fragment (column d, based on A Figure 4.6.8) were normalised against 
the control hybridisation values with S26 (column e, based on A Figure 
4.6.8) as shown in column f. The ratio of ip values (c) to mRNA values 
(f) gave the translation efficiency for each construct (column g, c/f). 
B. Comparison of translation efficiency between endogenous and 
transfected HaPrP 
All values were expressed in relation to values obtained from N2a cells 
transfected with pCEP construct. 
The ip' values in column a are the original numbers obtained by 
phosphorimager analysis based on samples immunoprecipitated with 
the 1A8 ab: lanes 2, 4, 6, 8, gel B.ip (Figure 4.6.8), and represent the signal 
from both the endogenous MoPrP and the HaPrP produced from the 
constructs. Therefore the value corresponding to the endogenous MoPrP 
signal (control pCEP-transfected N2a cells: 134728) was subtracted from 
the values obtained from the transfected N2a cells as shown in column b 
(ip"). These values were expressed in relation to the value obtained from 
control pCEP-transfected N2a cells (column c) and were subsequently 
normalised against TCA precipitation (column d) as shown in column e. 
mRNA values (f) were normalised against control hybridisation values 
(g) as shown in column h. The ratio between normalised ip values (e) 
were normalised against the normalised mRNA values (h) to give the 
translation efficiency values (colunm i). 
*The  mRNA levels representing the endogenous MoPrP message were 







a b c d I 	e f g 
construct ip TCA ip/TCA RNA co d/e c/f 
pGHaEPU 13.35 
116.81 
0.79 16.90 1.49 0.72 2.07 8.17 
pEHaKo 1.13 14.88 1.24 0.89 1.39 10.68 





1 	2 	3 
M. 
a b c d e f g h 
construct ip ip' ip TCA ip1TCA mRNA Co fig e/h 
pCEP4 134728 134728 1.00 0.81 1.23 0.15* 1.00* 0.14 8.82 
pCHaEPU 361582 226854 1,68 0.79 2.13 1.49 0.72 2.07 1.03 
pEHaKo 377524 242796 1.80 1.13 1.59 1.24 0.89 1.39 1.14 




1 	2 	3 	4 
figure4.6.9 
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immunoprecipitated samples in Figure 4.6.8B,C. Each protein extract was 
separated into two equal aliquots; one was immunoprecipitated with the 
3F4 ab and the other with the 1A8 ab. Transfection of cos7 cells was also 
performed, but the low mRNA levels (Figure 4.6.8A, lane 3) suggested 
that the transfections did not work very efficiently. Therefore, the HaPrP 
protein levels were very low (Figure 4.6.8B,C lanes 10, 11) and these 
samples were not included in the calculations. A loading dilution (1:5) 
was also performed (4.6.8C). Quantification of immunoprecipitations 
were based on gel B (Figure 4.6.813) and all values were expressed in 
relation to those obtained from N2a cells transfected with PCEN 
construct. The calculations are shown in Figure 4.6.9 and the translation 
results are presented both as a percentage and as a histogram (Figure 
4.6.9). These results suggest that there is more endogenous than 
transgene protein produced and confirm that the pC HaPd5' construct is 
very inefficiently translated. Furthermore a comparison between 
transgenic and normal mouse brain, transfected and non-transfected 
N2a cells was performed. The data in Figure 4.6.10 show that although 
PrP mRNA levels are very high in transfected N2a cell lines the 
translation efficiency is much lower than in the brain. Even if detectable 
amount of PrP protein was produced in the transfected cell lines it could 
be masked by the high background produced by the 3F4 ab. Low 
translation efficiency in comparison to brain is observed in all other 
tissues. The transgene-produced mRNA in Tg mouse brain is translated 
very inefficiently (if at all) due to the 5 truncation of the HaPrP 
fragment and therefore not detectable 
4.6.2 Conclusions 
The data presented above indicate that there was no significant 
difference in translation efficiency produced by the addition of the 3' or 
5' UTR of HaPrP, although the constructs that include the entire 5' UTR 
show up to 2-fold better translation efficiency. The presence of intron 
sequences in the vector does not appear to have any influence on 
translation efficiency. The most dramatic effect is observed with the pC 
HaPd5' construct where the first 32 nucleotides were deleted. This 
construct appears to show barely any protein translation (approximately 
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3%). When the initiation of translation sequence of this HaPrP fragment 
is compared to the consensus sequence and to that surrounding the first 
ATG of HaPrP, it does not appear to be similar (Figure 4.6.11). Especially 
the nucleotide at the crucial position +4 (regarding initiation of 
translation), which is I instead of G, has been shown to be responsible 
for five to ten-fold downregulation of translation (Kozak, 1987a). The 
nucleotide at position -3 (another crucial position), is a C instead of A, 
which is acceptable. The translation of this protein is therefore expected 
to be very low and furthermore, because it is missing the signal peptide, 
possibly it is not processed properly and might be degraded very quickly. 
The very small amount detected here (Figure 4.6.6, lane 7 and Figure 
4.6.8B, lane 7) is almost equivalent to background levels. 
Comparison of translation efficiencies in transfected and non-
transfected N2a cells suggested that the endogenous message is 
translated better than that produced by the transgene. Both endogenous 
and transgene-produced PrP mRNA are translated better in neuronal 
cell lines and in the brain. 
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Figure 4.6.10 
A. Northern blot analysis cell lines and mouse tissues 
The probe used was the HaPrP fragment (940 bp, see Figure 4.2.1) 
cells 	transfection 	construct 
N2a transient pC HaKo 
N2a 	transient 	pCEP 
Tg NSE 14 brain 
Fl mouse brain 
Ig NSE 20 brain 
Tg NSE 20 heart 
Tg NSE 20 lung 
Tg NSE 20 liver 
Tg NSE 20 spleen 
Tg NSE 20 kidney 
B. and C. Western blot analysis of cell lines and mouse tissues 
B. Probed with the mouse monoclonal HaPrP-specific ab 3F4 
C. Probed with the rabbit polyclonal anti-PrP ab 1A8 
The samples on both blots are in the same order 
mouse brain 
Tg NSE 14 brain 
Tg NSE 20 brain 
Tg NSE 20 heart 
Tg NSE 20 lung 
Tg NSE 20 liver 
Tg NSE 20 spleen 
Tg NSE 20 kidney 
 N2a transient pCEP 
 N2a transient pC HaP 
 N2a transient pC HaPU 
N2a 	transient 	pC HaKo 
No RNA data are shown for transiently transfected N2a with pC HaP 
and pC HaPU construct (lanes 10 and 11). 
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initiation of translation 
sequence of 5' truncated 
HaPrP (HaPd5') 
initiation of translation 
sequence of HaPrP 
consensus sequence 
for initiation of 
translation 
(Kozak 1991a, b) 
'optimal' consensus 
for initiation of 
translation 
(Kozak 1987b) 
5' 	 3' 
C' 11"!' GTG G CT (~My 
ATCA CCC A TCkG 
HaPrP ORF 
CCC ALG CCG 
CCC GCC AIG CC 




In this chapter the conclusions and the work discussed in previous 
chapters will be summarised. The objective of the project was to study 
the role of PrP in the etiology of TSEs by exploiting neuron-specific and 
region-specific expression of heterologous PrP in the brains of transgenic 
mice (chapter 2). The effect that this would have on the susceptibility, 
pathogenesis and species barrier of the disease was to be investigated. 
Also the ability of the isolated HaPrP ORF to produce HaPrP protein was 
assessed. However, problems were encountered with PrP protein 
translation in the transgenic mice generated and the original objectives 
(see also section 1.14) could not be met. Although trivial reasons account 
for the failure to express HaPrP protein in the transgenic mice generated, 
accumulating data from other studies suggested that sequences flanking 
the PrP ORF might contain regulatory sequences (section 2.8). Therefore, 
possible effects of the 5' and 3' untranslated sequences of HaPrP on the 
translation of lacZ and HaPrP were investigated (chapters 3 and 4). 
Neuron-specific expression of HaPrP in transgenic mice was 
attempted by using 5' regulatory sequences of the NSE gene. The levels 
of transgene mRNA in the Tg NSE HaPrP mice were low in comparison 
to endogenous PrP levels (section 2.8). Recent experiments have 
demonstrated that the presence of intron 1 together with the 5' upstream 
sequences are necessary for enhanced neuron-specific expression in cell 
culture (Sakimura et al., 1995). Furthermore, in a recent study a larger 
fragment of NSE 5' flanking sequences, together with exon 1, intron 1 
and a very small portion of exon 2 was used to drive the expression of 
HaPrP in transgenic mice (Race et al., 1995). The amount of transgene 
RNA in the single transgenic line generated was 5-fold higher than the 
endogenous MoPrP. These data indicate that regulatory elements 
necessary to produce high level expression were probably missing from 
• the 1.8 kb fragment of the 5' flanking sequence of the NSE gene used 
here. However, the possibility of variegated expression of the transgene 
observed in other transgenic models (Festenstein et al., 1996; Dobie et al., 
1996), could also explain the lowlevels of transgene expression. The 
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transgene could be expressed at high levels in some neurons, while it 
could be silenced in others and therefore, when total brain samples were 
analysed only low levels of PrP mRNA could be detected. 
The amount of HaPrP mRNA in the Tg NSE 20 line should have 
been sufficient to generate detectable HaPrP protein. The use of a 5' 
truncated HaPrP cDNA (Oesch et al., 1985) was thought to have an effect 
on the translation efficiency of the transgene mRNA and/or the 
processing of the protein. This effect was investigated in cell culture by 
comparing the translation efficiency of the 5' truncated HaPrP fragment 
with other HaPrP fragments (discussed in more detail below). 
A general point emerging from quantitative analysis of PrP mRNA 
and protein expression when tissues other than brain, were included in 
the analysis, is that translation of PrP appears to be more efficient in the 
brain, which agrees with quantitative analyses made recently by other 
groups (Horiuchi et a]., 1995). If PrP mRNA was translated as efficiently 
as that in the brain, PrP protein should be detected by the method used 
here at least in some other tissues apart from brain, including heart and 
lung (PrP mRNA is approximately 25% in comparison to that detected in 
the brain). However, no PrP protein was detected in any tissue other than 
brain. In agreement with these data were the conclusions from 
translation experiments in cell culture. 
Both endogenous and transgene-produced PrP mRNA are 
translated better in neuronal cell lines. Non-neuronal cell lines are also 
capable of producing PrP, but the translation efficiency is much lower 
and there could be differences in the processing of the protein. Although 
detection of PrP protein by Western blot analysis was performed 
successfully in brain protein extracts, difficulties were sometimes 
encountered with protein extracts from cultured cells. This suggested 
that the brain shows the highest levels of PrP translation and therefore 
PrP protein detection is much easier in that tissue regardless the 
detection method applied. Another finding was that the endogenous PrP 
message is translated more efficiently than the transgene-produced PrP 
in cultured cells. This could be because the endogenous message is either 
more stable or translated more efficiently. The turnover of the 
endogenous protein may also be slower, or the capacity of the cells to 
produce larger amounts of PrP than normal might be limited. The low 
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levels of transgene-produced mRNA probably made the detection of PrP 
protein more difficult. 
Comparison between constructs containing different fragments of 
HaPrP cDNA demonstrate that the addition of the 3' or 5' UTR of HaPrP 
does not have a major effect on the translation efficiency of either lacZ 
or PrP. Constructs that include the entire 5' UTR show up to 2-fold 
increase in translation efficiency, and a slight downregulation (to 79-
90%) in translation efficiency was observed with constructs that include 
the entire 3' UTR (especially with the lacZ constructs, see tables 3.4.1,2 
chapter 3). These differences were not considered statistically significant. 
Most constructs used previously in cell culture contained only the 
PrP ORF, but a larger fragment of HaPrP cDNA (1.3 kb), including the 5' 
UTR, the HaPrP ORF and a part of the 3' UTR (-500 bp) has also been 
used (Chesebro et al., 1993). When expressed in murine neuroblastoma 
cells a 60 kD protein containing HaPrP was identified in addition to the 
-25-40 kD species (Kocisko et al., 1994; Priola et al., 1995). It was suggested 
that this protein was a PrP dimer that was sensitive to proteinase K 
digestion. The dimer was not dissociated by denaturing treatments and 
tended to form large aggregates. Such forms have been identified in 
scrapie infected hamster brain, but the cells (MNB: mouse 
neuroblastoma) where the 60 kD PrP was identified were not infected 
with the disease agent. It is not clear whether the presence of the 60 kD 
protein was due to the use of 'a certain construct, the overexpression of 
HaPrP, improper processing or folding of HaPrP, a specific step during 
the isolation or immunoprecipitation Of HaPrP, or the specific type of 
cells. The only PrP species identified in both cos7 and N2a cells 
transfected with any of the constructs used here were the -25-40 kD 
species. 
The use of intron sequences in the, vector does not appear to have 
any influence on translation efficiency. The only construct that showed 
extremely low translation efficiency was the one containing the same 
HaPrP fragment as that used in the transgenic construct (the first 32 
nucleotides were deleted). The 'weak' consensus sequence surrounding 
the translation initiation codon appeared probably to be responsible for 
downregulation of translation. Even if some HaPrP protein was 
produced, the deletion of part of the signal peptide would affect further 
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processing of the protein. This result explains the absence of detectable 
amount of protein produced in the Tg NSE HaPrP transgenic mice. 
Recently transgenic mice have been generated containing 1 kb of 
the HaPrP sequence (including the 5' UTR, the HaPrP ORF and a small 
part of the 3' UTR) (Race et al., 1995). PrP expression was driven by the 
NSE promoter (containing NSE intron I, also see above and 1.12.1) that 
gave high and neuron-specific production of HaPrP protein. These mice 
were shown to be susceptible to the hamster infectious agent and 
developed degeneration of the brain. These data indicated that the 
intron and the 3' UTR are not necessary for PrP protein expression, in 
agreement with the translation experiments performed in tissue culture 
(chapter 4). Furthermore, it was shown that PrP sequences not included 
in the transgene, and sequences flanking the PrP gene included in the 
cosmid clones previously used, are not necessary for confering 
susceptibility to the disease. The absence of HaPrP expression in 
astrocytes, splenic cells and lymph nodes did not restrict replication of 
the infectious agent in the brain after intracerebral inoculation. 
However, the involvement of these cells in interspecies transmission 
following peripheral routes of inoculation was not investigated. 
We also attempted to generate transgenic mice that would express 
PrP in restricted regions of the brain, by using the TH promoter to drive 
HaPrP expression. The Tg TH HaPrP mice showed very low level of 
HaPrP mRNA only in some catecholaminergic neurons, indicating that 
the promoter fragment was possibly missing elements necessary for 
high-level and specific expression of the transgene. For this reason and 
because it became apparent that there was a translation problem created 
by the HaPrP fragment used in the transgenic constructs (see also 
sections 2.7, 2.8 and comments above), their analysis was not further 
pursued. Expression of the transgene in some catecholaminergic regions 
(eg. olfactory bulb) but not in other (eg. substantia nigra) could be due to 
position effects (section 2.1). 
In a recent study (Brandner et al., 1996) a different approach was 
taken in order to achieve region-specific expression of PrP. Embryonic 
telencephalic tissue from transgenic mice overexpressing PrP was grafted 
into the caudo-putamen or the lateral ventricles of Pm-p 0 ! 0  mice. 
When these mice were inoculated with the scrapie agent 
neuropathological changes were detected only in the graft. PrP 5c was 
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spread by diffusion within the extracellular space to regions surrounding 
the graft but no pathological changes were observed in these regions. 
Therefore the infectious agent can traverse urisusceptible brain leaving it 
unaffected and it can cause degeneration only in neurons that express 
PrPC. The evidence from these recent studies suggest that PrPsc can be 
toxic only when it is produced within the cell, but not when it is 
introduced from an extracellular source. Another explanation could be 
that PrPC is needed for the initiation of the conversion of PrPC to PrP 5C, 
or for the internalisation of PrPSC. 
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CHAPTER 6 
Materials and methods 
Unless otherwise stated, all chemicals were of analytical grade and 
supplied by BDH Laboratory Supplies or Sigma. Phenol saturated in Tris 
buffer was supplied by Fisons Bioscience (P/2318/05). Synthetic 
oligonucleotides were supplied by Oswel. Ethanol was supplied by 
Hayman. Kodak XAR-5 X-ray film was supplied by H.A. West. 
Radiochemicals were supplied by Amersham, DuPont-NEN and ICN. 
Computer software packages used for DNA and protein analyses 
were the DNAstar computer package and the University of Wisconsin 
Genetics Computer Group, (1991), GCG package version 7 (UWGCG). 
Computer software packages used for phosphorimager analysis 
were Molecular Dynamics. 
Many of the methods described in this work are based on those 
described by Sambrook et al., 1989, or in the Promega 'protocols and 
applications guide'. 
7.1 Standard solutions 
EDTA 
(ethylenediaminetetraacetic acid, disodium salt) 
0.5 M Na2EDTA  pH 8.0 
TE 
10 mM Tris.HC1 pH 7.4 
1 mM EDTA 
2OXTBE 
216 g Tris base 
110 g boric acid 
40 ml 0.5 M EDTA 
water to a litre 
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20 X SSC 
3MNaC1 
0.3 M Na3citrate 
pH adjusted to 7.0 with NaOH 
1 X PBS (phosphate buffered saline) 
0.01 M sodium and potassium phosphate buffer: 
0.8% (w/v) NaCl 
0.02% (w/v) KC1 
0.144% (w/v) Na2HPO4 
0.024% (w/v) KH2PO4 
pH adjusted to 7.4 with HC1 
or, phosphate buffered saline tablets (SIGMA P-4417) were used 
50 X Denhardt's solution 
5 g ficoll (Type 400, Pharmacia) 
5 g polyvinylpyrrolidone 
5 g bovine serum albumin. (BSA, Boehringer Mannheim 711454) 
water to 500 ml 
7.2 Preparation of electrocompetent E. coli 
LB growth medium 
10 g 	Bacto-tryptone (Difco 0123-01-1) 
5 g Bacto-yeast extract (Difco 0127-01-7) 
lOg NaCl 
water to 11 
adjust pH to 7.0 with NaOH and autoclave 
E. coli strain XL1 Blue (Stratagene 200130) was used to make 
electroporation competent cells according to the following protocol. The 
competence of the resultant cells was usually around 108 
transformants/ jig of plasmid DNA. The E. coli strain JM110 was also 
used (Stratagene 200239) when NruI restriction enzyme (sensitive to 
dam methylation) was required for cloning steps. 
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1 1 of LB growth medium was inoculated with a single colony of 
E. coli and grown in the incubator shaker at 37°C until an OD 600 of 0.6-
0.9. 
The flask was chilled on ice for 5 min and was not allowed to 
warm up thereafter. 
The cells were spun in 250 ml bottles (Sorvall) at 4,000 rpm, 4°C 
for 20 mm. The supernatant was removed immediately after 
centrifugation to prevent lifting of the pellet. 
Each pellet was gently resuspended in 250 ml of ice cold water, 
transferred to two pre-chilled 250 ml bottles and spun at 5,000 rpm, 4°C 
for 10 mm. The supernatant was removed, resuspended in 200 ml of ice 
cold water and spun as before. 
Each pellet was gently resuspended in 40. ml of ice cold 10% 
glycerol (BDH) in water, transferred to pre-chilled 50 ml conical tubes 
(Corning) and spun at 4,000 rpm, 4°C for 10 min.  
The pellet was resuspended in 2 ml of ice cold 10% (v/v) glycerol 
per litre of original culture volume, 50 pl  aliquots were transferred to 
pre-chilled microfuge tubes and snap frozen in liquid nitrogen. Store at 
-70°C. 
7.3 Electroporation of E. coli 
This method is based on that described by Dower et al., 1988. 
SOB 
2% (w/v) Bactotryptone 
0.5% (w/v) Bacto-yeast extract 
10 mM NaC1 
2.5 mM KC1 
autoclave, cool, add 1/100 volume 2 M MgC12-MgSO4 
SOC 
SOB + 1/100 volume 2M glucose (2 mM final) 
LB agar plates 
10 g 	Bactotryptone 
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5 g 	Bacto-yeast extract 
10 g NaC1 
20 g 	Bactoagar 
make up to 1 1, pH 7.0 with NaOH, autoclave and pour onto 9 cm 
plates (Corning) 
LB agar/X-gal plates 
The following solution was spread on 9 cm LB agar plates: 
40 il of 20 mg/ml X-gal (5-bromo-4-chioro-3-indonyl-S-galactoside) 
w/v in N,N, dimethyl-formamide 
4 p1 of 200 mg/mi IPTG (isopropyi -D-thiogaiactopyranoside) w/v 
in sterile water 
SOC to 100 p1 
Ampicillin (amp) 
Stock solution of 100 mg/ml in sterile water, kept in 500 p1 aliquots 
at -20°C. 
Electroporation of plasmids into E. coli was carried out using a 
Gene Puiser electroporator (BioRad) and 0.2 cm Gene Pulser 
electroporation cuvettes according to the following protocol: 
The electroporation cuvettes and the sliding cuvette holder were 
chilled on ice. 
The gene pulser apparatus was set to 25 mF capacitance, 1.8 kV 
voltage and 200 L2 resistance. 
The electrocompetent cells were thawed on ice. To a microfuge 
tube containing 50 tl of competent cell suspension the appropriate 
amount of DNA for electroporation was added. Usually 10 jil of a 
ligation (approximately 50 ng), or approximately 10 ng of a stock plasmid 
were used. 
The mixture of cells and DNA was transferred to a cold 0.2 cm 
electroporation cuvette, placed on the sliding holder and one pulse was 
applied at the above settings. This should result in a pulse of 12.5 kV/cm 
with a time constant of 4.5 - 5.0 msec. 
1 ml of ice cold SOC medium was immediately added to the 
cuvette and the cells were gently resuspended. 
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LI 
The cells were transferred to a 15 ml polypropylene pop-top tube 
(Falcon) and placed in an incubator shaker at 37°c for one hour to 
recover. 
100 ml of the cell suspension were plated on a 9 cm diameter LB 
agar (1.5% w/v) plate, containing appropriate selection agent (usually 100 
jig/ml of amp). Grow the plate overnight at 37°C. The remainder of the 
cells was kept at 4°C. 
7.4 Preparation of plasmid DNA 
7.4.1 Preparation of large amounts of plasmid DNA 
This method is based on that described by Birnboim and Doly, 1979. 
Media, solutions, antibiotics 
L-Broth medium (LBM) 
per litre 
10 g 	Bacto-tryptone 




50 mM glucose 
25 mM Tris.HC1 pH 8.0 
10 mM EDTA 
autoclave, store at -4°C 
High salt solution (pH 4.8) 
60 ml 5 M potassium acetate 
11.5 ml glacial acetic acid 
28.5 ml water 
1. A single colony was picked in a 1 litre flask containing 500 ml 
LBM with 100 pg/ml amp and incubated for approximately 16 h 
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(overnight) at 370c shaking at 300 rpm (New Brunswick Scientific series 
25 incubator shaker). 
The bacterial cells were harvested by centrifugation at 4,000 rpm 
for 5 min at 4°C (Sorvall RC5C Du Pont centrifuge) and the supernatant 
was discarded. 
The pellet was resuspended in 4 ml of ice cold GTE solution, 
transferred to a 50 ml polyallomer tube (Nalgene oak ridge centrifuge 
tube 31390050) and left for 5 min at room temperature. 
8 ml of freshly made 200 mM NaOH, 1% (w/v) sodium dodecyl 
sulphate (SDS) were added, shaken gently by inverting the tube several 
times and left on ice for 5 mm. 
To this 6 ml of ice cold high salt solution were added, mixed 
vigorously and left on ice for 5 mm. 
The mixture was centrifuged at 15,000 rpm for 15 min at 4°C 
(Sorvall RC5C centrifuge) and the plasmid containing supernatant was 
passed through a 0.45 micron syringe filter (Corning cellulose acetate 
membrane sterile acrylic filter). 
After this step one of the 2 following procedures was followed: 
7.4.1a Purification of closed circular DNA by centrifugation to 
equilibrium in cesium chloride-EtBr gradients. 
For every ml of the supernatant 1.22 g/ml of CsCl and 200 j.ti of 
750 pg/ml EtBr (ethidium bromide) were added. 
The solution was mixed thoroughly and transferred to a Quick 
Seal polyallomer centrifuge tube (Beckman 342413). The reminder of the 
tube was filled with water containing 1.22 g/ml CsCl and 200 j.il of 750 
ig/ml EtBr per ml. 
The plasmid preparation was centrifuged overnight at 55,000 rpm 
in a Beckman 27 Ultracentrifuge in a NVT65 rotor at 15°C. 
Two bands of DNA were visualized by ordinary light; the lower 
one consisting of closed circular plasmid DNA was extracted by using a 
syringe with a 19 gorge needle. 
The EtBr was extracted from the sample by using isopropanol 
saturated with CsCl and water. 
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The volume of the sample was measured, transferred to a 30 ml 
Corex tube and 2 volumes of water were added. The DNA was ethanol 
precipitated at room temperature for 1 h. 
The sample was centrifuged for 15 min at 15°C in a Sorvall RC5C 
centrifuge and the DNA pellet was washed with 2 ml of 70% (v/v) 
ethanol. 
The DNA was resuspended in 200 jil of TE and kept at -20°C. 
7.4.1b Quick isolation of plasmid DNA 
The supernatant was transferred to a Corex tube and the DNA 
was precipitated by addition of 0.8 volumes of isopropanol and standing 
for 1 h at room temperature. 
The sample was centrifuged and the pellet was resuspended in 
340 p1 0.5% (w/v) SDS in TE. This was transferred to an eppendorf tube 
and heated for 15 min at 90°C. 
113 itl of 10 M ammonium acetate were added and the mixture 
was left for 15 mm, or overnight at -20°C before centrifugation for 5 mm 
in a microfuge at 4°C. 
The supernatant was transferred to another eppendorf tube and 
the pellet was discarded. 
The plasmid DNA was ethanol precipitated from the supernatant 
(15 min at room temperature), washed with 70% (v/v) ethanol and the 
pellet was resuspended in 200 jfl TE containing 10 mg/mi RNase A 
(DNase free). 
After incubation at 37°C for 15 min the DNA sample was 
extracted twice with phenol : chloroform : isoamylalcohol 25 : 24: 1, once 
with chloroform : isoamylalcohol 24: 1, then ethanol precipitated (see 
section 7.6.4) and resuspended in 200 p1 of TE. 
These methods gave up to 500-1 mg of plasmid DNA. 
The DNA was quantitated by absorbance at 260 nm wavelength, 
assuming that 1 OD Unit = 50 j.tg/ml and by agarose gel electrophoresis 
(see section 7.5) against known standards. 
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7.4.2 Preparation of Plasmid DNA (medium scale) 
Medium scale purification of plasmid DNA was prepared from a 25 
ml bacterial culture grown in LBM overnight. A Qiagen Plasmid 
Purification Kit (Qiagen, tip-100 12143) was used to purify the plasmid 
DNA. This method is based on the optimised alkaline lysis method 
(Birnboim and Doly, 1979). Purification of the plasmid DNA by the 
Qiagen resin allows preparation of ultrapure plasmid DNA without the 
use of phenol, chloroform or EtBr. Approximately 75-100 jig of plasmid 
DNA were recovered. 
7.4.3 Preparation of plasmid DNA (small scale) 
A colony was picked into a 3 ml overnight culture (LBM 
medium, 10 j.tg/jil amp) and the bacteria were harvested, in 1.5 ml 
eppendorf tube by centrifugation at 13,000rpm for 3 mm. 
The supernatant was discarded and the cells resuspended in 100 
pl ice cold GTE. 
200 jil of freshly prepared 0.2 M NaOH, 1% (w/v) SDS were 
added, mixed by gentle inversion and the mixture was heated at 80-90°C 
for 10 mm. 
The tube was transferred on ice, 150 ml of high salt solution were 
added and mixed gently. 
The mixture was centrifuged in a microfuge at 13,000 rpm for 10 
mm, and the supernatant recovered into a fresh eppendorf tube. 
The DNA was ethanol precipitated, resuspended in 50 jil  sterile 
water and left on dry ice for 5 min to precipitate residual SDS. 
After centrifugation at 13,000 rpm, the supernatant was 
transferred to a fresh eppendorf tube. 
This method gave approximately 20 jig of plasmid DNA. 
7.5 Agarose gel electrophoresis 
agarose gels 
agarose (FMC BioProducts, Sea Kern Le Agarose, 50004) 
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usually 1% (w/v), or appropriate concentration, disolved by heating 
in 
1XTBE 
5 jil of 1 .tg/pi EtBr solution were added to 50 ml agarose 
gel solution 
loading sample buffer (for DNA or RNA) 
30% (v/v) glycerol in water 
6XTBE 
50 j.tl/ml of bromophenol blue saturated solution 
DNA size markers 
1 kb ladder GIBCO-BRL, 15615-016 
diluted in loading sample buffer to give final concentration 50 
ng/tl 
The gel tanks used for horizontal agarose gel electrophoresis were 
GIBCO BRL Horizon 58 1060BD (small size) or GIBCO BRL Horizon 11.14 
1068BD (medium size). 
7.6 General Cloning Techniques 
7.6.1 Restriction digestion of DNA 
Restriction enzymes and buffers were supplied by Boehringer 
Mannheim and Biolabs. The conditions recommended for DNA 
digestion by the Boehringer and Biolabs catalogue were generally 
followed. Usually 2 units of enzyme were used for 1 jig of plasmid DNA. 
Digestions of genomic DNA were carried out as following: 
10 jig genomic DNA 
4 jil 0.1 M spermidine.HC1 
10 jil 10 X restriction buffer 
2 p1 of enzyme (10 units/ jil) 
sterile water to 100 pJ 
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The reaction was incubated for 2 h before another 40 units of 
enzyme were added and the incubation was continued overnight. 
The products of DNA restriction digests were analysed by 
electrophoresis using agarose gels at appropriate concentrations in TBE 
buffer. 
7.6.2 Elution of DNA fragments from agarose gels 
The DNA fragment of interest was excised after electrophoresis 
from an agarose gel and the DNA was eluted by one of the following 
methods: 
The Gelase kit (Cambio) was used for fragments over 1 kb according 
to the manufacturer's instructions. For smaller fragments the Geneclean 
II kit (Stratech Scientific 3106) was used according to the manufacturer's 
instructions, or the DNA was directly spun through siliconised glass 
wool (as described in Trends in Genetics 1992, 8:81). 
7.6.3 Purification of DNA 
For purification of DNA from enzymes, small DNA fragments 
(<175 nucleotides), mononucleotides and salts the "Wizard" Clean-up 
system (Promega A 7280) was used according to the manufacturer's 
instructions. 
7.6.4 Ethanol precipitation of nucleic acids 
DNA or RNA was precipitated by the addition of a 0.1 volume of 3 
M sodium acetate (pH 5.2), followed by 2.5 volumes of -20°C ethanol. 
The mixture was held at -20°C for 1 h and the nucleic acids were pelleted 
by centrifugation, at 13,000rpm, 4°C. Small amounts of DNA (<1 jig) 
were precipitated as above, with the addition of 1 p1 of glycogen 
(Boehringer 901393). To remove trace amounts of salt remaining from 
the precipitation, the nucleic acid pellet was washed in 1 ml of 70% (v/v) 
ethanol, recovered by centrifugation, dried in a vacum centrifuge 
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(Stratech Savant) and dissolved in an appropriate volume of sterile 
water or TE buffer. 
7.6.5 Phenol-chioroform-isoamylalcohol extraction of DNA or 
RNA solutions 
DNA or RNA solutions were phenol-chioroform-isoamylalcohol 
extracted to remove any contaminating proteins. The extraction solution 
(PCA) was phenol (Fisons T/p633/05) : chloroform : isoamylalcohol 
(25:24:1). Generally the DNA or RNA solutions were made up to at least 
100 d with sterile water or TE, an equal volume of PCA was added, the 
mixture was vortexed for 1 min and centrifuged for 5 mm. The aqueous 
phase (upper) was transferred to a fresh eppendorf and re-extracted with 
PCA. Then an equal volume of chloroform:isoamylalcohol 24:1 was 
added, vortexed, microfuged and the aqueous phase was transferred to a 
new eppendorf and ethanol precipitated. 
7.6.6 Dephosphorylation of linearised plasmid DNA 
solutions 
10 X STE 
100 mM Tris.HC1 pH 7.4 
1MNaC1 
10 mM EDTA 
Removal of the 5' terminal phosphate groups of linearised plasmid 
DNA with identical termini was required to prevent recircularisation of 
the plasmid DNA in subsequent ligation steps. 
1. After restriction digestion of DNA, the volume was made up to 
50 p1 with TE and 5 units of alkaline phosphatase (Boehringer, 713023) 
were added directly, and incubated at 37°C for 45 mm. 
2 The reaction was stopped by the addition of 2.5 p1 10% (w/v) SDS 
and 5p1 10 X STE and the sample was incubated for 15 min at 70°C. 
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3. An equal volume of phenol:chloroform 1:1 was added, vortexed 
briefly, and centrifuged at 13,000 rpm before recovering the aqueous 
phase. 
4 The DNA was ethanol precipitated and resuspended in TE. 
7.6.7 Ligation of DNA fragments 
solutions 
10 X ligation-kinase buffer 
660 mM Tris.HC1 pH 7.4 
10 mM spermidine.HC1 
100 mM M902 
150 mM dithiothreitol (DTT) 
2 p.g/p.l nuclease-free bovine serum albumin (BSA) 
store at -20°C in 200 p.1 aliquots 
Generally 1:3 molar ratio vector DNA: insert DNA was used for the 
ligations. A control ligation containing no insert DNA was always 
included to assess the extent of self-ligation. 100-200 ng of vector was the 
optimal concentration for a 10 p.1 reaction, assembled as following: 
1 p.1 lox ligation-kinase buffer 
1p.11OmMATP 
1 p.1 (lu/p.l) T4 DNA ligase (Boehringer, 716 359) 
vector DNA (usually 100-200 ng) 
insert DNA (3 x molar excess) 
sterile water to 10 p.1 
The reaction components were assembled fresh each time. The 
reaction was left to proceed overnight at 15°C, or for 2 h at room 
temperature (approximately 25°C). 
The reaction was ethanol precipitated and the DNA was 
resuspended in 20 p.1 of sterile water. Half of that was electroporated in 
competent cells. 
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7.6.8 Blunt-ending DNA fragments 
solutions 
10 X T4 DNA polymerase buffer 
50 mM Tris.HC1 pH 8.5 
15 mM ammonium sulfate 
7 mM MgC12 
0.1 mM EDTA 
10 mM i-mercaptoethanol 
200 pg/ml BSA 
store in 200 jil aliquots at -20°C 
With this reaction protruding 5' ends of double stranded DNA that 
resulted after restriction digestion, were filled in by the T4 DNA 
polymerase (5' to 3' polymerase activity) and protruding 3' ends were 
recessed (3' to 5' exonuclease activity). The reaction was assembled as 
following: 
2 il dNTPs 2.5 mM each 
5 p1 T4 DNA polymerase buffer 
42 il of DNA fragment (usually up to 5 j.tg) 
1 p1 (lu/p.l) T4 DNA polymerase ( Boehringer 1004 786) 
The. reaction was incubated at 37°C for 1 h before it was ethanol 
precipitated. The DNA was resuspended so as to give 400 ng/p.l. 
7.6.9 Phosphorylation of nonphosphorylated linkers and ligation to 
DNA fragment 
Before adding linkers to a DNA fragment it was first necessary to 
phosphorylate their 5' ends. The reaction was assembled as following: 
1 p1 10 X ligation-kinase buffer 
1p1 10 mM AlP 
2 jig nonphosphorylated linkers (approximately 700 pmol) 
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0.2 p1 (10 u/pJ) T4 DNA polynucleotide kinase (Boehringer 174 645) 
sterile water to a final volume of 10 p1 
The reaction was incubated at 37°C for 1 h and was used directly for 
ligation to the DNA fragment. The following components were added to 
the 10 j.i1 reaction: 
1 p.1 ligation-kinase buffer 
1p.l 10 mM AlP 
1 p1 blunt-ended DNA fagment (400 ng) 
2 p.1 (lu/p.l) DNA T4 DNA ligase 
sterile water to 20 p1 
The reaction was incubated overnight at 15°C, or at room 
temperature for 2 h. Subsequently it was ethanol precipitated and 
resuspened in 5 p.1 sterile water. 
7.6.10 Phosphorylation of adaptors and ligation to DNA fragment 
To 10 pmol ends of DNA fragment a 20 X molar excess of 
oligonucleotide adaptors was added (100 pmol), as following 
200 pmol adaptor(1) 
1 p1 10 X kinase-ligase buffer 
1p.11OmMATP 
0.1jil T4 polynucleotide kinase 
sterile water to 10 p.1 
The reaction was incubated at 37°C for 1 h, then for 5 min at 70°C 
and chilled on ice. To that 200 pmol of adaptor(2) and sterile water to 20 
p.1 were added. The mixture was incubated for 10 min at 70°C and left to 
cool at room temperature. 
The phosphorylated adaptors (final concentration 10 pmol/pl) were 
used for the ligation to the DNA fragment as following: 
10 pmol. of DNA ends 
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10 j.tl (100 pmoi) adaptors 
10 j.ti 10 X ligation - kinase buffer 
10 jil BSA (1 mg/mi) 
10 p1 (lu/p1) T4 DNA ligase 
steriie water to 100 p1 
The iigation was incubated for 2 h at room temperature or at 15°C 
overnight. The ligase was inactivated by heating at 70°C for 5 mm. 
Subsequentiy the cioned adaptors were phosphorylated by adding the 
following components to the 100 jil reaction: 
8p11OmMATP 
1 j.il 10 X ligation-kinase buffer 
1 p1 (10 u/p1) T4 DNA polynucleotide kinase 
The reaction was incubated at 37°C for 1 h and then at 70°C for 5 
mm. The sample was loaded on a 2% (w/v, agarose in TBE) agarose gel 
and the band was eluted in a volume that would give 50 ng/jil. 
7.6.11 Polymerase Chain Reaction (PCR) 
When the template for the amplification of the fragment of interest 
was plasmid DNA, 20 ng of DNA were used and when the template was 
genomic DNA, 500 ng of DNA were used. 
The reaction was assembled as following: 
0.5 p1 (5 u/pi) Taq DNA polymerase (Promega M1862) 
5 p1  25 mM M902  (provided by Promega) 
• 	5 p1 10 X PCR buffer (Provided by Promega) 
2 p1 dNTP mix 2.5 mM each 
50 j.tM primer(1) 
50 pM primer(2) 
sterile water to 50 jil 
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The reaction was placed in the PCR machine which was set at the 
following temperatures (unless otherwise stated): 
95°C for 2 mm (melting temperature) 
55°C for 1 min 30 sec (annealing temperature) 
72°C for 2 mm (extension temperature) 
This was repeated for 30 cycles and followed by 1 cycle of: 
95°C for 2 mm 
55°C for 1 min 30 sec 
72°C for 10 mm 
before placed on ice. 
A 5 jil aliquot of the reaction was run on a 1% agarose gel to 
visualise the products of the reacion. 
The annealing temperature could vary (50°C-60 0C) depending on 
the stringency required. 
7.6.12 Reverse transcription PCR (RT-PCR) 
Approximately 500 ng to 1 jig of total RNA were used for the 
reverse transcription reaction. The components were assembled as 
following: 
2 jil 25 mM MgCl2 
2 jil 10 X PCR buffer 
2 jil dNTP mix 10 mM each 
0.5 jil (20U) RNA guard (Pharmacia 27 0815 01) 
1 p1 (100 pmol, 50u/pJ) random hexamer primers (Pharmacia, 
27216601) 
1 p1 (12u/p.l) Moloney Murine Leukemia Virus Reverse 
Transcriptase (Pharmacia, 27 0925 02) 
sterile water.  to 20 p1 
The reaction was placed in the PCR machine and incubated at the 
following temperatures for 1 cycle: 
10 min at 23°C 
45 min at 42°C 
5 min at 95°C 
After placing on ice the following components were added for the 
PCR step: 
8 p.1 25 mM M902 
8 p.1 10 X PCR buffer 
1 p.1 50 p.M primer (1) 
1 p.1 50 p.M primer (2) 
0.5 p.1 (5u/p.l) Taq DNA polymerase 
water to 100 p.1 
At this point the temperatures described before for the PCR 
amplification were used. 
7.6.13 Cloning of PCR fragments 
When primers including specific restriction sites for cloning were 
used for the PCR amplification, the PCR product was digested with the 
equivalent restriction enzymes to generate the ends. The restriction sites 
were never placed at the end of the primers because most restriction 
enzymes do not cut at the end of a fragment. At least 3 extra nucleotides 
were included in the primers beyond the restriction sites. 
Taq. DNA polymerase has a terminal transferase activity adding a 3' 
A-overhang to each end of the PCR products. A vector with a T 
overhang was therefore used for direct cloning of PCR fragments (TA 
cloning kit, Invitrogen, K2030-01). 
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7.7 Genomic DNA extraction 
solutions 
Proteinase K (PK) buffer: 
50 mM Tris.HC1 pH 7.5 
100 mM EDTA 
50 mM NaC1 (optional) 
0.5% SDS 
Proteinase K (PK) 
10 mg/ml in sterile water 
7.7.1 from tissues 
100 p.g of tissue were digested at 55°C overnight in 1 ml (10 
volumes) of PK buffer containing 0.5 mg/ml PK. 
The sample was extracted once with phenol, the aqueous phase 
was transferred to a fresh eppendorf and then PCA extracted. 
The aqueous phase was transferred to a new eppendorf and the 
DNA became visible as white strings after the addition of 2.5 volumes of 
ethanol. At that stage it was picked with the tip of a Pasteur pipette, 
which was made into a hook. 
The DNA which adhered to the pipette was transferred to an 
eppendorf containing 70% ethanol and the pipette was shaken until the 
DNA fa1l in the solution. 
After a spin at 13,000rpm for 3 min the pellet was dried in a 
vacuum microfuge, 400 p1 of TE buffer were added and it was left to 
resuspend overnight at 4°C. 
100 jig/mi of RNase (DNase free) were added and the sample was 
incubated at 37°C for 1 h. 
The sample was PCA extracted, ethanol precipitated and 
resuspended in 200 p1 TE at 4°C overnight. 
When the tissue for the DNA extraction was mouse tail, 1 cm 
approximately of mouse tail was cut off in 500 p1 PK buffer containing 
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0.5 mg/mi PK and left at 55°C overnight. The same procedure was 
applied to mouse ear-punches, but the volume of PK buffer added was 
100 p1. At this point either of the f6ilowing two procedures were 
followed: 
7.7.1a Preparation of DNA for Southern blot analysis 
Procedures 2-7 were followed as described above (section 7.7.1). 
7.7.1b Preparation of DNA for dot/slot blot analysis 
150 p.1, or 30 p.1 of 5 M NaCl were added to 500 p.1 PK-treated mouse 
tails, or ear-punches respectively, vortexed for 5 mm, then equal volume 
of chloroform was added and vortexed. Most of the supernatant would 
be stored at -4°C and 50 p.1 would be further incubated with 150 p.1 0.53 M 
NaOH (0.4 M final concentration) for 30 min at 37°C. 
7.7.2 from cells grown in tissue culture 
Cells from a 9 cm culture dish (10 6_107 cells), were washed twice 
with ice cold PBS and scraped with a rubber policeman in 1 ml of PBS. 
After being transferred to an eppendorf tube, they were 
centrifuged for 3 min at 13,000rpm and resuspended in 500 p.1 PK buffer 
containing 0.5 mg/mi PK. 
The sample was incubated for 3 h at 55°C followed by procedures 
2-7 described for the extraction of genomic DNA from tissues. 
7.8 Total RNA extraction 
DEPC (diethyl pyrocarbonate) treatment of solutions (any solution 
that does not contain Tris base): add DEPC 1:1000 (v/v) and autoclave. 
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For the extraction of total RNA from tissue or cells grown in cell 
culture the RNAzo1 B method (8050-4014, Biogenesis) was used. 
Approximately 50 mg of tissue was homogenised in a glass 
Dounce homogenizer with 1 ml RNAzo1 B, before being transferred to 
an eppendorf tube. Cells grown in monolayer were lysed directly on the 
culture dish by the addition of RNAzo1 B (1 ml for 106  cells) and then 
transferred to an eppendorf tube. 
100 .d (1:10 v/v) of chloroform were added and vortexed for 15 
sec before standing on ice for 5 min.  
The samples were centrifuged for 15 min at 13,000 rpm. 
The aqueous phase was transferred to another eppendorf and an 
equal volume of isopropanol was added. The sample was left on ice for 
30 min or kept at -20°C overnight. 
The sample was microfuged at 13,000 rpm for 15 mm, the RNA 
pellet was washed with70% (v/v) ethanol, dried and resuspended in 30-
50 .il DEPC-treated water. 
• 	6 Quantitation was done by absorbance at 260 nm, assuming that 1 
OD=40 j.tg/ml and by agarose gel electrophoresis against known 
standards. 
7.9 mRNA extraction 
mRNA was purified by the mRNA purification kit (Pharmacia 27-
9258-01), from total RNA prepared previously from tissue or cells by the 
RNAzo1 method, following the instructions of the manufacturers. 
7.10 In vitro transcription 
1. CsC1 purified DNA was used to produce linear DNA template by 
restriction digest with enzyme that cuts at the 3' end of the DNA 
fragment to be transcribed. An aliquot of the reaction was run on an 
agarose gel to ensure that restriction had gone to completion. The 
remainder of the reaction was PCA extracted and ethanol precipitated. 
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The DNA was resuspended in DEPC treated water at a concentration of 1 
pg/p1.. 
2. In vitro transcription was carried out using T3 RNA polymerase 
(Promega P2083) The reaction was assembled as following: 
2 p1 5 X Transcription buffer (Promega) 
1 p1 RNA guard 
0.5 p1 100 mM DTT 
2 p1 dNTP mix 2.5 mM each 
1 p1 DNA template (1 pjg) 
3 p1 T3 RNA polymerase 20 u/p1 
The reaction was incubated at 37°C for 1 h and then DNase I was 
added (lOu) and the reaction was incubated for another 30 mm. The 
volume was made up to 50 p1 with sterile DEPC-treated water and the 
sample was purified through a sterile DEPC-treated G-50 Sephadex 
column. 1 p1 of the purified sample was run on an agarose gel and the 
rest was precipitated by the addition of 1 volume isopropanol and 1/10 
volume of 3 M amonium acetate. The sample was left for 1 h on ice then 
centrifuged at 13,000rpm, washed with 70% (v/v) ethanol and 
resuspended in 5 p1 sterile DEPC-treated water. 
7.11 Preparation of G-50 Sephadex columns for purification of in 
vitro prepared RNA 
DEPC-treated 10 X STE (100 mM Tris.HC1 pH 7.5, 10mM EDTA, 2 
M NaCl) was made as following: 
DEPC treat 10 mM EDTA, 1 M NaCl in water (leave overnight 
before autoclaving), then add Tris base (to 100 mM), adjust the pH to 7.0 
with HC1, autoclave again. 
2 mg of G-50 sephadex was added to 35 ml DEPC-treated water 
and autoclaved. To that 4 ml 10 X STE (final concentration 1 X) was 
added. 
The colunins were made in 1 ml syringe barrels by using sterile 
Whatman filters and G-50 Sephadex in 1 X STE. The column was 
centrifuged at 2,000 rpm for 5 mm. 
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7.12 Dideoxy-termination sequencing of double-stranded DNA 
templates and cycle sequencing (Sanger et al., 1977). 
For standard sequencing approximately 2 jig of uncut plasmid 
DNA was denatured by incubating in 200 mM NaOH for 5 min at room 
temperature. The DNA was precipitated with 1/5 volume of 10 M 
ammonium acetate and 4 volumes of absolute ethanol at -20°C for 15 
mm. 
The DNA precipitate was washed with 1 ml of 70% (v/v) ethanol, 
dried and resuspended in 7 ml of water. 
The sequencing reactions were prepared using the Sequenase 
Version 2.0 kit (USB, 70770) according to the manufacturers instructions. 
Direct cycle sequencing of DNA fragments was done with Vent 
polymerase (New England Biolabs, 2575) according to the manufacturer's 
instructions. 
7.13 Sequencing gel 
Sequencing products were electrophoresed through a 0.2 mm 6% 
(v/v) denaturing (i.e. 8 M urea) acrylamide gel in TBE. 
The gel was made using solutions obtained from the 'Sequagel' 
kit of National Diagnostics. For a 50 ml gel the following quantities were 
used: 
14.4 ml concentrate 
39.6 ml diluent 
6 ml buffer 
0.48 ml 10% (v/v) ammonium persuiphate (APS) 
50 jil N,N,N',N'-tetramethyl-ethylenediamine (TEMED) 
The gel was poured between glass plates, one of which had been 
siliconised and an appropriate comb was used to create the wells in situ. 
Samples were denatured at 90°C for 10 min and then 2 jil of each 
was loaded into the wells in a defined order (A-C-G-T was used here). 
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The gel was subjected to electrophoresis (30-40 W, 2000 V for 3 h or 
more, 
After electrophoresis, the gel was soaked in 10% (v/v) methanol, 
10% (v/v) acetic acid for 15 min to leach out the urea and to fix the DNA. 
The gel was transferred to 3MM Whatmann paper and dried at 80°C 
under vacuum using an ice-trap to condense the evaporating fix 
solution. 
Sequencing products were visualised by autoradiography using 
Kodak BioMax film. 
7.14 Southern Blot 
This method was based on that described by Southern, 1975. 
solutions 
acid depurination solution 
0.25 M HC1 
denaturing solution 
0.5 M NaOH 
1.5 M NaCl 
neutralising solution 
1 M Tris.HC1 pH 7.4 
1.5 M NaCl 
The samples were electrophoresed on a 1% agarose gel containing 
0.5 mg/ml EtBr. 
The gel was photographed and then acid depurinated for 20 mm. 
The gel was rinsed with distiled water and then denatured for 30 
mm. 
Following denaturation the gel was neutralised 2 X 5 mm. 
The gel was rinsed briefly in 20 X SSC and then transferred to a 
vacuum blotting device (Pharmacia LKB VacuGene XL). The membrane 
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used in all transfers was Hybond-N (Amersham RPN.303N) and it was 
prewet in distiled water and 20 X SSC. The transfer buffer was 20 X SSC. 
6. After the transfer, the filter was rinsed briefly in 2 X SSC and then 
UV crosslinked on a UV Crosslinker (Stratagene Stratalinker 1800) at 
1,200 .tJou1es. 
7.15 Dot/slot blot 
A Hybond-N filter was cut at the size of the dot blot apparatus and 
prewet in 1 X TBE and then in 0.4 M NaOH for 5 mm. 3MM Whatman 
paper was soaked in 0.4 M NaOH and placed under the Hybond-N filter. 
The apparatus (BioRad, Bio-Dot apparatus) was assembled following the 
manufacturer's instructions. 
After preparation of DNA samples (200jil) from mouse tails, or ear-
punches for dot blot analysis (section 7.7.1b), they were loaded into the 
slots of the assembled apparatus and left for 30 min before vacuum was 
applied. 
7.16 Northern Blot 
solutions 
2OXFRB 
0.4 M MOPS (3- [N-morpholino}propanesulphonic acid).NaOH pH 
7.0 
100 mM sodium acetate 
10 mM EDTA (pH 8.0) 
denaturing solution 
50 mM NaOH 
10 mM NaCl 
neutralising solution 




50% (v/v) formamide 
7% (v/v) formaldehyde 
0.5 mg/mi EtBr 
bromophenol blue 
RNA samples were ethanol precipitated. 
The RNA samples were resuspended in sample buffer and heated 
at 65°C for 15 min before being loaded onto al% agarose gel containing 1 
X FRB and 7% (v/v) formaldehyde. 
The gel was electrophoresed for 2 h at 100 V/cm, until the 
bromophenol blue was near the end of the gel. 
After electrophoresis and photography, the gel was denatured for 
20 min, neutralised for 10 mm, rinsed 3 X sterile water and blotted. The 
vacum transfer of. RNA to a Hybond-N (Amersham RPN.303N) 
membrane was exactly the same as for DNA. 
The size markers used were obtained from GIBCO-BRL (15620-
016). When total RNA was used, the 28S and 18S ribosomal RNA would 
also serve as a size indicator (4.7 kb and 1.9 kb respectively). 
7.17 Radiolabelling of DNA 
7.17.1 Oligonucleotide-labeling of DNA fragments 
This method is based on that described by Fienberg and Vogelstemn, 
1984. 
solutions 
5X labeling mix 
250 mM Tris.HC1 pH 7.5 
25 mM M902 
10 mM DTT 
1 mM Hepes.HC1 pH 6.6 
26 u/ml random hexamer primers (Pharmacia 27-2166-01) 
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dNTP mix 
500 iM dATP 
500 iM dGTP 
500 iM dTTP 
DNA fragments for radiolabeling were firstly excised and eluted 
from agarose gels. 
10-25 ng of DNA in a final volume of 28.5 p1 of water was 
denatured by boiling for 5 mm. 
Tubes were placed on ice, then centrifuged briefly in a microfuge 
to collect the contents to the bottom. 
The following 50 p1 reaction was assembled: 
28.5 p1 DNA 
10 p1 labeling mix 
2 p1 10 mg/ml BSA 
2 p1 dNTP mix 
5 p1 [a-32P] dCTP 50 mCi (3,000 Ci/mmol)(Amersham AA0005) 
2 p1 (2 u/p1) Klenow fragment of E. coli DNA polymerase I 
(Boehringer 
1008412) 
The reaction was incubated at room temperature for 2-3 h, or for 
lhat37°C.. 
Labeled DNA was purified from unincorporated [a- 32P}-dCTP 
using the a G-50 sephadex spin colunm. 
Lately the 'High Prime' kit (Boehringer 1585 592) was used 
according to the manufacturer's instructions. 
7.17.2 T4 polynucleotide kinase-labeling of 5' termini. 
Oligonucleotides may be labeled directly using this method, 
however DNA restriction fragments require prior dephosphorylation. 
168 
The procedure described for phosphorylating linkers (section 7.6.9) 
was followed in both occasions but instead of ATP, 50 mCi of [y- 33P]ATP 
(NEN NEG-302H) were added. The kinase was subsequently inactivated 
by heating at 68°C for 10 mm. The labeled oligonucleotide was purified 
by ethanol precipitation in the presence of glycogen. 
7.17.3 Terminal Transferase tailing of 3' termini 
This method was used to label oligonucleotides with a tail of 35S 
for in situ hybridisation. 
1. 10 ng of oligonucleotide was tailed in a 20 p.1 reaction. The 
following were added in order: 
3 p.1 sterile water 
2 p.1 oligonucleotide (0.5 - 1.0 nmol) 
4 p.1 5 X terminal transferase buffer (Boehringer) 
6 p.15 mM C0C12 
25 units terminal transferase (Boehringer 220 582) 
40 p.Ci [a-35S] dATP (1,000 Ci/mmol) (Amersham SJ1304) 
2. The reaction was incubated at 37°C for 1 h. 
3. 80 p.1 of TE and 20 mg yeast tRNA (Boehringer 109495) were 
added to quench the reaction. 
4. The sample was PCA precipitated, the pellet was dried and 
resuspended in 50 ml TE. If the labeled oligonucleotide was to be used 
for in situ hybridisation, the TE for resuspension contained 10 mM DTT. 
2 p.1 would be mixed in a scintillation vial with 3 ml scintillation 
fluid (Ultima gold, Packard 6013329) and in order, to determine the 
incorporation of radioactivity. 
7.17.4 Synthesis of riboprobes 
Riboprobes were prepared from the 250 bp SV40 sequence cloned in 
modified pBluescriptll (LtPS.N.A construct, appendix 2). Antisense SV40 
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probe was synthesised with T3 RNA polymerase after XhoI digestion of 
the plasmid and sense SV40 probe was synthesised with T7 RNA 
polymerase after KpnT digestion of the plasmid. 
6 j..tl 5 X Transcription buffer (Promega) 




1 i.t110 mMGTP 
10 i1 (-125 .tCi) [a- 35S] UTP (Amersham SJ1381) 
5 p1 linear DNA template (-5 jtg) 
3 j.tl T3 RNA polymerase 20 u/j.il (Promega P2083) 
(or, 3 p1 T7 RNA polymerase 20 u/pd (Promega P2075)) 
sterile DEPC-treated water to 30 p1 
The reaction was incubated for 30 min at 37°C before 2 p1 tRNA (10 
mg/ml) and 1 p1 DNase were added. 
After 10 min incubation at 37°C, 1 p1 of 200 mM EDTA and TE (with 
50 mM DTT) to a final volume of 100 il were added. 
The reaction was extracted once with phenol then twice PCA 
extracted and 10 p1 of 3 M sodium acetate were added followed by 
ethanol precipitation. 
The pellet was washed 1 X 80%(v/v) ethanol/50 mM DTT and 1 X 
100% ethanol. After drying it was resuspended in appropriate volume of 
TE/50 mM DTT to give approximately 1 X 106  cpm/ml. 
7.18. Hybridisation Conditions (Southern and Northern analysis) 
Hybridisation conditions used were based on those described by 
Church and Gilbert, 1984. 
1M NaHPO4 pH7.0 
72 g anhydrous Na2HPO4 
4 ml H3PO4 (85% v/v) 
up to 1 litre with sterile water 
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Hybridisation Buffer: 
0.25 M NaHPO4 pH 7.2 
1 mM EDTA 
7% (w/v) SDS 
1% (w/v) BSA 
Wash Buffer I: 
20 mM NaHPO4 pH 7.2 
2.5% (w/v) SDS 
0.25% (w/v) BSA 
1 mM EDTA 
Wash Buffer II: 
20 mM sodium phosphate pH 7.2 
1 mM EDTA 
1% (w/v) SDS 
Filters were pre-wet in distilled water and then in 2 X SSC 
(section 7.1). 
The hybridisation was performed in a rotating glass cylinder 
(Techne Hybridiser ovens). 10 ml of Hybridisation Buffer were added to 
the cylinder with the filter. 
Prehybridisation and hybridisation were carried out at 65°C 
unless otherwise specified. 
The filters were prehybridised for 1 h, after which the probe was 
added directly and hybridisation proceeded overnight. (Double-stranded 
probes were denatured by boiling for 5 min and then placed on ice). 
Washes were performed at 65°C (unless otherwise stated) with 2 
changes of Wash Buffer I for 10 min each, followed by three changes of 
Wash Buffer II each for 20 mm. 
The filters were blotted dry, but not allowed to dry out, then 
placed between Saran wrap, and against X-ray film for autoradiography 
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7.19 Colony screening - identification of recombinants 
Some plasmids used for cloning (i.e. pBluescriptllKS-, Stratagene) 
contain a segment of E. coli DNA encoding for I-galactosidase (lacZ 
gene). Such plasmids form dark blue. colonies when plated in the 
presence of the chromogenic substrate, X-gal and inducer, IPTG. The 
multiple cloning site (MCS) of these plasmids is upstream of the lacZ 
gene and therefore cloning of a foreign DNA fragment would result in a 
shift of the reading frame and loss of I-galactosidase activity (formation 
of white colonies). After electroporation with such plasmids the cells 
woud be plated on LB agar/X-gal plates (containing 100 pg/ml amp) and 
incubated over night at 37°C. The white colonies would be picked and 
DNA would be prepared by the small scale plasmid preparation method 
(section 7.4.3). 
Trying to identify positive recombinant colonies after cloning 
attempts by small scale plasmid preparation was not always possible, due 
to the number of colonies to be screened, or the absence of reporter gene 
in the plasmid used for cloning. In that case colony hybridisation was 
used as an alternative. 
Colonies to be screened were replated on LB-amp plate using a 
circular paper grid and grown overnight at 37°C. 
A circular nitrocellulose filter was laid on to the plate for 20 sec, 
then removed and laid on to a new LB-amp plate which was incubated 
at 37°C overnight so as to create a replica. Another nitrocellulose filter 
was laid on the original plate to create a duplicate. Both filters were 
treated as following: 
3 min in 10% (w/v) SDS 
5 min in 1.5 M NaCl, 0.5 M NaOH 
5 min in 1.5 M NaCl, 0.5 M Tris.HC1 pH 7.5 
The filters were washed thoroughly in2 X SSC and UV crosslinked 
before they were left to air dry. The hybridisation of the filters was the 
same as for Southerns and Northerns. 
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7.20 Stripping of filters 
Filters that needed to be reprobed were stripped by placing them in 
boiling 0.1% (w/v) SDS and leaving the solution to cool to room 
temperature. This was repeated if necessary until no signal could be 
detected using the Geiger counter. Stripped filters were exposed to 
autoradiographic film at least overnight before reprobing, to ensure that 
all previous signals had been removed. 
7.21. Protein manipulation 
7.21.1 protein extraction 
solutions 
Lysis buffer I 
100 mM NaCl 
10 mM Tris.HC1 pH 7.8 
10 mM EDTA 
0.5% (w/v) sodium deoxycholate 
0.5% (v/v) Nonidet P-40 
Lysis buffer II 
0.5% (v/v) Nonidet P-40 
0.5% (w/v) sodium deoxycholate 
PBS 
PMSF solution 
phenylmethanesulfonyl fluoride (PMSF) 1% (v/v) in isopropanol 
7.21.1a from tissues 
Mouse tissues were kept on dry ice until they were homogenised in 
lysis buffer II. 
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Approximately 100 mg of tissue was weighed and placed in a 
Dounce homogenizes with 900 p1 of lysis buffer II and 10 p1 of PMSF 
solution. 
After homogenization the sample was transferred to a 1.5 
eppendorf tube on ice and sonicated 4 X 1 min at 24 microns with a 
Soniprep 150 MSE sonicator. 
The sample was centrifuged at 3,000 rpm for 5 min and the 
superriatant was precipitated with 4 volumes of methanol for at least 1 
h. 
After 10 min centrifugation at full speed the pellet was 
resuspended in 200 p1  lysis buffer. 
The sample was kept at -20°C in 50 p1 aliquots. 
7.21.1b from cells 
Tissue culture cells from a 9 cm culture dish (10 6 10 7 cells) were 
washed 3 times in ice cold PBS and then lysed with 1 ml of ice cold lysis 
buffer I containing 10 p1 PMSF solution. 
The cells were left at room temperature for 5 min with occasional 
rocking, scraped with a rubber policeman and transferred to an 
eppendorf tube. 
The sample was passed several times through a 26 gauge needle 
and left for 10 min on ice with occasional vortexing. 
Nuclei and insoluble debris were removed by 5 mm 
centrifugation at 3,000 rpm. 
The supernatant was transferred to a new eppendorf and 
precipitated with 4 volumes of methanol at -20°C for at least 1 h. 
Samples were centrifuged at 13,000 rpm for 15 min at 4°C and the 
pellet was resuspended in a small volume of lysis buffer I. 
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7.21.2 Quantification of protein concentration by using the BioRad 
protein assay 
5 p1 of the protein sample to be assayed were added to 800 p1 of 
water in a 1 ml plastic UV cuvette. 200 p1 of BioRad protein assay reagent 
(BioRad 500-0006) were added and mixed thoroughly. 
The sample was incubated at room temperature for 10-15 mm 
and the absorbance was read at 595 nm. 
14 reactions containing 5, 10, 15, and 20 jig of BSA were set al.,ong 
with the samples and used as a standard. 
7.21.3 SDS - PAGE electrophoresis 
solutions 
The acrylamide used was either Protogel (National diagnostic EC-
890) or prepared as following: 
acrylarnide stock 30% T 2.67%C 
29.2 g acrylamide 
0.8 g bisacrylamide (N,N-methylenebisacrylamide) 
make up to 100 ml with distilled water 
wrap in foil and store in the fridge 
sample buffer 
4% (w/v) SDS 
20% (v/v) glycerol 
125 jiM Tris.HC1 pH 7.4 
10% (v/v) L-mercaptoethanol added just before use 
0.001% (w/v) bromophenol blue 
running buffer 
1.5 M Tris.HC1 pH 8.8 
stacking buffer 
0.5 M Tris.HC1 pH 6.8 
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electrode buffer 
25 mM Tris.HC1 pH 6.3 
192 mM glycine 
0.1% (w/v) SDS 
10% (w/v) ammonium persuiphate (APS) 
0.1 g in 1 ml sterile water 
Proteins isolated from tissues, culture cells, or generated by in vitro 
translation were examined for size heterogeneity by SDS polyacrylamide 
gel electrophoresis (SDS-PAGE) (Laemmli, 1970). A BioRad 'mini 
Protean' or a BioRad 'Protean II Xi cell' gel systems were used. 
10% or 15% slab gels, with 6% stacking gels were generally used and 
the ingredients are given below: 
separating gel 10 X 7 cm 10 X 7 cm 16 X 16 cm 
10% 15% 15% 
H20 1.4 ml 2.4 ml 4.7 ml 
running buffer 1.5 ml 1.5 ml 5 ml 
acrylamide 2 ml 3 ml 10 ml 
10% SDS 0.06 ml 0.06 ml 0.2 ml 
10% APS 20 j.il 20 j.il 0.16 ml 
TEMED 3pi 3p1 5tl 
total 6 ml 6 ml 20 ml 
stacking gel 10 X 7 cm 16 X 16 cm 
H20 1.53 ml 5.7 ml 
stacking buffer 0.63 ml 2.5 ml 
acrylamide 0.33 ml 2 ml 
10% SDS 25 p1 0.1 ml 
10% APS 12 p1 0.1 ml 
TEMED 2p1 5p1 
total 2.5 ml 10 ml 
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10-20 j.tl of protein sample was mixed with 1 volume sample buffer, 
boiled for 10 min and electrophorised at 20 mA through the stacking gel 
and 40 mA through the separating gel. 
3 p.1 of prestained protein molecular weight standards (GIBCO-BRL 
26041-020) were mixed with equal volume of sample buffer boiled for 10 
min and loaded along with the samples. 
An overnight electrophoresis on the big gel was carried out at 40 V 
through the stacking gel and at 70 V through the separating gel. 
7.21.4 Gel staining 
Coomassie Blue solution 
100 ml methanol 
20 ml acetic acid 
80 ml distilled water 
0.02 g  Coomassie Blue 
In order to visualize all proteins contained in the samples the gel 
was stained with Coomassie Blue solution and destained for several 
hours in a solution of 10% (v/v) methanol, 10% (v/v) acetic acid. 
7.21.5 Gel fixing-amplifying-exposing 
Gels bearing radiolabeled proteins were fixed in 10% (v/v) 
methanol, 10% (v/v) acetic acid for 15 mm and rinsed several times with 
distilled water. Then they were treated with fluorographic reagent 
Autofluor (National Diagnostics, LS-315) containing 0.5% glycerol for 1 h 
and dried on 3MM Whatman paper on a vacuum gel drier for 1 h and 
exposed on X-ray film. 
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7.21.6 Immunoblotting 
The gel was transferred to a nitrocellulose filter and probed with 
anti-PrP primary antibodies and peroxidase conjugated secondary 
antibodies as described below. 
7.21.6a Transfer 
transfer buffer 
5.8 g Iris base 
2.9 g glycine 
3.7 ml 10% (w/v) SDS 
200 ml methanol 
make up to 11 with water 
6 pieces of 3MM Whatman paper were cut out exactly to the size 
of the gel and soaked in transfer buffer. 
A piece of nitrocellulose (Millipore immobilon-p IPVH00010) cut 
out to the exact size of the gel was soaked in methanol for 2 min and 
then in distilled water for 5 mm. 
The gel was rinsed with distilled water. 
These were loaded on the transfer apparatus in this order: 
3 Whatman 3MM papers 
gel 
nitrocellulose filter 
3 Whatman papers 
The transfer was done at 10 V, 80-100 mA for 1 h. 
The apparatus was unloaded and the filter allowed to dry slightly. 
The filter was rewet in methanol and then PBS (section 7.1). 
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7.21.6b Western Blotting 
block solution 
3% (w/v) BSA in PBS 
The filter was washed shaking in blocksolution for at least 3 h. 
The block solution was poured of and the filter was washed twice 
with PBS. 
The filter was placed in a plastic bag cut to the same size as the 
filter and 2 ml 3% (w/v) BSA in PBS containing the primary antibody at 
appropriate dilution were added. Usually the mouse anti-hamster PrP 
monoclonal antibody 3F4 (Kascsak et al., 1987) was used at 1:500 dilution, 
or the rabbit anti-PrP polyclonal antibodies 1133 and A8 (Farquhar et al., 
1989) were used at 1:1,000 dilution. The filter was incubated in this 
solution shaking overnight. 
The filter was washed 4 X 5 min in PBS. 
The filter was incubated with the secondary antibody: peroxidase 
conjugated rabbit IgG (SIGMA, A 9169), or mouse IgG (SIGMA, A 9044) 
diluted (usually 1:2,000) in 3% (w/v) BSA in PBS, for 1 h. 
The filter was washed 4 X 5 min in PBS. 
The filter was over-laid with the substrate solution (3,3' 
diaminobenzidine tetrahydrochloride, SIGMA FAST DAB tablets D4293) 
to allow the color (brown) to develop. 
The filter was washed several times in PBS to stop the reaction. 
7.22.1 Metabolic radiolabeling of cellular proteins. 
48 h after transfection of the cells, the medium was drawn off and 
they were washed twice with DMEM (see section 7.29.1) lacking 
methionine and cysteine (Gibco). 
The cells were incubated with 3 ml DMEM minus methionine-
cysteine for 1 h. 
This medium was replaced with 1 ml DMEM minus methionine-
cysteine supplemented with [35S]-methionine at 200 jiCi/ml (Tran 35S 
label ICN 51006) and the cells were incubated for 2 h. 
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The cells were lysed in 1 ml lysis buffer I and the protein 
extraction procedure from cells (7.21.1b) was followed up to the 
methanol precipitation step. 
7.22.2 Pulse-chase 
The cells were incubated with 3 ml DMEM minus methionine-
cysteine for 1 h. 
This medium was replaced with 1 ml DMEM minus methionine-
cysteine supplemented with [ 35S]-methionine at 100 j.tCi/ml (Tran 35S 
label ICN 51006) and the cells were incubated for 1 h. 
The medium was replaced with DMEM and the cells incubated 
for different duration of time before they were lysed. 
7.23 Immunoprecipitation (ip) of PrP 
This method is based on that described by Borchelt et al., 1993 and 
by Dr S.A. Priola (personal communication). 
Buffers 
DLPC 
100 mg of L-a-lecithin (Phosphatidylcholine SIGMA P-3556) 
1.3 ml Tris.HC1 pH 7.5 
21.3 ml sterile saline (NaCl 0.8% (w/v)) 
2.5 ml 20% (w/v) Sarcosyl 
The buffer was sonicated for 5-10 mm, until the lecithin went into 
solution. 250 pA of PMSF solution (see section 7.21.1) were added. The 
solution was stored at 4°C. 
TN buffer + 1% (wlv) Sarkosyl 
25 ml 1 M Tris.HC1 (pH 7.0) 
50 ml 5M NaCl 
25m1 20% (w/v) Sarcosyl 
Im 
The volume was made up to 500 ml with water and filtered. 
Stored at 4°C. 
Protein-A-sepharose beads 
Dry protein-A-sepharose (SIGMA P3391) was equilibrated in lysis 
buffer I at 100 mg/mi. After vortexing briefly the beads were spun down 
at low speed, the supernatant was discarded and the beads were 
resuspended in 900 jil lysis buffer I. This procedure was repeated twice 
and the beads were kept in 900 jtl lysis buffer I and stored at 4°C. 
After methanol precipitation, the protein samples were spun at 
13,000 rpm and the supernatant was discarded. 
The samples were left on ice for 5 min and the residual 
supernatant was removed. 
The remaining pellet was resuspended in 1 ml of DLPC and 
sonicated for 1 min at maximum output (until the pellet was completely 
sonicated into the buffer). 
5 pi of preimmune serum (mouse or rabbit, depending on the 
antibody) were added and the samples were incubated at room 
temperature for 30 min with constant mixing. 
50 p1 of protein-A-sepharose beads were added and the samples 
were incubated for another hour at room temperature with constant 
mixing. 
After centrifugation for 2 min at full speed the supenatant was 
transferred to a new eppendorf and the beads were discarded. 
At this point 10 j.tl of the supernatant were removed for TCA 
precipitation (7.24). 
4jil of 3F4 (Kascsak et al., 1987) (1:500 dilution of mouse anti-
hamster PrP monoclonal antibody) or 2.t1 of 1B3 or 1A8 (Farquhar et al., 
1989) (1:1,000 dilution of rabbit anti-PrP polyclonal antibody) were added 
and the samples were incubated for minimum 1 h (usually overnight) at 
4°C. 
30 p1 of beads were added and the samples were incubated at 
room temperature with constant mixing for 1 h. 
The samples were microfuged at low speed and the supernatant 
was discarded. 
500 jtl of DLPC were added and vortexed. 
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The beads were spun down at low speed and 500 il of TN buffer 
with 1% (w/v) Sarcosyl were added and vortexed. 
The beads were spun down and the supernatant was discarded. 
Steps 11 and 12 were repeated twice. 
1 ml sterile water was added and votexed. 
The beads were spun down, the supernatant removed and they 
were resuspended in 20 p.1 of sample buffer. 
The samples were boiled for 10 min and loaded on a 15% 
acrylamide gel. 
For immunoprecipitation of in vitro translated PrP (section 7.25) 5-
20 p.1 of sample would be diluted in lysis buffer I (section 7.21.1) and then 
steps 7-15 were followed, but instead of DLPC and TN buffer, lysis buffer I 
was used. 
7.24 TCA precipitation 
solutions 
25% (w/v) TCA/2% (w/v) casamino acids (Difco 0230-01) 
5% (w/v) TCA 
1 N NaOH 
10 p.1 of labeled protein extract was removed (step 6, 7.23) for TCA 
precipitation. To that 190 p.1 1 N NaOH were added and the mixture was 
incubated at 37°C for 10 mm. 
1 ml of ice-cold 25% TCA/2% casamino acids was added and 
incubated on ice for 30 mm. 
The precipitate was collected by filtering under vacuum on 
Whatman GF/A glass filters. The filters were pre-rinsed in ice-cold 5% 
TCA. 
After filtering of the sample the filter was rinsed three times with 
3 ml ice-cold 5% TCA and once with 3 ml acetone. 
The filter was allowed to dry completely at room temperature. 
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6. The filter was placed in a scintillation vial and covered with 3 ml 
scintillation fluid (Ultima gold, Packard 6013329) before incorporated 
radioactivity was measured on the scintillation counter. 
7.25 In vitro translation 
In vitro translation was performed by using the Promega Rabbit 
Reticulocyte Lysate - System (Promega L4960) as per the manufacturer's 
instructions. L-[ 35S]-methionine (NEN DuPont NEG 009A) was used to 
label the newly synthesised proteins and thus enable small quantities of 
product to be visualized by X-ray fluorography. 
The RNA was heated to 65°C for 10 min and cooled immediately 
on ice prior to addition to the reaction, to prevent inhibition by 
secondary structures. 
Negative control reactions were performed by adding an equal 
volume of water instead of the RNA substrate and positive control 
reactions were performed by using luciferase control RNA provided by 
the manufacturer. 
A standard reaction contained: 
17.5 .tl rabbit reticulocyte lysate 
0.5 p1 RNA guard 
0.5 jfl 1 mM amino acid mixture minus methionine 
2 tl 10 jiCi/pJ L- [35SJ-methionine 
500 ng in vitro produced mRNA substrate in DEPC-treated water 
(section 7.8) 
The volume was made up to 25 p1 and the reaction was incubated 
at 30°C for lh. 
4. 10 p1 of the reaction would be analysed by SDS-PAGE (section 
7.21.3). 	 - 
The GIBCO-BRL Rabbit Reticulocyte Lysate Translation System 
(GIBCO-BRL 18127-019) was used alternatively to the Promega one in 
order to compare the efficiency and the background produced. The 
reaction (final volume 30 jfl) was assembled according to the 
manufacturer's instructions. The control RNA provided encoded 
bacterial chloramphenicol acetyltransferase. 
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7.26 Preparation of cell extract using the reporter lysis buffer (for 
adherent cells grown in tissue culture) 
4 volumes of water were added to 1 volume of 5 X reporter lysis 
buffer to give a 1 X buffer solution. 
The growth medium was removed from the cells to be assayed. 
The cells were washed twice with PBS buffer at room temperature, being 
careful not to dislodge any of the cells. The rest of the final PBS wash was 
removed with a Pasteur pipette. 
The cells were lysed by adding a sufficient volume of 1 X reporter 
lysis buffer to cover the cells (400 p1 for a 60 mm culture dish, 900 jil for a 
90 mm dish). The dish was rocked slowly several times to ensure 
complete coverage of the cells and incubated at room temperature for 15 
mm, rocking the dish halfway through the incubation period. 
All areas of the plate surface were scraped with a rubber 
policeman, then the dish was tilted and the cell lysate was scraped to the 
lower edge of the plate. The cell 'lysate was transferred to a 
microcentrifuge tube with a pipet and the samples placed on ice. If 
several samples were being harvested at the same time, a different 
rubber policeman was used each time to prevent enzyme carry over 
from one plate to the next. 
The lysates were microfuged at full speed in a microcentrifuge for 
2 min at 4°C. The supernatant was transferred to afresh tube. 
The extracts would be assayed directly (BioRad protein assay, g 
galactosidase assay, CAT assay) or stored at -20°C. 
7.27 13-galactosidase enzyme assay 
This assay is based on that described by Ulman et al., 1967 and in the 
Hoeffer technical bulletin. 
This assay measures the hydrolysis of a 13-galactosidase substrate 
linked to a fluorogen. Cleavage of 4-methy1umbelliferyl--D-galactoside 
by 13-galactosidase yields the 4-methylumbelliferone (7-hydroxy-4-
methylcoumarin, MU) molecule. This molecule excited at 365 nm emits 
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fluorescence which can be measured at 460 nm wavelength using a 
fluorometer. 
Solutions and buffers 
reporter lysis buffer,. 5 X (Promega, E3971). 
This buffer was diluted 5 times before use. 
Reaction cocktail: 
25 mM Tris.HC1 pH 7.5 
125 mM NaCl, 2 mM MgCl2 
12 mM -mercaptoethanol 
0.3 mM 4-methy1umbellifery1--D-ga1actoside 
Add 4-methylumbelliferyl--D-galactoside (Sigma Ml 633) (20 
mg/ml in 100% (v/v) ethanol, stored at -20°C) just before use and vortex 
immediately to obtain a 0.3 mM concentration. 
Glycine-carbonate reagent: 
133 mM-glycine 
83 mM Na2CO3.NaOH  pH 10.7 
Clarify solution by filtering it through a 0.45 .t cellulose nitrate 
filter. 
This prevents instability in fluorometer readout. 
1.tM-4-methy1umbelliferone (MU) sodium salt (Sigma, M1508) 
19.8 mg 4-methylumbelliferone 
distilled water to 100 ml 
Dilute 10 jil of the above solution into 10 ml distilled water. 
Store both solutions at 4°C protected from light. 
1. A volume of cellular extract containing 10 jtg of protein was 
transferred to an eppendorf tube. The volume was made up to 40 il with 
1 X lysis buffer. 
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160 ml of the reaction cocktail was added, mixed and incubated 
37°C for 30 mm. 
The reaction was stopped by adding 50 jil of 0.2 M Na2CO3  and 
cooling on ice. 
The solution was clarified by centrifugation in a microcentrifuge 
for 1-2 mm. 
The fluorescence (resulting of MU yield) was read by using the 
Hoeffer fluorometer TK100, following the procedure described below: 
The fluorometer was calibrated with a MU solution, as explained: 
The fluorometer was switched on for at least 15 min before use. 
The SCALE knob of the fluorimeter was adjusted to 50% sensitivity 
(5 complete turns from the fully anticlockwise position). 
A 'glass cuvette was filled with 2.0 ml of glycine-carbonate 
reagent, placed in the fluorometer and the display was brought to zero by 
adjusting the ZERO knob of the fluorometer. 
A glass cuvette was filled with 1.9 ml of glycine-carbonate 
reagent plus 100 pl of a 1 pM/MU solution (gives 2 ml of glycine-
carbonate solution containing 0.1 nmole of MU) and the SCALE knob 
was adjusted to obtain a readout of 500. So 500 fluorescence corresponds 
to 0.1 nmole MU and one unit of I-galactosidase corresponds arbritarily 
to enzyme level yielding 0.1 nmole MU in 30 min at 37°C. 
After the calibration the fluorescence of samples (cellular extract) 
could be read: 
100 jil of the supernatant was used and the volume was made up to 
2.0 ml with glycine-carbonate reagent. If MU level in 100 jil was too high 
to be measured, the measurement would be done on 10 or 1 jfl of 
supernatant (volume of supernatant used for assay depends on  is-
galactosidase level in cellular extract, and then of quantity of MU yield). 
To check the right linearity of the assay, the fluorescence of samples 
containing known quantities of E. coli 13-galactosidase enzyme' 
(Boehringer 567799), would be measured, (L-galactosidase 0 to 200 pg in 
40 p.1 1 X-lysis buffer treated as explained above for samples). 
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7.28 CAT assay 
This method is based on that described by Seed and Sheen, 1988. 
Chioramphenicol acetyltransferase (CAT), encoded by a bacterial 
drug-resistance gene, inactivates chioramphenicol by acetylating the 
drug at one or both of its two hydroxyl groups. This gene is not found in 
eukaryotes, and therefore eukaryotic cells contain no background level 
of CAT activity. 
This assay is based on liquid scintillation counting of CAT reaction 
products. Cell extracts were incubated in a reaction mix containing [ 3H]-
labeled acetyl CoA and chloramphenicol. CAT enzyme, present in 
cellular extract, catalyzes transfer of the acetyl group from acetyl CoA to 
chloramphenicol. This assay does not require any extraction because [ 3H] 
acetyl CAT (but not [ 3H] acetyl C0A) is soluble in the organic phase 
containing scintillant; liquid scintillation counting detects the product 
but not the substrate. A continuous data stream can be generated, 
providing quantitative results within minutes or several hours. 
Solutions and buffers 
reporter lysis buffer, 5 X. 
1 M Tris.HC1 pH 7.8 
5 mM Chioramphenicol 
Cell extract containing 25 mg protein and 100 mM Tris.HC1 pH 7.8 
were mixed in a 5 ml plastic mini-scintillation vial to give a total 
volume of 50 ml. 
To the 50 ml of cell extract 200 ml of the following freshly 
prepared reaction mix were added: 
1 ml [3H] acetyl CoA (250 Ci/ml from Amersham, code TRK. 688) 
50 ml 5 mM chloramphenicol 
25 ml 1 M Tris.HC1 pH 7.8 
124 ml H20  per reaction 
187 
The reaction mixture was gently overlaid- with 3 ml of water-
immiscible scintillation fluid (Econofluor-2, NEN No. NEF 969), and the 
vials were placed directly in the scintillation counter to be counted for 1 
mm. Vials were counted repeatedly to give a time course curve (arrange 
to cycle vials). 
The linearity of the reaction was checked with known E. coli CAT 
concentrations from 0 to 0.0100 u/50 jil Tris.HC1 pH 7.8 (E. coli CAT, 
Pharmacia 27-0847-01). 
7.29 Tissue Culture 
7.29.1 Solutions 
Cell Culture Medium 
distilled water 170 ml 
10 X Dulbecco's modified Eagle's medium (DMEM, Gibco) 20 ml 
sodium bicarbonate (7.5% (w/v) stock, Gibco) 6.6 ml 
glutamine, 200 mM + pyruvate, 100 mM (Gibco) 4 ml 
I-mercaptoethanol (Sigma) 200 ml 
foetal calf serum (Gibco) 20 ml 
Trypsin 
0.25% trypsin (from 2.5% (w/v) solution in normal saline, Gibco) 
1 mM EDTA (AnalaR, BDH) 
1% (v/v) chick serum (Gibco) 
Store at -20°C. 
Nerve growth factor (NGF) (SIGMA, N0513) 
Hygromycin B (50 mg/ml Boehringer Mannheim, 843555) 
7.29.2 General notes 
Tissue culture cells were maintained in the Centre for Genome 
research, initially obtained from 'European Collection of Animal Cell 
Cultures', or the 'American Type Culture Collection. 
ic.I. 
It.'. 
All tissue culture manipulations were undertaken inside a laminar 
flow sterile hood (ICN, Flow). All objects were washed with 70% (v/v) 
industrial methylated spirits (IMS, BDH) before being placed in the hood. 
Cells were maintained in tissue culture grade plastic flasks and culture 
dishes (Corning). The cells were grown in a humidified incubator at 
37°C, in a 6% CO2 atmosphere. The growth medium used was DMEM 
supplemented with 10% (v/v) foetal calf serum. Medium in the flasks 
was replaced when it began to turn from orange to yellow, usually every 
2 days. Confluent cultures were passaged into fresh flasks at 1/10 their 
original density. The medium was removed from the flasks the cells 
were then rinsed twice with PBS pre-warmed to 37°C, then overlaid with 
1 ml trypsin and incubated at 37°C until the cells lifted from the surface 
of the flask. The flasks were tapped to remove the cells from the base. 
The trypsin was neutralised by the addition of 5m1 of fresh medium and 
a single cell suspension formed by drawing the medium several times 
through a glass pipette. The cells were pelleted by centrifugation at 1,200 
rpm for 5 mm, the medium removed and the pellet resuspended in 5m1 
of fresh culture medium. 0.5 ml of cell suspension was then added to 
pre-warmed fresh culture medium, and placed in a new flask. 
7.29.3 Freezing Cells 
Cells were removed from the growth surface by trypsin digestion 
and resuspended in culture medium to which 1/10 volume of DMSO 
(AnalaR, BDH) was then added. The cell suspension was then 
centrifuged at 1,200rpm for 5 mm, the medium was removed, and the 
pellet resuspended in freezing medium (culture medium supplemented 
with 10% (w/v) DMSO). 0.5m1 of freezing medium was used for each 5 X 
106 cells. The suspension was then placed into cryotubes (Nunc) in 0.5 
ml aliquots and frozen at -80°C. After 24 h, the vials were transferred to a 
liquid nitrogen cell bank (XLC110, Minnesota Valley Engineering 
Cryogenics). 
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7.29.4 Thawing cells 
Vials of frozen cells were removed from the liquid nitrogen storage 
bank and thawed rapidly. The cell suspension was then transferred to a 
15 ml centrifuge tube (Corning) containing 4.5 ml of culture medium 
using a sterile Pasteur pipette. The cells were pelleted by centrifugation at 
1,200rpm for 5 mm, resuspended in 10 ml of fresh culture medium and 
transferred to a gelatinised 25 cm 2 flask. The medium was changed 
when the cells were firmly attached to the growth surface (usually after 
about 7 h or next day). The cells were subsequently maintained as above. 
7.29.5 Calcium phosphate transfection of cells 
Solutions 
BES solution 
1.630 g NaCl 
1.060 g BES (Calbiochem 391334) 
0.020 g Na2HPO4 
Water was added to 100 ml the pH was adjusted to 6.95 and the 
solution 
was filter sterilised and stored at 4°C in 20 ml aliquots. 
Cells were grown to 40-50% confluence and the medium was 
changed 1 h (at least) before transfection. Usually a 25 cm 2 flask or 90 
mm dish were used and 4.5 ml of medium. The cells were placed in an 
incubator at 2.5% CO2 and 37°C. 
The transfection mix was prepared as following: 
10 p.1 of 1 p.g/p.l plasmid DNA 
25 p.1 CaC12 2.5 M 
215 p.1 sterile water (filtered AnalaR) 
and was mixed well 
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For stable transfections the DNA was linearised by restriction digest 
with an appropriate enzyme and purified through a "Wizard" column 
(section 7.6.3) before adding to the transfection mix. 
For cotransfections a 5:1 ratio of DNA:control DNA (usually pCAT 
plasmid) was used. 
250 j.tl of BES were added dropwise to the transfection mix 
vortexed and left for 15 min at room temperature. 
The transfection solution was added dropwise to the cells. At this 
point the medium should look pink with obvious fine grains of DNA 
precipitate. 
The cells were incubated overnight in a 2.5% CO2, 37°C incubator, 
the medium was replaced the next day and the cells returned to a 6% 
CO2, 37°C incubator. 
The cells were left for 2-3 days before any further treatment. 
7.30 In situ staining of cells for 13-galactosidase 
Solutions 
0.1 M sodium phosphate, pH 7.0 
60 mM Na2HPO4 
40 mM NaP2HO4 
fix solution 
1% (v/v) glutaradehyde in 0.1 M sodium phosphate pH 7.0 and 1 
mM MgC12 
X-gal solution 
0.2% (w/v) X-gal (Bachem SRB020) 
in 10 mM sodium phosphate pH 7.00 
1 mM MgC12 
150 mM NaCl 
3.3 mM K4Fe(CN)63H20 
3.3 mM K3Fe(CN)6 
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The solution was prepared freshly each time and filtered through a 
0.2 micron syringe filter to remove large crystals present. 
Cells transfected with -galactosidase containing plasmids were 
tested for R-galactosidase enzyme expression by incubating with the 
substrate X-gal (5-bromo-3-indolyl--D-galactosidase). Transfected cells 
could be visualized under the microscope as the would appear blue after 
the incubation. 
The cells were washed 5 times with PBS. 
The cells were fixed with 1% (v/v) glutaraldehyde solution for 15 
min.  
The glutaraldehyde solution was removed, the X-gal solution 
was added and incubated for at least 2 h overnight at 37°C. 
The X-gal solution was removed, the cells were covered with 70% 
(v/v) glycerol and viewed with a light microscope. 
7.31 Transgenics 
7.31.1 Animal maintenance 
Mice were bred under standard controlled temperature (22°C) and 
lighting (12 h light, 12 h dark). Mice were fed with mouse chow (SDS Ltd, 
UK) and water. At 21 days of age offspring were weaned from their 
mothers, separated according to sex and ear-punched for identification. 
All manipulations on live animals were carried out according to UK 
Home Office Regulations. 
7.31.2 Generation of transgenic animals 
DNA fragments produced by BssHll restriction digestion from the 
plasmid constructs (see Figure 2.3.6) were isolated by gel electrophoresis. 
The fragments were excised from the gel and the DNA was extracted (see 
section 7.6.2) and purified (see section 7.6.3). The DNA was ethanol 
precipitated (7.6.4), resuspended in sterile, particle free water to give 100 
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ng/jil. An aliquot of this was electrophoresed in parallel with known 
DNA standards so that the concentration could be estimated precisely. 
DNA was diluted 1:10 (final concentration 10 ng/jil) in particle free 
water and used for microinjection into pronuclei of fertilized mouse 
eggs (C57BL/6 X CBA/Ca) by Dr P.Estibeiro and Rosie Allen. The eggs 
were transferred to the oviducts of pseudopregnant foster mothers 
according to methods described in (Hogan et al., 1986). Weanling 
animals were screened for the presence of HaPrP gene by dot-blot or 
Southern analysis of tail, or ear biopsy. Founder mice were mated to 
F1(C57BL/6 X CBA/Ca) mice to yield the first generation of transgenic 
animals. First generation transgenic animals were mated to Fl mice as 
before to give second generation transgenic animals. Non-transgenic 
litermates were incorporated in the experiments. 
7.31.3 Calculation of transgene copy number 
1 copy of the NSE HaPrP fragment, which is 4 kb, would correspond 
to 6.6 pg of the fragment per 10 jig of genomic DNA (2x10 9 bp per diploid 
genome) and 1 copy of the TH HaPrP fragment (6.5 kb), would 
correspond to 10.8 pg of that fragment per 10 jig of genomic DNA. 
•Different amounts of these fragments (representing 1, 2, 5, or 10 copies) 
were mixed with 10 jig of genomic DNA, digested with the same 
restriction enzyme as the rest of the genomic DNA samples and used as 
a copy number control for the dot blots. 
Southern blots hybridised with the random primed HaPrP ORF 
fragment, which is 90% homologous to the MoPrP ORF, would reveal 
the endogenous, single copy, MoPrP gene, which could serve as a copy 
number control. 
7.32 In situ hybridisation 
Frozen mouse brains were sectioned on a cryostat (Anglia 
Scientific) to give 10 ji sections and paraffin embedded mouse brains 
were sectioned on a microtome (Anglia Scientific) to give 6-8 ji sections 
(either coronal or horizontal). - 
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7.32.1 Paraffin embedding of mouse brains 
solutions 
saline 
0.8% (w/v) NaC1 in DEPC-treated water 
Mouse brains were dissected in five segments (coronal) so that they 
could be effectively fixed in 4% paraformaldehyde over night. The 
segments were immersed in the following solutions: 
PBS for 30 mm 
saline: 0.8% (w/v) NaCl in DEPC-treated water 
for 30 mm 
saline:ethanol 1:1 for 15 mm 
dehydration through a series of ethanol solutions (50%-100% v/v) 
in water for 10 min each 
100% ethanol 2 X 10 mm 
histoclear (National Diagnostics) for 2 X 30 min then 1 X 1 h 
paraffin (Shandon), 56°C 2 X 60 mm 
The brain segments were embedded in blocks of paraffin and stored 
in 4°C. 
7.32.2 Pretreatment of glass slides 
Glass slides (Chance Propper) were cleaned by a brief immersion in 
10% (v/v) HC1, followed by a 70% ethanol wash and rinsed in water then 
95% ethanol. They were heated to 150°C and allowed to cool before they 
were immersed in 4% 3-aminopropyltrioxysilane (TESPA) (v/v) (Sigma 
A3648) and then acetone. They were rinsed twice in acetone, then water 
and allowed to dry at 42°C. Following this treatment they could be stored 
dessicated in the fridge for up to a month. 
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7.32.3 Preparation of sections for in situ hybridisation 
solutions 
Paraformaldehyde 
PBS was heated to 65°C on a stirrer, then the paraformaldehyde 
(Sigma P-6148) was added to 4% (w/v). 
5 M NaOH was added to help the paraformáidehyde to dissolve 
(approximately 5 drops). 
Once in solution, the solution was cooled to room temperature and 
adjusted to pH 7.4 with concentrated HC1. 
saline 
0.8% (w/v) NaCl 
acetic anhydride 
0.25% (v/v) was added to 0.1 M triethanolamine in 0.8% 
(w/v)NaC1. 
(Acetic Anhydride is very unstable and was made as close to usage 
time as possible). 
All manipulations were carried out at room temperature. All 
solutions were 0.1% (v/v) DEPC-treated and autoclaved. Microscope 
slides were placed back-to-back in Coplin jars, with the following 
solutions poured on or off for each step. For each step, 30-35 ml of each 
solution per Coplin jar was required. 
7.32.3a from frozen brain sections 
Sections were fixed in 4% (w/v) paraformaidehyde in PBS for 10 
mm. 	 - 
Sections were rinsed in two changes of PBS for 5 mm. 
Sections were proteinase K treated by immersing in 20 mg/mi 
proteinase K in 50 mM Tris.HCi (7.4), 5 mM EDTA for 5 mim 
Sections were rinsed in PBS for 5 mm. 
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Sections were fixed again in 4% (w/v) paraformaldehyde in PBS 
for 10 mm. (The same solution was reused from step 1). 
Sections were rinsed in water for 5 mm. 
The sections were acetylated by placing in 0.25% (v/v) acetic 
anhydride for 2 X 10 mm. 
The sections were rinsed briefly in PBS. 
The sections were rinsed in saline for 5 mm. 
The sections were- dehydrated by passing through a series of 
ethanols (30 %-100%) for 1 min each and then 2 X 5 min in 99% ethanol. 
Sections were immersed in chloroform for 5 mm, rinsed briefly 
in two changes of absolute ethanol and a final rinse in 95% ethanol. 
The slides were removed from the Coplin jars and allowed to 
air dry before hybridisation. 
7.32.3b from paraffin embedded brain sections 
Sections were immersed in xylene 2 X 10 min then 99% ethanol 2 X 
2 min and rehydrated through a series of ethanols (99%-50%) 1 mm 
each, then ethanol:saline 1:1 for 2 mm, then saline for 5 mm, PBS for 5 
min and then the procedure described above (7.32.1a) was followed. 
7.32.4 Hybridisation Conditions 
7.32.4a for oligonucleotide probes 
hybridisation buffer 
4 X SSC (section 7.1) 
50% (v/v) deionised formamide 
10% (w/v) dextran sulphate 
1 X Denhardt's solution (section 7.1) 
0.1% (w/v) SDS 
500 pg/ml salmon sperm DNA 
250 pg/ml yeast tRNA 
the buffer was de-gassed before use 
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Oligonucleotides probes were labeled by homopolymer tailing 
using [a-35S]-dATP and terminal transferase as described (see section 
7.17.3) 
The prepared 35S-tailed probe (resuspended in 10 mM DTT in TE) 
was diluted to 2 x 106 cpm/ml in hybridisation buffer. DTT is also added 
to this mixture to a final concentration of 50 mM. 
100 ml of the probe mixture was carefully layered on to each 
microscope slide. A piece of parafilm cut to the size of the microscope 
slide was then layered over the probe mixture, allowing the probe and 
hybridisation mixture to cover all the sections. Air bubbles under the 
parafilm were avoided. 
The slides were placed in a humidified container, sealed, and 
incubated at 37°C overnight. 
After hybridisation, the parafilm was carefully removed using 
forceps. 
The slides were placed back in Coplin jars, and the hybridised 
sections washed in four changes of 1 X SSC for 15 min at 55°C or 60°C, 
and then two changes of 1 X SSC for 30 min at room temperature. 
The slides were rinsed briefly in dH20, then left to air dry. 
7.32.4b for riboprobes 
hybridisation buffer 
50% (v/v) deionised formamide 
10% (w/v) dextran sulphate 
1 X Denhardt's solution. 
300 mM NaC1 
20 mM M Tris.HC1 pH 8.0 
10 mM sodium phosphate pH 8.0 
100 mM EDTA 
1 mg/ml yeast tRNA 
sterile DEPC-treated water to 20 ml 
the buffer was de-gassed before use 
I 
10 mM Tris.HC1 pH 7.5 
0.5 M NaCl 
5 mM EDTA 
Riboprobes were synthesised as described in section 7.17.4. 
Riboprobes resuspended in appropriate volume of TE/50 mM DTT to 
give approximately 1 X 10 6 cpm/ml were finally diluted 1:10 in 
hybridisation buffer/50 mM DTT. 
100 ml of the probe mixture was carefully layered on to each 
microscope slide. A piece of parafilm cut to the size of the microscope 
slide was then layered over the probe mixture, allowing the probe and 
hybridisation mixture to cover all the sections. Air bubbles under the 
parafilm were avoided. 
The slides were placed in a humidified container, sealed, and 
incubated at 55°C overnight. 
After hybridisation, the parafilm was carefully removed using 
forceps. 
The slides were placed back in Coplin jars, and the hybridised 
sections washed in the following solutions: 
5 X SSC/10 mM DTT for 30 mm, 55°C 
50% formamide/2 X SSC/10 mM DTT for 20 mm, 65°C 
TNE for 3 X 10 mm, 37°C 
TNE with 40 mg/ml RNase for 30 mm, 37°C 
50% formamide/2 X SSC/10 mM DTT for 20 mm, 65°C 
2 X SSC for 3 X 10 mm, room temperature 
0.1 X SSC for 3 X 10 mm, room temperature 
30% ethanol in 0.3 M NH4 acetate for 1 mm, room temperature 
50% ethanol in 0.3 M NH4 acetate for 1 mm, room temperature 
70% ethanol in 0.3 M NH4 acetate for 1 mm, room temperature 
94% ethanol in 0.3 M NH4 acetate for 1 mm, room temperature 
99% ethanol in 0.3 M NH4 acetate for 1 mm, room temperature 
100% ethanol 2 X 5 mm 
The slides were rinsed briefly in dH20, then left to air dry. 
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7.32.5 Autoradiography 
Detection of hybridisation signals was by autoradiography. Slides 
were placed against Kodak XAR-5 film for 2-7 days for a low resolution 
image. For a- high resolution image, a photographic liquid emulsion 
(LM-1, Amersham RPN.40) was used. All manipulations were carried 
out under safelight conditions. 
The emulsion was melted by placing in a 43°C water bath. 
Once melted, the emulsion was poured into a dipping vessel. 
• 	3. Blank microscope slides were first dipped into the emulsion until 
no bubbles could be seen on the slides. 
Each test slide was dipped evenly into the emulsion vertically for 
1-2 sec. 
Slides were withdrawn from the emulsion, allowed to drain 
briefly then the back of each wiped with a' tissue to remove excess 
emulsion. 
'6. The slides were laid flat to dry. 
Once dry, the slides were laid flat in a container containing silica 
gel, and left at room temperature overnight. 
The slides were transferred into a plastic slide box containing 
more silica gel, and sealed with tape. The box was covered with two 
layers of aluminium foil and stored at 4°C for exposure. 
When ready for developing, the emulsion-dipped slides were 
brought back to room temperature. 
Hybridised sections were placed in D19 developer (Kodak, 502 
7065) for 2 mm, then transferred to 1% (v/v) acetic acid, 1% (v/v) 
glycerol for 1 minute, then to 30% (w/v) sodium thiosulphate for 2 mm. 
The sections were finally washed in a large volume of running 
water for 10 mm. 
7.32.6 Counterstaining and Mounting of Sections 
While the sections were still wet, the slides were placed in 0.1% 
(w/v) methyl green stain (Sigma, M-8884), and stained for 1-2 min. 
The sections were briefly rinsed in water to remove excess stain 
and left to air dry. 
199 
3. Sections were mounted in DePeX (BDH, 36125), and covered with 












5'HaP GT AAGCTT TGTGGCTATGTG 
3'HaP GC GAATTC TGGTCTACTGTAC 
SV40.1 GA CTCGAG ATCATAATCAGCCATA 
SV40.2 GG GGTACC AGACATGATAAG 
HNE I AGCTTGCGGCCGCG 
HNE II AATTCGCGGCCGCA 
EcoRl 1. CGGAATTCCG 















lacZ.1 TCGGCG GAATTC CAGCTG 
lacZ.2 AAT GCGGCCGC CGAGTTTGTCA 
201 
3'UTR.l TCAG CTCGAG GAAGCCTCCCTGCTTGTA 
3'UTR.2 GTC GGATCC AAACATTTATAAACTTTTA 
5'ex.2.a CAGT GTCGAC ATCAGCCATCATGGCGAACC 
5'ex.l.a CAGT GTCGAC CGCGGCGTCCGAGCAGCAGA 
5'Ko CAGT GTCGAC GCCGCCACCATGGCGAACCT 
3'HalacZ CAGT TCGCGA GCTCCCACCATCAGGAAGATGAG 
5'ex.2.b ACTG CTCGAG CTTTGTGGCTATGTGGA 
5'ex.l.b CAGT CTCGAG CGGCGTCCGAGC 
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pEE6hCMVneoHaPrP: the HaPrPORF (with a short 5' UTR sequence 
comprising of the 'optimal' initiation of translation sequence was 
cloned into the HindilI-EcoRI sites of the polylinker 
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